<SEC-DOCUMENT>0001129928-18-000047.txt : 20180803
<SEC-HEADER>0001129928-18-000047.hdr.sgml : 20180803
<ACCEPTANCE-DATETIME>20180803140019
ACCESSION NUMBER:		0001129928-18-000047
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20180630
FILED AS OF DATE:		20180803
DATE AS OF CHANGE:		20180803

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38512
		FILM NUMBER:		18991334

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>q22018form6-k.htm
<DESCRIPTION>2018 SECOND QUARTER 6-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sDDA58A71149BC8AC76DE811694E6D156"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Washington, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;  </font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">Form 6-K</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Report of Foreign Private Issuer</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pursuant to Rule&#160;13a-16 or 15d-16</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">of the Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the month of&#160;August </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commission File Number 000-31062</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Oncolytics Biotech Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Translation of registrant&#8217;s name into English)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Suite&#160;210, 1167 Kensington Crescent NW</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Calgary, Alberta, Canada T2N 1X7</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Address of principal executive offices)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F or Form&#160;40-F.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:40%;"></td><td style="width:20%;"></td><td style="width:40%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form&#160;20-F&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#254;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form&#160;40-F&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(1):&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note:</font><font style="font-family:inherit;font-size:10pt;">&#32;Regulation&#160;S-T Rule&#160;101(b)(1) only permits the submission in paper of a Form&#160;6-K if submitted solely to provide an attached annual report to security holders.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(7):&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note:</font><font style="font-family:inherit;font-size:10pt;">&#32;Regulation&#160;S-T Rule&#160;101(b)(7) only permits the submission in paper of a Form&#160;6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on which the registrant&#8217;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#8217;s security holders, and, if discussing a material event, has already been the subject of a Form&#160;6-K submission or other Commission filing on EDGAR.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="sB77E4F8C5A904E80786F8116950D490E"></a></div><div style="line-height:174%;text-align:center;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INCORPORATION BY REFERENCE</font></div><div style="line-height:174%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Registrant&#8217;s Management&#8217;s Discussion and Analysis of Operations and Financial Condition for the Three and Six Months Ended June 30, 2018, included as Exhibit&#160;99.2 of this Form&#160;6-K and the Interim Financial Statements as of and for the Three and Six Months Ended June 30, 2018, included as Exhibit&#160;99.1 of this Form&#160;6-K (Commission File No.&#160;001-31062), furnished to the Commission on&#160;August 3, 2018, are incorporated by reference into the Registrant&#8217;s Registration Statement on Form&#160;F-10 (Commission File No. 333-224432).</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:82%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NUMBER</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DESCRIPTION</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex991-interimfsjun302018.htm"><font style="font-family:inherit;font-size:10pt;">Oncolytics Biotech&#174; Inc. June 30, 2018 Interim Financial Statements</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex992-q22018mda.htm"><font style="font-family:inherit;font-size:10pt;">Oncolytics Biotech&#174; Inc. June 30, 2018 Management Discussion &amp; Analysis</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex993-q22018certificationx.htm"><font style="font-family:inherit;font-size:10pt;">Certification of June 30, 2018 interim filings - CEO</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex994-q22018certificationx.htm"><font style="font-family:inherit;font-size:10pt;">Certification of June 30, 2018 interim filings - CFO</font></a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:4%;"></td><td style="width:3%;"></td><td style="width:38%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Oncolytics Biotech Inc.</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Registrant)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: August 3, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;Kirk Look</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kirk Look</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991-interimfsjun302018.htm
<DESCRIPTION>2018 SECOND QUARTER INTERIM FINANCIAL STATEMENTS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s51D81CED95D00968619C811699C8F6E6"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Interim Consolidated Financial Statements</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">(unaudited)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Oncolytics Biotech</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:12pt;">&#32;and </font><font style="font-family:inherit;font-size:12pt;color:#000000;text-decoration:none;">2017</font></div><div><br></div><hr style="page-break-after:always"><div><a name="s6813B766BB791F7EB57B811688249BB1"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:536px;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:304px;"></td><td style="width:40px;"></td><td style="width:91px;"></td><td style="width:4px;"></td><td style="width:91px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,<br>2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,<br>2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18,741,347</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,836,119</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,767,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other receivables</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">89,714</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,726</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,489,212</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,176,063</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total current assets</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">20,320,273</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,817,008</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Non-current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">373,213</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333,441</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total non-current assets</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">373,213</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333,441</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">20,693,486</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,150,449</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liabilities And Shareholders&#8217; Equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Current Liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,996,438</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,684,023</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liability</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">927,400</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,545,645</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,923,838</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,229,668</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Non-current liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5,802,887</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,636,935</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total non-current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5,802,887</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,636,935</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;font-style:italic;">Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9,726,725</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,866,603</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Commitments and contingencies</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">9</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shareholders&#8217; equity</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share capital<br>&#160;&#160;Authorized: unlimited<br>&#160;&#160;Issued:<br>  June 30, 2018 &#8211; 16,521,430  <br>  December 31, 2017 &#8211; 141,805,722 pre-consolidation<br>  December 31, 2017 &#8211; 14,926,918 post-consolidation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">282,458,995</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">271,710,138</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,617,570</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contributed surplus</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">27,710,089</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,028,238</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive income</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">508,380</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">373,730</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(303,328,273</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(294,446,160</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Total shareholders&#8217; equity</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10,966,761</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,283,846</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Total liabilities and equity</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">20,693,486</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,150,449</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes</font></div><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:30px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><a name="sE15D1E5855CFB74268F3811688442EB7"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">INTERIM CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:656px;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:246px;"></td><td style="width:60px;"></td><td style="width:82px;"></td><td style="width:4px;"></td><td style="width:82px;"></td><td style="width:4px;"></td><td style="width:83px;"></td><td style="width:4px;"></td><td style="width:84px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Month Period Ending June 30, 2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Month Period Ending June 30, 2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Month Period Ending June 30, 2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Month Period Ending June 30, 2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">6, 13, 14</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,045,417</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,918,673</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,980,308</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,186,744</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Operating</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">6, 13, 14</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,638,802</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,444,543</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,401,355</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,744,843</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Loss before the following</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(3,684,219</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,363,216</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(8,381,663</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,931,587</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Interest</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">20,538</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,163</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">47,428</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,878</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Loss before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(3,663,681</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,349,053</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(8,334,235</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,866,709</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Income tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(547,758</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(89</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(547,878</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(152</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(4,211,439</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,349,142</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(8,882,113</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,866,861</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other comprehensive income (loss) items that may be reclassified to net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Translation adjustment</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">64,029</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(44,740</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">134,650</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(65,488</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(4,147,410</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,393,882</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(8,747,463</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,932,349</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basic and diluted loss per common share</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">7</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(0.27</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.32</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(0.58</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.60</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Weighted average number of shares (basic and diluted)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">7</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">15,406,944</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,405,220</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">15,191,457</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,086,393</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:30px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><a name="sDBAAA0A2EC99AE90FFFF81168863FC8F"></a></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:883px;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:260px;"></td><td style="width:73px;"></td><td style="width:86px;"></td><td style="width:4px;"></td><td style="width:86px;"></td><td style="width:4px;"></td><td style="width:86px;"></td><td style="width:4px;"></td><td style="width:95px;"></td><td style="width:4px;"></td><td style="width:86px;"></td><td style="width:4px;"></td><td style="width:86px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Capital</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrants</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contributed Surplus</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Other Comprehensive Income</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Deficit</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:normal;">As at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262,321,825</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,643,044</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">554,060</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(278,829,309</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,689,620</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss and other comprehensive loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(65,488</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,866,861</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,932,349</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" agreement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">668,648</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">668,648</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to public offering</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,893,600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,511,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to stock option plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">461,823</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(166,473</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">295,350</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">289,597</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">289,597</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,254,523</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,254,523</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As at June 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">270,091,373</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,900</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,766,168</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">488,572</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(286,696,170</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,267,843</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:normal;">As at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">271,710,138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,028,238</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">373,730</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(294,446,160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,283,846</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss and other comprehensive income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">134,650</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,882,113</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,747,463</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" Agreement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">553,650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">553,650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to public offering</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,606,882</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,606,882</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to stock option plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,269</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,359</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,910</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to warrant agreement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,747</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(330</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,417</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">696,210</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">696,210</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,451,691</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,451,691</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As at June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">282,458,995</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,617,570</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">27,710,089</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">508,380</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(303,328,273</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10,966,761</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:18px;text-indent:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><a name="sA7CFFC57CC859FDFCE0A81168882EFB5"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:680px;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:296px;"></td><td style="width:57px;"></td><td style="width:78px;"></td><td style="width:4px;"></td><td style="width:78px;"></td><td style="width:4px;"></td><td style="width:78px;"></td><td style="width:4px;"></td><td style="width:76px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Month Period Ending June 30, 2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Month Period Ending June 30, 2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Month Period Ending June 30, 2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Month Period Ending June 30, 2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Activities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss for the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(4,211,439</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,349,142</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(8,882,113</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,866,861</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization - property and equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">21,126</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,688</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">40,984</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,724</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">6, 13, 14</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">157,092</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">155,708</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">696,210</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">289,597</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized foreign exchange gain</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(97,832</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(164,676</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(102,345</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(112,644</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net change in non-cash working capital</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">12</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,720,317</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(216,906</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,227,770</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(854,552</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash provided by (used in) operating activities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">589,264</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,549,328</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(4,019,494</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,494,736</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Investing Activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition of property and equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(37,443</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(80,050</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(80,062</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(85,886</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redemption of short-term investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,088,800</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash (used in) provided by investing activities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(37,443</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(80,050</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(80,062</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,002,914</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financing Activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from "At the Market" equity distribution agreement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">570,027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">520,315</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">559,527</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from public offering</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10,188,526</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,366,098</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10,188,526</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,366,098</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from exercise of options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">23,910</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">295,350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">23,910</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">295,350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from exercise of warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,417</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,417</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash provided by financing activities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10,213,853</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,231,475</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10,734,168</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,220,975</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Increase in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10,765,674</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,602,097</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,634,612</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,729,153</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents, beginning of period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7,745,255</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,102,393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11,836,119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,034,282</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impact of foreign exchange on cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">230,418</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,192</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">270,616</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(87,137</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and cash equivalents, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18,741,347</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,676,298</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18,741,347</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,676,298</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><a name="s074C3FFA468DC8E7F11D81169AE38F7E"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s9149D514D852559D01F2811688A1E7BE"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 1: Incorporation and Nature of Operations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oncolytics Biotech Inc. was incorporated on April 2, 1998 under the Business Corporations Act (Alberta) as 779738 Alberta Ltd.  On April 8, 1998, we changed our name to Oncolytics Biotech Inc.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our interim consolidated financial statements for the period ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, were authorized for issue in accordance with a resolution of the Board of Directors (the "Board") on </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">August&#160;2, 2018</font><font style="font-family:inherit;font-size:10pt;">.  We are a limited company incorporated and domiciled in Canada.  Our shares are publicly traded and our registered office is located at 210, 1167 Kensington Crescent NW, Calgary, Alberta, Canada.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a development stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for the treatment of cancers that have not been successfully treated with conventional therapeutics.  Our lead product, REOLYSIN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, is a potential immuno-oncology viral-agent that may be a novel treatment for certain types of cancer and may be an alternative to existing cytotoxic or cytostatic therapies. Our clinical development program for REOLYSIN emphasizes three programs: chemotherapy combinations to trigger selective tumor lysis;  immune modulator (IMiD) combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s0347D35BA7F58D5914C5811688A142AD"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 2: Basis of Financial Statement Presentation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our interim consolidated financial statements include our financial statements and the financial statements of our subsidiaries as at June 30, 2018 and are presented in Canadian dollars, our functional currency.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our accounts are prepared in accordance with International Financial Reporting Standards ("IFRS") issued by the International Accounting Standards Board ("IASB"). The accounts are prepared on the historical cost basis, except for certain assets and liabilities which are measured at fair value as explained in the notes to these financial statements.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These interim consolidated financial statements have been prepared in compliance with International Accounting Standard 34 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interim Financial Reporting.  </font><font style="font-family:inherit;font-size:10pt;">The notes presented in these interim consolidated financial statements include only significant events and transactions occurring since our last fiscal year end and are not fully inclusive of all matters required to be disclosed in our annual audited consolidated financial statements.  Accordingly, these interim consolidated financial statements should be read in conjunction with our most recent annual audited consolidated financial statements, for the year ended December 31, 2017. We have consistently applied the same accounting policies for all periods presented in these interim consolidated financial statements as those used in our audited consolidated financial statements for the year ended December 31, 2017, except for the adoption of new standards effective as of January 1, 2018.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sA8498927CBE5E8BE3AE4811688A1E3E2"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 3: Significant Accounting Policies</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">IFRS 9 - </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financial Instruments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IFRS 9 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments ("IFRS 9")</font><font style="font-family:inherit;font-size:10pt;">&#32;replaces IAS 39 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments: Recognition and Measurement</font><font style="font-family:inherit;font-size:10pt;">&#32;for annual periods beginning on or after January 1, 2018. IFRS 9 includes guidance on the classification and measurement of financial assets and financial liabilities and impairment of financial assets.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have applied IFRS 9 retrospectively, with the initial application date of January 1, 2018. There were no changes to the measurement of our financial assets and liabilities or adjustments to comparative information as a result of the adoption of IFRS 9. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Classification and measurement</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial assets</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial assets are initially measured at fair value.  In the case of a financial asset not at fair value through profit or loss, the financial asset is initially measured at fair value plus or minus transaction costs. </font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font></div></div><div><br></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under IFRS 9, financial assets are subsequently measured at amortised cost, fair value through profit or loss (FVPL), or fair value through other comprehensive income (FVOCI). The classification is based on two criteria: the Company&#8217;s business model for managing the assets; and whether the financial asset&#8217;s contractual cash flows represent &#8216;solely payments of principal and interest&#8217; on the principal amount outstanding (the &#8216;SPPI criterion&#8217;). </font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our financial assets include cash and cash equivalents and other receivables. The classification and measurement of these financial assets are at amortized cost, as these assets are held within our business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the SPPI criterion. Under IAS 39, our financial assets were classified as follows: cash and cash equivalents - held for trading and other receivables - loans and receivables. The accounting for our financial assets remained the same as it was under IAS 39.</font></div><div style="line-height:120%;text-align:justify;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial liabilities</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial liabilities are initially measured at fair value and are subsequently measured at amortised cost. The accounting for our financial liabilities remained the same as it was under IAS 39.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impairment</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under IFRS 9, accounting for impairment losses for financial assets uses a forward-looking expected credit loss (ECL) approach.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IFRS 9 requires that we record a loss allowance for ECLs on all financial assets not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive. The shortfall is then discounted at an approximation to the asset&#8217;s original effective interest rate.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have applied the simplified approach permitted by IFRS 9 and calculated ECLs based on lifetime expected credit losses. We have established a provision matrix that is based on historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were no adjustments in impairment allowances of our financial assets as a result of the adoption of the ECL requirements of IFRS 9. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s720CBBB326B102EB6C6E811688A1480F"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 4: Cash Equivalents </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Equivalents</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents consist of interest bearing deposits with our bank totaling $</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">12,814,805</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$9,204,919</font><font style="font-family:inherit;font-size:10pt;">).&#160;&#160;The current annual interest rate earned on these deposits is </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1.46%</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;(</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1.38%</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s7E41584B832BDC06002B811688B1E748"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 5: Share Capital</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Authorized:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unlimited number of no par value common shares</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Consolidation:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 22, 2018, we completed the consolidation of our common shares on the basis of </font><font style="font-family:inherit;font-size:10pt;">9.5</font><font style="font-family:inherit;font-size:10pt;">&#32;pre-consolidation common shares for each one post-consolidation common share (the "Share Consolidation"). Fractional interests were rounded down to the nearest whole number of common shares. Outstanding stock options, restricted share units and performance share units were similarly adjusted by the consolidation ratio. Outstanding warrants were adjusted such that, following the Share Consolidation, </font><font style="font-family:inherit;font-size:10pt;">9.5</font><font style="font-family:inherit;font-size:10pt;">&#32;2017 warrants will entitle the holder to purchase </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;whole common share until June 1, 2022.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:665px;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:293px;"></td><td style="width:88px;"></td><td style="width:4px;"></td><td style="width:88px;"></td><td style="width:4px;"></td><td style="width:88px;"></td><td style="width:4px;"></td><td style="width:88px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued:</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrants</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount<br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121,258,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262,321,825</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to stock option plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">801,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">536,949</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" equity distribution agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:7pt">(a)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,301,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,348,821</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to public offering</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:7pt">(b)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,893,600</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,900</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,391,057</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">141,805,722</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">271,710,138</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,900</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" equity distribution agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:7pt">(a)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">519,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">553,650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33,335</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,325,222</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">272,230,453</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,900</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to stock option plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,269</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, May 22, 2018 - pre-consolidation</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,396,222</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">272,268,722</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,900</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, May 22, 2018 - post-consolidation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,988,995</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">272,268,722</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,900</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to public offering</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(c)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,532,278</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,606,882</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to warrant agreement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,747</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,500</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(330</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,418,356</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance, June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">16,521,430</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">282,458,995</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">16,443,500</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,617,570</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 25, 2016, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. acting as our sole agent with an aggregate offering value of up to </font><font style="font-family:inherit;font-size:10pt;">$4.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;which allows us to sell our common shares through the facilities of the Toronto Stock Exchange or other "marketplace&#8221; (as defined in National Instrument 21-101 Marketplace Operation) in Canada (our "Canadian ATM"). Subject to the terms of our Canadian ATM, we are able to determine, at our sole discretion, the timing and number of shares to be sold under this ATM facility. During the period  ending June 30, 2018, we sold </font><font style="font-family:inherit;font-size:10pt;">519,500</font><font style="font-family:inherit;font-size:10pt;">&#32;pre-consolidation shares (approximately </font><font style="font-family:inherit;font-size:10pt;">54,684</font><font style="font-family:inherit;font-size:10pt;">&#32;post-consolidation shares) (2017 - </font><font style="font-family:inherit;font-size:10pt;">842,000</font><font style="font-family:inherit;font-size:10pt;">&#32;pre-consolidation shares (approximately </font><font style="font-family:inherit;font-size:10pt;">88,631</font><font style="font-family:inherit;font-size:10pt;">&#32;post-consolidation shares)) for gross proceeds of $</font><font style="font-family:inherit;font-size:10pt;">553,650</font><font style="font-family:inherit;font-size:10pt;">&#32;(2017 - </font><font style="font-family:inherit;font-size:10pt;">$668,648</font><font style="font-family:inherit;font-size:10pt;">). We incurred share issue costs of $</font><font style="font-family:inherit;font-size:10pt;">33,335</font><font style="font-family:inherit;font-size:10pt;">&#32;(2017 - </font><font style="font-family:inherit;font-size:10pt;">$109,121</font><font style="font-family:inherit;font-size:10pt;">).</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 1, 2017, pursuant to an underwritten public offering, </font><font style="font-family:inherit;font-size:10pt;">16,445,000</font><font style="font-family:inherit;font-size:10pt;">&#32;units were sold at a purchase price of </font><font style="font-family:inherit;font-size:10pt;">$0.70</font><font style="font-family:inherit;font-size:10pt;">&#32;per unit for gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">$11,511,500</font><font style="font-family:inherit;font-size:10pt;">.  Each unit included </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;pre-consolidation common share with an ascribed value of </font><font style="font-family:inherit;font-size:10pt;">$0.48</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">0.106</font><font style="font-family:inherit;font-size:10pt;">&#32;post-consolidation common share with an ascribed value of </font><font style="font-family:inherit;font-size:10pt;">$4.56</font><font style="font-family:inherit;font-size:10pt;">) and </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;pre-consolidation common share purchase warrant with an ascribed value of </font><font style="font-family:inherit;font-size:10pt;">$0.22</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;post-consolidation common share purchase warrant with an ascribed value of </font><font style="font-family:inherit;font-size:10pt;">$2.09</font><font style="font-family:inherit;font-size:10pt;">). Each pre-consolidation common share purchase warrant entitled the the holder to purchase one pre-consolidation common share at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$0.95</font><font style="font-family:inherit;font-size:10pt;">.   Following the Share Consolidation, </font><font style="font-family:inherit;font-size:10pt;">9.5</font><font style="font-family:inherit;font-size:10pt;">&#32;pre-consolidation common share purchase warrants entitles the holder to purchase </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;post-consolidation common share in the capital of the Company until June 1, 2022, </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font></div></div><div><br></div><div style="line-height:120%;padding-left:24px;text-align:justify;"><font style="font-family:inherit;font-size:10pt;">at an exercise price of approximately </font><font style="font-family:inherit;font-size:10pt;">$9.025</font><font style="font-family:inherit;font-size:10pt;">. The post-consolidation common share purchase warrants will be subject to acceleration if the volume weighted average price of the Company's common shares equals or exceeds </font><font style="font-family:inherit;font-size:10pt;">$23.75</font><font style="font-family:inherit;font-size:10pt;">&#32;for </font><font style="font-family:inherit;font-size:10pt;">15</font><font style="font-family:inherit;font-size:10pt;">&#32;consecutive trading dates.  The ascribed value was determined using the relative fair value method. The ascribed value of the common share purchase warrants was determined using the Black Scholes option pricing model. We incurred share issue costs of </font><font style="font-family:inherit;font-size:10pt;">$1,145,402</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 5, 2018, pursuant to an underwritten public offering, </font><font style="font-family:inherit;font-size:10pt;">1,532,278</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares were sold at a purchase price of  US</font><font style="font-family:inherit;font-size:10pt;">$5.83</font><font style="font-family:inherit;font-size:10pt;">&#32;per share for gross proceeds of US</font><font style="font-family:inherit;font-size:10pt;">$8,933,181</font><font style="font-family:inherit;font-size:10pt;">. We incurred share issue costs of $</font><font style="font-family:inherit;font-size:10pt;">1,418,356</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Warrants</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our outstanding warrants at June 30, 2018:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:625px;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:6px;"></td><td style="width:77px;"></td><td style="width:4px;"></td><td style="width:100px;"></td><td style="width:4px;"></td><td style="width:102px;"></td><td style="width:4px;"></td><td style="width:90px;"></td><td style="width:4px;"></td><td style="width:90px;"></td><td style="width:4px;"></td><td style="width:134px;"></td><td style="width:4px;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Exercise Price</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Outstanding, Beginning of the Period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Granted During the Period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Exercised During the Period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Outstanding, End of the Period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual Life (years)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9.025</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,443,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.92</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sB24A122BED5108591F57811688EF3818"></a></div><div style="line-height:120%;padding-top:1px;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 6: Share Based Payments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 22, 2018, we completed our Share Consolidation (see Note 5), as a result, all stock option and share award disclosures have been retrospectively adjusted to reflect the Share Consolidation.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Stock Option Plan</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have issued stock options to acquire common stock through our stock option plan of which the following are outstanding at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:655px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:214px;"></td><td style="width:99px;"></td><td style="width:4px;"></td><td style="width:112px;"></td><td style="width:107px;"></td><td style="width:4px;"></td><td style="width:112px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, beginning of the period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">647,156</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">912,995</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.71</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted during the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">313,867</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7.38</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,735</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.82</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited during the period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(39,680</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7.33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(73,887</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30.94</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired during the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,882</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.38</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised during the period</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(7,473</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.20</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(72,250</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.09</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">913,870</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11.54</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">779,711</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.10</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px solid #000000;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercisable, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">666,693</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13.35</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">606,905</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.02</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information about the stock options outstanding and exercisable at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:182px;"></td><td style="width:96px;"></td><td style="width:4px;"></td><td style="width:100px;"></td><td style="width:100px;"></td><td style="width:96px;"></td><td style="width:4px;"></td><td style="width:100px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Range of Exercise Prices</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number Outstanding</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual Life (years)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number Exercisable</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$2.47 - $3.99</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">342,454</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.36</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">304,436</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.29</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$4.84 - $7.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">345,225</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">136,066</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.17</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$13.77 - $19.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">103,956</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16.87</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">103,956</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16.87</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$20.23 - $36.96</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">56,722</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">32.47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">56,722</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">32.47</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$38.09 - $63.84</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">65,513</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">50.74</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">65,513</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">50.74</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">913,870</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11.54</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">666,693</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13.35</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-exercisable options vest either annually over periods ranging from </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">three years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated fair value of stock options issued during the period was determined using the Black Scholes Option Pricing Model using the following weighted average assumptions and fair value of options: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:449px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:273px;"></td><td style="width:90px;"></td><td style="width:85px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.88%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.90%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected hold period to exercise</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.0 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.0 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility in the price of the Company's shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">84.11%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88.71%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rate of forfeiture</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.67%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.67%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nil</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average fair value of options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$4.04</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.05</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use historical data to estimate the expected dividend yield and expected volatility of our stock in determining the fair value of the stock options. The risk-free interest rate is based on the Government of Canada benchmark bond yield rates in effect at the time of grant and the expected life of the options represents the estimated length of time the options are expected to remain outstanding.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incentive Share Award Plan</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Share Units</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have issued restricted share units ("RSUs") to non-employee directors through our incentive share award plan. Grants of RSUs to non-employee directors vest either on the third anniversary date from the grant date or when the director ceases to be a member of the board. We have also issued RSUs to certain officers and employees of the Company. Grants of RSUs to certain officers and employees of the Company vest over a </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;year period. The following RSUs are outstanding at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:511px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:325px;"></td><td style="width:88px;"></td><td style="width:4px;"></td><td style="width:88px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">190,407</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139,237</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Granted during the period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8,891</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,212</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">199,298</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148,449</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:48px;text-align:justify;text-indent:36px;"><font style="text-align:justify;font-family:inherit;font-size:8pt;padding-right:24px;">(1)</font><font style="font-family:inherit;font-size:8pt;">The weighted average fair value of the RSUs granted was </font><font style="font-family:inherit;font-size:8pt;">$6.27</font><font style="font-family:inherit;font-size:8pt;">&#32;in 2018 (2017 - </font><font style="font-family:inherit;font-size:8pt;">$5.65</font><font style="font-family:inherit;font-size:8pt;">).</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Performance Share Units</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have also issued performance share units ("PSUs") to certain officers and employees of the Company. Grants of PSUs require completion of certain performance criteria and cliff vest after </font><font style="font-family:inherit;font-size:10pt;">3 years</font><font style="font-family:inherit;font-size:10pt;">&#32;or vest over a </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;year period, depending on the grant. PSU grants to certain officers will vest immediately upon a change of control of the Company. If certain officers cease employment </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">with the Company, vesting occurs on a pro rata basis prior to the third anniversary of the grant but after the first anniversary. The following PSUs are outstanding at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:511px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:325px;"></td><td style="width:88px;"></td><td style="width:4px;"></td><td style="width:88px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">94,734</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,419</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Granted during the period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,315</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited during the period</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(31,578</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">63,156</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,734</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:84px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1)    The weighted average fair value of the PSUs granted in 2017 was </font><font style="font-family:inherit;font-size:8pt;">$3.33</font><font style="font-family:inherit;font-size:8pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have reserved </font><font style="font-family:inherit;font-size:10pt;">1,652,143</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares for issuance relating to our outstanding equity compensation plans. Compensation expense related to stock options, RSUs and PSUs was $</font><font style="font-family:inherit;font-size:10pt;">157,092</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$696,210</font><font style="font-family:inherit;font-size:10pt;">&#32;for the three and six month periods ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, respectively (</font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;- $</font><font style="font-family:inherit;font-size:10pt;">155,708</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$289,597</font><font style="font-family:inherit;font-size:10pt;">, respectively).  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s236C5966702A8816787E8116893D4CFB"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 7: Loss Per Common Share</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss per common share is calculated using net loss for the year and the weighted average number of common shares outstanding for the three and six month periods ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;of </font><font style="font-family:inherit;font-size:10pt;">15,406,944</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">15,191,457</font><font style="font-family:inherit;font-size:10pt;">, respectively (June 30, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;">13,405,220</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">13,086,393</font><font style="font-family:inherit;font-size:10pt;">, respectively). The effect of any potential exercise of our stock options and warrants outstanding during the year has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s84888383C483B9D158598116894D8731"></a></div><div style="line-height:120%;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 8: Contract Liability and Receivable</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Regional licensing agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We entered into a regional licensing agreement (the "Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai") in November 2017. Under the terms of the Agreement, Adlai will have exclusive development and commercialization rights to REOLYSIN in China, Hong Kong, Macau, Singapore, South Korea and Taiwan. We are entitled to receive upfront license fees, development and regulatory milestone payments, royalties and sales-based milestone payments. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Warrant purchase agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also entered into a warrant purchase agreement with Adlai. Under the terms of the warrant purchase agreement, we are entitled to receive two milestone payments totaling US</font><font style="font-family:inherit;font-size:10pt;">$8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;made up of two common share purchase warrants:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">One common share purchase warrant of US</font><font style="font-family:inherit;font-size:10pt;">$2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;whereby, upon exercise, Adlai may purchase our common shares priced at a </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;">&#32;premium to the </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-day weighted average closing price immediately preceding the exercise date. We have the right to call this warrant when the first patient is enrolled in the phase 3 metastatic breast cancer study or </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;">&#32;months after execution of the Agreement, whichever is later.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">One common share purchase warrant of US</font><font style="font-family:inherit;font-size:10pt;">$6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;whereby, upon exercise, Adlai may purchase our common shares priced at a </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;">&#32;premium to the </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-day weighted average closing price immediately preceding the exercise date. We have the right to call this warrant upon the enrollment of the </font><font style="font-family:inherit;font-size:10pt;">50</font><font style="font-family:inherit;font-size:10pt;">th patient in the phase 3 metastatic breast cancer study.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contract liability</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">Our contract liability balance, which w</font><font style="font-family:inherit;font-size:10pt;">e expect to record in revenue over the next </font><font style="font-family:inherit;font-size:10pt;">five years</font><font style="font-family:inherit;font-size:10pt;">, is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:443px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:236px;"></td><td style="width:102px;"></td><td style="width:4px;"></td><td style="width:96px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,<br>2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,<br>2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,182,580</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regional licensing agreement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">547,707</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,182,580</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue recognized in the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,730,287</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,182,580</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liability - current</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">927,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,545,645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liability - non-current</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5,802,887</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,636,935</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,730,287</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,182,580</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contract receivable</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our contract receivable due from Adlai at June 30, 2018 is </font><font style="font-family:inherit;font-size:10pt;">nil</font><font style="font-family:inherit;font-size:10pt;">&#32;(December 31, 2017 - </font><font style="font-family:inherit;font-size:10pt;">$4,767,100</font><font style="font-family:inherit;font-size:10pt;">&#32;(US</font><font style="font-family:inherit;font-size:10pt;">$3,800,000</font><font style="font-family:inherit;font-size:10pt;">)). On collection of the contract receivable, an income tax expense of </font><font style="font-family:inherit;font-size:10pt;">$547,707</font><font style="font-family:inherit;font-size:10pt;">&#32;was recorded with a corresponding credit to the contract liability.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sE0CE92333BC2ACA5B89D8116896C2BE7"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 9: Commitments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are committed to payments totaling </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$6,063,389</font><font style="font-family:inherit;font-size:10pt;">&#32;for activities related to our clinical trial, manufacturing and collaboration programs which are expected to occur over the next </font><font style="font-family:inherit;font-size:10pt;">two years</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are committed to rental payments (excluding our portion of operating costs and rental taxes) under the terms of our office leases.  Annual payments under the terms of these leases are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:33.984375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:59%;"></td><td style="width:40%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remainder of 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">209,680</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">449,360</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">361,848</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162,286</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,183,174</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under a clinical trial agreement entered into with the Alberta Cancer Board (&#8220;ACB&#8221;), we have agreed to repay the amount funded under the agreement together with a royalty, to a combined maximum amount of </font><font style="font-family:inherit;font-size:10pt;">$400,000</font><font style="font-family:inherit;font-size:10pt;">&#32;plus an overhead repayment of </font><font style="font-family:inherit;font-size:10pt;">$100,000</font><font style="font-family:inherit;font-size:10pt;">, upon sales of a specified product.&#160;&#160;We agreed to repay the ACB in annual installments in an amount equal to the lesser of: (a) </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;">&#32;of gross sales of a specified product; or (b) </font><font style="font-family:inherit;font-size:10pt;">$100,000</font><font style="font-family:inherit;font-size:10pt;">&#32;per annum once sales of a specified product commence.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s03B18A3ABB3074FE28348116896C8EA5"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 10: Capital Disclosures</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our objective when managing capital is to maintain a strong statement of financial position.  We achieve our objective by obtaining adequate cash resources to support planned activities which include the clinical trial program, product manufacturing, administrative costs and intellectual property expansion and protection.&#160;We include shareholders&#8217; equity and cash and cash equivalents in the definition of capital.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:72%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,<br>2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,<br>2017<br>$</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18,741,347</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,836,119</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholders&#8217; equity</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10,966,761</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,283,846</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not have any debt other than trade accounts payable and we have potential contingent obligations relating to the completion of our research and development of REOLYSIN.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the costs associated with these activities. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#8217;s activity.&#160;&#160;Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares.&#160; Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital.&#160;&#160;There are no assurances that funds will be made available to us when required.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 4, 2018, we renewed our short form base shelf prospectus (the "Base Shelf") that qualifies for distribution of up to </font><font style="font-family:inherit;font-size:10pt;">$150,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of common shares, subscription receipts, warrants, or units (the "Securities") in either Canada, the US or both. Under a Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents or other intermediaries and also may sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Renewing our Base Shelf  provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in our company. Funds received as a result of using our Base Shelf would be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf will be effective until May 25, 2020. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are not subject to externally imposed capital requirements and there have been no changes in how we define or manage our capital in 2018.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sF8ECB3257F327E2206CE8116897C7666"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 11: Financial Instruments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our financial instruments consist of cash and cash equivalents,&#160;other receivables and accounts payable.&#160;&#160;As at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, there are no significant differences between the carrying values of these amounts and their estimated market values.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Credit risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credit risk is the risk of financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;&#160;We are exposed to credit risk on our cash and cash equivalents and contract receivable in the event of non-performance by counterparties, but we do not anticipate such non-performance.&#160;Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents and contract receivable.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We mitigate our exposure to credit risk by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;For our foreign domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable or payroll.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest rate risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&#160;We are exposed to interest rate risk through our cash and cash equivalents and our portfolio of short-term investments.&#160;&#160;We mitigate this risk through our investment policy that only allows investment of excess cash resources in investment grade vehicles while matching maturities with our operational requirements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the investments held.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Currency risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Currency risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates.&#160;In the normal course of our operations, we are exposed to currency risk from the purchase of goods and services primarily in the U.S., the U.K. and the European Union. In addition, we are exposed to currency risk to the extent cash is held in foreign currencies from either the purchase of foreign currencies or when we receive foreign currency proceeds from operating and financing activities.  As well, we are exposed to currency risk related to our regional licensing agreement. The impact of a </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;">&#32;increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;by approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$78,308</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;The impact of a </font><font style="font-family:inherit;font-size:10pt;">$0.10</font><font style="font-family:inherit;font-size:10pt;">&#32;increase in the value of the British pound against the Canadian dollar would have increased our net loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;by approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$15,848</font><font style="font-family:inherit;font-size:10pt;">.  The impact of a </font><font style="font-family:inherit;font-size:10pt;">$0.10</font><font style="font-family:inherit;font-size:10pt;">&#32;increase in the value of the Euro against the Canadian dollar would have increased our net loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;by approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$4,658</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We mitigate our foreign exchange risk by maintaining sufficient foreign currencies, through the purchase of foreign currencies or receiving foreign currencies from financing activities, to settle our foreign accounts payable.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balances in foreign currencies at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:596px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:197px;"></td><td style="width:128px;"></td><td style="width:4px;"></td><td style="width:128px;"></td><td style="width:4px;"></td><td style="width:128px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">US dollars </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-align:center;">British pounds</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-align:center;">&#163;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Euro<br>&#8364;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,698,664</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,212</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,347</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(916,806</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,060</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,781,858</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,152</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,347</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities.&#160;We manage liquidity risk through the management of our capital structure as outlined in Note 10. Accounts payable are all due within the current operating period.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s9E5D7C27D4BEB9CD66C18116898BD040"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 12: Additional Cash Flow Disclosures</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change In Non-Cash Working Capital</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:681px;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:369px;"></td><td style="width:74px;"></td><td style="width:4px;"></td><td style="width:74px;"></td><td style="width:4px;"></td><td style="width:74px;"></td><td style="width:4px;"></td><td style="width:74px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Month Period Ending June 30, 2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Month Period Ending June 30, 2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Month Period Ending June 30, 2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Month Period Ending June 30, 2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Change in:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,899,720</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,767,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other receivables</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(50,826</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,625</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(51,988</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,703</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(402,199</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(302,178</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(313,149</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(224,234</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(204,913</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,818</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(687,585</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(757,716</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liability</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">547,707</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">547,707</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash impact of foreign exchange</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(69,172</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148,715</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(34,315</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135,101</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in non-cash working capital related to operating activities</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,720,317</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(216,906</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,227,770</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(854,552</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Cash Flow Disclosures</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:591px;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:342px;"></td><td style="width:58px;"></td><td style="width:4px;"></td><td style="width:58px;"></td><td style="width:4px;"></td><td style="width:58px;"></td><td style="width:4px;"></td><td style="width:58px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Month Period Ending June 30, 2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Month Period Ending June 30, 2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Month Period Ending June 30, 2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Month Period Ending June 30, 2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash interest received</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">20,538</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,163</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">47,428</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,878</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash taxes paid</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,752</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,752</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sF2805C865328D9836B6B811689AAFF34"></a></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 13:  Other Expenses and Adjustments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We present our expenses based on the function of each expense and therefore include realized foreign exchange gains and losses, unrealized non-cash foreign exchange gains and losses and non-cash stock based compensation associated with research and development activity as a component of research and development expenses and amortization of property and equipment and stock based compensation associated with operating activities as a component of operating expenses.  </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:679px;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:294px;"></td><td style="width:91px;"></td><td style="width:4px;"></td><td style="width:91px;"></td><td style="width:4px;"></td><td style="width:91px;"></td><td style="width:4px;"></td><td style="width:91px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Month Period Ending June 30, 2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Month Period Ending June 30, 2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Month Period Ending June 30, 2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Month Period Ending June 30, 2017<br>$</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Included in research and development expenses:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Realized foreign exchange loss (gain)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,289</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,340</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(47,505</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(44</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized non-cash foreign exchange gain</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(161,862</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(119,937</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(236,996</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(47,156</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash share based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">29,551</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,270</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">330,509</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">126,103</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Included in operating expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">21,126</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,688</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">40,984</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,724</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash share based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">127,541</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97,438</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">365,701</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">163,494</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office minimum lease payments</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">74,567</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,069</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">147,316</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98,138</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s51C9B9E563E85A201F9F811689AABEA8"></a></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 14:  Related Party Transactions</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Compensation of Key Management Personnel</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Key management personnel are those persons having authority and responsibility for planning, directing and controlling our activities as a whole.  We have determined that key management personnel consists of the members of the Board of Directors along with certain officers of the Company.   </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:643px;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:273px;"></td><td style="width:91px;"></td><td style="width:4px;"></td><td style="width:86px;"></td><td style="width:4px;"></td><td style="width:87px;"></td><td style="width:4px;"></td><td style="width:87px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Month Period Ending June 30, 2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Month Period Ending June 30, 2017<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Month Period Ending June 30, 2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Month Period Ending June 30, 2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term employee compensation and benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">445,493</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">528,407</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">956,555</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,110,802</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Termination benefits</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">779,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">779,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">119,867</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113,172</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">486,682</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">211,663</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">565,360</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,421,245</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,443,237</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,102,131</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Assumption Agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2017, with the signing of a regional licensing agreement with upfront license fees (see Note 8), the Company triggered a liability of US</font><font style="font-family:inherit;font-size:10pt;">$178,125</font><font style="font-family:inherit;font-size:10pt;">&#32;to an officer as detailed in the Assumption Agreement (see Note 12 of our audited consolidated financial statements for the year ended December 31, 2017). As at June 30, 2018, US$</font><font style="font-family:inherit;font-size:10pt;">142,500</font><font style="font-family:inherit;font-size:10pt;">&#32;was included in accounts payable and accrued liabilities. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ex992-q22018mda.htm
<DESCRIPTION>2018 SECOND QUARTER MD&A
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s2A55C0C6A4DD098945E481169E254A0B"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;"><img src="oncolyticslogobluea02.jpg" alt="oncolyticslogobluea02.jpg" style="height:290px;width:665px;"></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">MANAGEMENT DISCUSSION &amp; ANALYSIS</font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;color:#000000;font-weight:bold;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:16pt;font-weight:bold;">&#32;</font></div><div><br></div><hr style="page-break-after:always"><div><a name="sF861FB3E20BD0FA4BAD581169E57AE73"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;color:#000000;font-weight:bold;text-decoration:none;">August&#160;2, 2018</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This discussion and analysis should be read in conjunction with the unaudited interim consolidated financial statements of Oncolytics Biotech</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;Inc. as at and for the three and six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, and and should also be read in conjunction  with the audited consolidated financial statements and Management's Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&amp;A&#8221;) contained in our annual report for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. The financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS"). </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s4E13CDABF855B207B0A981169E77A908"></a></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">FORWARD-LOOKING STATEMENTS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following discussion contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and under applicable Canadian provincial securities legislation.  Forward-looking statements, including our belief as to the potential of REOLYSIN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">(pelareorep), an intravenously delivered immuno-oncolytic virus, as a cancer therapeutic and our expectations as to the success of our research and development, clinical and manufacturing programs in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and beyond, future financial position, business strategy and plans for future operations, and statements that are not historical facts, involve known and unknown risks and uncertainties, which could cause our actual results to differ materially from those in the forward-looking statements.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Such risks and uncertainties include, among others, the need for and availability of funds and resources to pursue research and development projects, the efficacy of pelareorep </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></font><font style="font-family:inherit;font-size:10pt;">as a cancer treatment, the success and timely completion of clinical studies and trials, our ability to successfully commercialize pelareorep, uncertainties related to the research, development and manufacturing of pelareorep, uncertainties related to competition, changes in technology, the regulatory process and general changes to the economic environment.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to the forward-looking statements made within this MD&amp;A, we have made numerous assumptions regarding among other things: our ability to obtain financing to fund our clinical development plan, our ability to receive regulatory approval to commence enrollment in the clinical studies which are part of our clinical development plan, our ability to maintain our supply of pelareorep and future expense levels being within our current expectations.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investors should consult our quarterly and annual filings with the Canadian and US securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Forward-looking statements are based on assumptions, projections, estimates and expectations of management at the time such forward-looking statements are made, and such assumptions, projections, estimates and/or expectations could change or prove to be incorrect or inaccurate. Investors are cautioned against placing undue reliance on forward-looking statements.  We do not undertake to update these forward-looking statements except as required by applicable law.</font></div><div><a name="s997B1BD5064931488F3481169EB72066"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">REOLYSIN Development Update For </font><font style="font-family:inherit;font-size:16pt;color:#000000;font-weight:bold;text-decoration:none;">2018</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Oncolytics Biotech Inc. is a Development Stage Company</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since our inception in April of 1998, Oncolytics Biotech Inc. has been a development stage company. We have focused our research and development efforts on the development of REOLYSIN, also known as pelareorep, an intravenously delivered immuno-oncolytic (I-O) virus with the potential to treat a variety of cancers. We have not been profitable since our inception and expect to continue to incur substantial losses as we continue research and development efforts. We do not expect to generate significant revenues until, and unless, pelareorep becomes commercially viable.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our goal each year is to advance pelareorep through the various steps and stages of development required for potential pharmaceutical products.  In order to achieve this goal, we believe that we have to actively manage the development of our clinical trial program, our pre-clinical and collaborative programs, our manufacturing process and pelareorep</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></font><font style="font-family:inherit;font-size:10pt;">supply, and our intellectual property.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><a name="sD2D3CC78555AC80148F381169EDDFA04"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Clinical Trial Program</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our clinical development plan objectives are twofold. First, we are seeking to obtain regulatory approval for pelareorep based on the compelling metastatic breast cancer survival data that was presented at the 2017 American Association for Cancer Research (AACR) Annual Meeting, in Washington, D.C. Second, we are looking to expand pelareorep into commercially valuable new treatment areas that include immuno-therapy along with immuno-modulatory (IMiD) and other targeted agents in collaboration with pharmaceutical partners. Our clinical development program focuses on the three components of pelareorep's mechanism of action (MOA) and includes the following:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Chemotherapy combinations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chemotherapy combinations focus on the investigation of chemotherapy combination clinical trials investigating the use of different chemotherapy agents in various cancer indications. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Targeted/IMiD combinations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Targeted/IMiD combinations focus on the potential of pelareorep to stimulate a patient's innate immunity and the potential for an infection to cause a cascade of chemokines/cytokines activating natural killer (NK) cells to attack cancer cells.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Immunotherapy combinations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Immunotherapy combinations focus on the potential for pelareorep to cause a specific adaptive immune response triggered by tumor- and viral-associated antigens displayed by antigen-presenting cells (APCs), infected tumor cells and/or dendritic cells to T cells.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-style:italic;font-weight:bold;">Second Quarter 2018 Developments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Chemotherapy Combinations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Metastatic Breast Cancer</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2017, we reported a statistically significant increase of 7 months (10.4 months to 17.4 months) in median overall survival from an open-label, randomized phase 2 metastatic breast cancer (mBC) study of intravenously-administered pelareorep given in combination with the chemotherapy agent paclitaxel. Pelareorep was awarded fast track designation by the United States Food and Drug Administration (FDA) for the treatment of mBC. We announced a productive End-of-Phase 2 meeting with the FDA for pelareorep in combination with paclitaxel, for the treatment of hormone receptor positive, HER2 receptor negative (HR+/HER2-) metastatic breast cancer (mBC) patients. The purpose of the meeting was to discuss the preclinical and clinical programs, including the design of the phase 3 registration study to support a future Biologics License Application (BLA) submission in the U.S. We also received a supportive Final Advice Letter from the European Medicines Agency (EMA) suggesting that a phase 3 study may be acceptable to form the basis of  a Marketing Authorization Application (MAA) in Europe for the proposed use of pelareorep in combination with paclitaxel for the treatment of HR+/HER2- mBC. As a result of our statistically significant phase 2 data supported by a fast track designation, productive End-of-Phase 2 meeting with the FDA and supportive Final Advice Letter from the EMA, our objective is to advance pelareorep in combination with paclitaxel, into a phase 3 registration study for the treatment of HR+/HER2- mBC.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2018, we reached agreement with the FDA under a Special Protocol Assessment for the protocol design, clinical endpoints and statistical analysis approach for our phase 3 clinical study evaluating pelareorep for the treatment of metastatic breast cancer.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Targeted/IMiD combinations </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The initial activity supporting the innate immunity component of REOLYSIN's MOA, is in collaboration with Celgene Corporation (Celgene) and Myeloma UK, a cancer charity. MUK </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">eleven</font><font style="font-family:inherit;font-size:10pt;">&#32;was launched in March of 2017: a first of its kind immuno-therapy trial that aims to modulate the immune system to target myeloma. The Phase 1b trial will study REOLYSIN in combination with Celgene's Imnovid</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(pomalidomide) or Revlimid</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(lenalidomide) as a rescue treatment in relapsing myeloma patients. The dose escalation trial will look at the safety and tolerability of these combinations, and will investigate whether the addition of REOLYSIN extends disease control in this patient group. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The trial, which commenced enrollment in September 2017 and continued to enroll through the second quarter of 2018, will recruit approximately 44 patients across up to six Myeloma UK Clinical Trial Network centres in the UK. MUK </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">eleven</font><font style="font-family:inherit;font-size:10pt;">&#32;is part of the Myeloma UK Clinical Trial Network, a portfolio of early-stage trials coordinated by the Clinical Trials Research Unit at the University of Leeds, which aims to test and speed up access to promising new treatments for patients.  Oncolytics and Celgene </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">UK &amp; Ireland are providing their respective products for MUK </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">eleven</font><font style="font-family:inherit;font-size:10pt;">: Oncolytics is providing REOLYSIN and Celgene UK &amp; Ireland is providing Imnovid</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;and Revlimid</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Immunotherapy combinations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In support of the adaptive immunity component of the MOA, we expanded out immunotherapy combinations to include two additional research collaborations.  In May 2018, we announced an investigator sponsored study supported by Merck Inc., Northwestern University and Oncolytics. This study is an extension of the REO 024 study that will investigate pelareorep in combination with Merck&#8217;s anti-PD1 checkpoint inhibitor Keytruda</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, to treat second line pancreatic cancer patients. The study will plan to enroll approximately 40 patients with advanced pancreatic cancer and will be conducted at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As well, during the second quarter of 2018, we announced a collaboration with the Keck School of Medicine of University of Southern California (USC) using pelareorep in combination with Keytruda</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, Velcade</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;and dexamethasone, to treat multiple myeloma. This study is an extension of the current REO 019 study evaluating pelareorep in combination with Velcade and dexamethasone to treat multiple myeloma and will be conducted at the USC Norris Comprehensive Cancer Center.&#160; It will add Keytruda which is being provided by Merck.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Pre-clinical/Research collaborations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">During the second quarter of 2018, the following presentations were made:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:14%;"></td><td style="width:16%;"></td><td style="width:15%;"></td><td style="width:55%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Presenter</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Location</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Description/Conclusion</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Potentiating effect of reovirus in anti-PD1 therapy in colorectal cancer</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sanjay Goel, MD, Associate Professor of Medicine, Montefiore Medical Center</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">American Association for Cancer Research (AACR) Annual Meeting 2018, Chicago, Illinois</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Data presented in the poster demonstrated:</font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">pelareorep administration increased PD-L1 expression on MSS CRC cells;</font></font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">possible evidence of a vaccine effect: immunologically competent mice were re-challenged with the original tumor and the tumor was unable to propagate;</font></font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">combination therapy made statistically significant improvements in survival compared to controls in both BALB/c (median 42 vs. 16 days, p="0".003) and C57BL/6 (median 24 vs. 17 days, p="0".02) mice; and</font></font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">pelareorep treated xenografted tumor tissue showed a higher infiltration of T lymphocytes as confirmed by CD8-positive and intensified granzyme staining.</font></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Pelareorep promotes the expression of a chemokine signature that predicts response to immunotherapy</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Grey Wilkinson, PhD, Translational Scientist, Oncolytics Biotech</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">American Association for Cancer Research (AACR) Annual Meeting 2018, Chicago, Illinois</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Data presented in the poster demonstrated:</font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">the expression of a chemokine signature that predicts response to immunotherapy;</font></font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">global changes in gene expression are unique and different for each cell line following pelareorep infection and changes in gene expression occur before significant cell lysis;</font></font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">pelareorep differentially promotes the expression of innate and adaptive immunity related genes in HCC, CRC, NSCLC cell lines; and</font></font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">pelareorep promotes the expression of gene signatures that predict response to immuno-therapies in HCC cells.</font></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:14%;"></td><td style="width:16%;"></td><td style="width:15%;"></td><td style="width:55%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">B and T lymphocyte attenuator (BTLA) and PD-L1 significantly upregulated in reovirus treated TRAMP-C2 tumours</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Guy Simpson, Department of Clinical and Experimental Medicine, University of Surrey</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11th International Oncolytics Virus Conference (IOVC), Oxford, UK</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Data presented in the poster demonstrated:</font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">treatment of subcutaneous TRAMP-C2 prostate tumors with a combination of pelareorep and anti-PD-1 (Keytruda&#174;) or anti-CD73 antibody significantly enhanced survival of mice compared to pelareorep or antibody therapy alone;</font></font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">immune profiling of pelareorep treated and untreated tumors confirmed the ability of pelareorep to increase tumour immune cell infiltration;</font></font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">pelareorep infection of tumours is needed before a therapeutic effect of anti-immune inhibitory/suppressive antibodies is seen;</font></font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">pelareorep-initiated antitumor immunity protects against subsequent tumour challenge; and</font></font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">after the study of negative regulators, only B and T lymphocyte attenuator (BTLA) and PD-L1 were significantly upregulated in the pelareorep treated TRAMP-C2 tumors compared to untreated tumour.</font></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Pelareorep to promote the expression of a IFN-gamma-related gene signature that predicts response to checkpoint blockade therapy</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Grey Wilkinson, PhD, Translational Scientist, Oncolytics Biotech</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">American Society of Clinical Oncoloty (ASCO) 2018 Annual Meeting, Chicago, Illinois</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Highlights in the poster include:</font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">Pelareorep promotes expression of gene signatures that are predictive of response to checkpoint inhibitors in select cell lines</font></font></div><div style="padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">- HCC - hepatocellular carcinoma</font></div><div style="padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">- HR+BC - hormone receptor positive breast cancer</font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">Pronounced tumor inflammatory effects of pelareorep in HR+ BC cells may explain the prominent increase in overall survival in a previous phase 2 randomized clinical study in HR+ mBC patients treated with pelareorep and may render this large breast cancer population susceptible to conventional immunotherapy regimes</font></font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">Results warrant further investigation of pelareorep in combination with checkpoint inhibitors</font></font></div><div style="padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sA28100323FA1385A14EB81169EFDE1BD"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Manufacturing and Process Development </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the second quarter of 2018, we supplied our clinical development program with previously filled product from our existing supply of REOLYSIN, labeled for the applicable usage. As well, we continued our activities to source and develop commercial production capabilities to fill REOLYSIN into vials, the next step in the process validation master plan. Process validation is required to ensure that the resulting product meets required specifications and quality standards and will form part of the Company&#8217;s submission to regulators, including the FDA, for product approval. We also commenced startup activities for drug product filling to support ongoing and upcoming clinical development projects. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s1850C624A9BAC7F83AE981169F1F3C43"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Intellectual Property</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the end of the second quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;">, we had been issued over </font><font style="font-family:inherit;font-size:10pt;">396</font><font style="font-family:inherit;font-size:10pt;">&#32;patents including </font><font style="font-family:inherit;font-size:10pt;">49</font><font style="font-family:inherit;font-size:10pt;">&#32;US and </font><font style="font-family:inherit;font-size:10pt;">21</font><font style="font-family:inherit;font-size:10pt;">&#32;Canadian patents as well as issuances in other jurisdictions. We have an extensive patent portfolio covering the oncolytic reovirus that we use in our clinical trial program including a composition of matter patent that expires in 2028.  Our patent portfolio also includes methods for treating proliferative disorders using modified adenovirus, HSV, parapoxvirus and vaccinia virus.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sD33BAB3259A5FBB626CE81169F50146D"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Financing Activity</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share Consolidation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 22, 2018, we completed a consolidation of our common shares on the basis of 9.5 pre-consolidation common shares for each one post-consolidation common share (the "Share Consolidation"). Fractional interests were rounded down to the nearest whole number of common shares. Outstanding stock options, restricted share units and performance share units were similarly adjusted by the consolidation ratio. Outstanding warrants were adjusted such that, following the Share Consolidation, 9.5 pre-consolidation warrants entitle the holder to purchase one post-consolidation common share until June 1, 2022.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Listing on the Nasdaq Capital Market</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 1, 2018, we announced that our common shares were approved for listing and commenced trading on the Nasdaq Capital Market. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Public offering</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 5, 2018, we closed a public offering whereby we sold 1,532,278 common shares at a purchase price of US$5.83 per share for gross proceeds of US$8,933,181. We incurred share issue costs of </font><font style="font-family:inherit;font-size:10pt;">$1,418,356</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">"At-the-Market" equity distribution agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 25, 2016, we entered into an "at-the-market" equity distribution agreement with Canaccord Genuity Inc. acting as sole agent in Canada (our "Canadian ATM"). Under the terms of our Canadian ATM, we may, from time to time, sell shares of our common stock having an aggregate offering value of up to $4.6 million through Canaccord Genuity Inc. Sales of  common shares, if any, pursuant to the Canadian ATM, will be made in transactions that are deemed to be "at-the-market distributions", through the facilities of the Toronto Stock Exchange or other "marketplace" (as defined in National Instrument 21-101 Marketplace Operation) in Canada. We will determine, at our sole discretion, the timing and number of shares to be sold under this ATM facility.   During the six month period ending June 30, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, we sold </font><font style="font-family:inherit;font-size:10pt;">519,500</font><font style="font-family:inherit;font-size:10pt;">&#32;pre-consolidation common shares (approximately 54,684 post-consolidation common shares) for gross proceeds of $</font><font style="font-family:inherit;font-size:10pt;">553,650</font><font style="font-family:inherit;font-size:10pt;">. We incurred share issue costs of $</font><font style="font-family:inherit;font-size:10pt;">33,335</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Options</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the second quarter of 2018, we received cash proceeds of $23,910 with respect to the exercise of 71,000 pre-consolidation options (approximately 7,473 post-consolidation options) by a former employee.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Warrants</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the second quarter of 2018, we received cash proceeds of $1,417 with respect to the exercise of 1,500 warrants.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sA980B6532C9BF21984EA81169F71DD36"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Financial Impact</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We estimated at the beginning of the second quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;that our cash requirements to fund our operations for the year will be between $14 - $16 million depending on our ultimate clinical program. Our cash usage for the six month period ending June 30, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$4,019,494</font><font style="font-family:inherit;font-size:10pt;">&#32;for operating activities and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$80,062</font><font style="font-family:inherit;font-size:10pt;">&#32;for the acquisition of property and equipment. Our net loss for the period was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$8,882,113</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sAB2F20652F6F87C5059881169FB1ECFF"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Cash Resources </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We exited the second quarter of </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;with cash and cash equivalents totaling </font><font style="font-family:inherit;font-size:10pt;">$18,741,347</font><font style="font-family:inherit;font-size:10pt;">&#32;(see </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Liquidity and Capital Resources&#8221;)</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s55696CEF402F393529A081169FD18EB7"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">REOLYSIN Development for the Remainder of 2018</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our planned 2018 development activity for REOLYSIN focuses on our clinical development plan along with our  manufacturing and intellectual property programs. For the remainder of 2018, our clinical objective  is to incorporate our immuno-oncology combination strategy that includes checkpoint inhibitors, targeted therapies and other anti-cancer agents as we finalize our registration strategy and clinical protocol in preparation for a phase 3 clinical study in mBC. We expect to enter into additional clinical collaborations examining potential biomarkers and commence enrollment in our combination studies with Keytruda in second line pancreatic cancer and multiple myeloma.   Our expectation is that these combination studies will assist us in refining our phase 3 protocol for mBC and may also support further development around the innate and adaptive immunity components of the mechanism of action. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our 2018 manufacturing program includes preparation for continued production of 100-litre cGMP batches along with the related analytical testing and product filling, as well as labeling, packaging and shipping of REOLYSIN to our various clinical sites for ongoing and upcoming activities. These actions also contribute to progression through our process validation master plan and related conformity testing in 2018. Finally, our intellectual property program includes filings for additional patents along with monitoring activities required to protect our patent portfolio.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s8ACFAAC91BD8526A698881169FF6AED4"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Second Quarter Results of Operations</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(for the three months ended June 30, 2018 and 2017)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss for the three month period ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$4,211,439</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$4,349,142</font><font style="font-family:inherit;font-size:10pt;">&#32;for the three month period ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Research and Development Expenses (&#8220;R&amp;D&#8221;)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:544px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:384px;"></td><td style="width:75px;"></td><td style="width:4px;"></td><td style="width:75px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trial expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">813,555</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">725,358</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturing and related process development expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">441,066</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">421,468</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">183,712</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244,495</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research collaboration expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">37,681</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,573</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other R&amp;D expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">699,425</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,488,106</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange gain</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(159,573</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(74,597</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">29,551</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,270</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,045,417</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,918,673</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Clinical Trial Expenses</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:79.8828125%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:70%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trial expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">813,555</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">725,358</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our clinical trial expenses for the second quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$813,555</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$725,358</font><font style="font-family:inherit;font-size:10pt;">&#32;for the second quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">. Our clinical trial program activities related primarily to the preparation and development of our breast cancer registration study. In the second quarter of 2018, these costs included phase 3 startup activities and activities related to obtaining the Special Protocol Assessment from the FDA, and in the second quarter of 2017 included costs to complete our supporting regulatory documents, regulatory filing fees and key opinion leader activities. During the second quarters of 2018 and 2017, our clinical trial activities also included patient enrollment in our checkpoint inhibitor pancreatic cancer study investigating pembrolizumab (KEYTRUDA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">) in combination with REOLYSIN.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Manufacturing &amp; Related Process Development Expenses (&#8220;M&amp;P&#8221;)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.90625%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:70%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product manufacturing expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">384,609</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">344,328</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Process development expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">56,457</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77,140</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturing and related process development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">441,066</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">421,468</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our M&amp;P expenses for the second quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$441,066</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$421,468</font><font style="font-family:inherit;font-size:10pt;">&#32;for the second quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">. During the second quarter of 2018, our product manufacturing costs included shipping and storage costs of our bulk and vialed product along with startup costs for a product fill required to support our clinical development plan.  We were able to partially offset these costs by entering into a contract with a new storage depot with lower fees. During the second quarter of 2017, our product manufacturing costs mainly related to shipping and storage costs of our bulk and vialed product.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our process development expenses for the second quarter of 2018 focused on analytic development and stability studies and in the second quarter of 2017 focused on stability studies. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intellectual Property Expenses</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.7109375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:70%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">183,712</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244,495</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our intellectual property expenses for the second quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$183,712</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$244,495</font><font style="font-family:inherit;font-size:10pt;">&#32;for the second quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">. The change in intellectual property expenditures reflects the timing of filing costs associated with our patent base. At the end of the second quarter of </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, we had been issued over </font><font style="font-family:inherit;font-size:10pt;">396</font><font style="font-family:inherit;font-size:10pt;">&#32;patents including </font><font style="font-family:inherit;font-size:10pt;">49</font><font style="font-family:inherit;font-size:10pt;">&#32;US and </font><font style="font-family:inherit;font-size:10pt;">21</font><font style="font-family:inherit;font-size:10pt;">&#32;Canadian patents, as well as issuances in other jurisdictions. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research Collaboration Expenses </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.7109375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:70%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research collaboration expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">37,681</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,573</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our research collaboration expenses were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$37,681</font><font style="font-family:inherit;font-size:10pt;">&#32;for the second quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$55,573</font><font style="font-family:inherit;font-size:10pt;">&#32;for the second quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">.  Our research collaborations during the second quarters of 2018 and 2017 included biomarker studies and studies investigating the interaction of the immune system and pelareorep. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Research and Development Expenses</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.7109375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:70%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">R&amp;D salaries and benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">640,710</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,393,431</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other R&amp;D expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">58,715</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,675</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other research and development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">699,425</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,488,106</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our other research and development expenses were </font><font style="font-family:inherit;font-size:10pt;">$699,425</font><font style="font-family:inherit;font-size:10pt;">&#32;for the second quarter of </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$1,488,106</font><font style="font-family:inherit;font-size:10pt;">&#32;for the second quarter of </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">. The change in our R&amp;D salaries and benefits was mainly due to severance payments to certain officers of the Company who were terminated during the second quarter of 2017. The change in our Other R&amp;D expenses was due to a decrease in meeting attendance and related travel expenses.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Foreign Exchange Gain</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.7109375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:70%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange gain</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(159,573</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(74,597</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">Our foreign exchange gain was </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:normal;">$159,573</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#32;for the second quarter of 2018 compared to </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:normal;">$74,597</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#32;for the second quarter of 2017.  The change in foreign exchange gain was primarily due to the fluctuation in the U.S. dollar exchange rate on the translation of U.S. currency received from our June 2018 public offering and the settlement of our contract receivable. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Based Payments</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.7109375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:70%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">29,551</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,270</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash share based payment expenses for the second quarter of 2018 were $</font><font style="font-family:inherit;font-size:10pt;">29,551</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to $</font><font style="font-family:inherit;font-size:10pt;">58,270</font><font style="font-family:inherit;font-size:10pt;">&#32;for the second quarter of 2017. We incurred share based payment expenses associated with the granting of options and restricted share units to officers and employees associated with our research and development activities and the vesting of previously granted options and share awards. In the second quarter of 2018, we also recognized a recovery of share based payment expenses due to the departure of the Chief Medical Officer and the forfeiture of unvested share awards and options.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Operating Expenses</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:537px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:377px;"></td><td style="width:75px;"></td><td style="width:4px;"></td><td style="width:75px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Public company related expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">767,896</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">760,560</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">722,239</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">560,857</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">21,126</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,688</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">127,541</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97,438</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,638,802</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,444,543</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our operating expenses for the second quarter of </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;">$1,638,802</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$1,444,543</font><font style="font-family:inherit;font-size:10pt;">&#32;for the second quarter of </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">. Public company related expenses include costs associated with investor relations, business development and financial advisory activities, legal and accounting fees, corporate insurance, director fees and transfer agent and other fees relating to our Canadian and U.S. stock listings. Our public company related expenses were $</font><font style="font-family:inherit;font-size:10pt;">767,896</font><font style="font-family:inherit;font-size:10pt;">&#32;for the second quarter of 2018 compared to $</font><font style="font-family:inherit;font-size:10pt;">760,560</font><font style="font-family:inherit;font-size:10pt;">&#32;for the second quarter of 2017. The change in our public company related expenses in the second quarter of 2018 was due to an increase in expenses related to the Nasdaq listing and an increase in travel expenses offset by a decrease in business development activities.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office expenses include compensation costs (excluding share based payments), office rent and other office related costs. During the second quarter of 2018, our office expenses were $</font><font style="font-family:inherit;font-size:10pt;">722,239</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to $</font><font style="font-family:inherit;font-size:10pt;">560,857</font><font style="font-family:inherit;font-size:10pt;">&#32;for the second quarter of 2017. The change was due to an investment in our business development department and an increase in office expenses related to the opening of our U.S. office.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash share based payment expenses in the second quarter of 2018 were $</font><font style="font-family:inherit;font-size:10pt;">127,541</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to $</font><font style="font-family:inherit;font-size:10pt;">97,438</font><font style="font-family:inherit;font-size:10pt;">&#32;in the second quarter of 2017. We incurred share based payment expenses associated with the granting of options to officers and employees and the vesting of previously granted options and share awards.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s9cea9d3e347b4f638164b99fa67ca0d3"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Results of Operations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(for the six month period ending </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2017</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">)</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$8,882,113</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$7,866,861</font><font style="font-family:inherit;font-size:10pt;">&#32;for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">.     </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Research and Development Expenses (&#8220;R&amp;D&#8221;)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:544px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:384px;"></td><td style="width:75px;"></td><td style="width:4px;"></td><td style="width:75px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trial expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,846,300</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,411,531</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturing and related process development expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">858,769</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">875,032</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property expenditures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">590,227</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">496,085</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research collaboration expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">227,728</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,952</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other R&amp;D expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,411,276</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,182,241</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange gain</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(284,501</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(47,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">330,509</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">126,103</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,980,308</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,186,744</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Clinical Trial Program</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:529px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:376px;"></td><td style="width:75px;"></td><td style="width:4px;"></td><td style="width:68px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trial expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,846,300</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,411,531</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our clinical trial expenses were </font><font style="font-family:inherit;font-size:10pt;">$1,846,300</font><font style="font-family:inherit;font-size:10pt;">&#32;for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$1,411,531</font><font style="font-family:inherit;font-size:10pt;">&#32;for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">. Our clinical trial activities related primarily to the preparation and development of our breast cancer registration study. During the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, these costs included phase 3 startup activities and activities related to obtaining the Special Protocol Assessment from the FDA, and in the six month period ending June 30, 2017 included costs to complete our supporting regulatory documents, regulatory filing fees and key opinion leader activities.  During the six month periods ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, our clinical activities included patient enrollment in our checkpoint inhibitor pancreatic cancer study investigating pembrolizumab (KEYTRUDA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">) in combination with REOLYSIN. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We still expect our clinical trial expenses to increase in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">. For the remainder of </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, we expect to enter into additional clinical collaborations examining potential biomarkers and commence enrollment in our combination studies with Keytruda in second line pancreatic cancer and multiple myeloma as we finalize our registration strategy and clinical protocol in preparation for a phase 3 clinical study in mBC. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Manufacturing &amp; Related Process Development (&#8220;M&amp;P&#8221;)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.3203125%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:71%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product manufacturing expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">637,312</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">648,829</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Process development expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">221,457</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">226,203</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturing and related process development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">858,769</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">875,032</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our M&amp;P expenses for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;">$858,769</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$875,032</font><font style="font-family:inherit;font-size:10pt;">&#32;for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">. During the six month periods ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, our product manufacturing costs included shipping and storage costs of our bulk and vialed product along with startup costs for a product fill required to support our clinical development plan.  We were able to largely offset these costs by entering into a contract with a new storage depot with lower fees. During the six month period ending June 30, 2017, our product manufacturing costs mainly related to shipping and storage costs of our bulk and vialed product.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our process development expenses for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;">$221,457</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$226,203</font><font style="font-family:inherit;font-size:10pt;">&#32;for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">. During the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, our process development activities focused on analytic development and stability studies. During the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, our activities focused on stability studies.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We still expect our M&amp;P expenses for </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;to increase compared to 2017. In </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, we expect to fill, label and store sufficient product as we commence enrollment in our clinical development program and produce sufficient supply to support our registration efforts in breast cancer.  We also expect to continue to perform stability testing and analytical development related to our process validation master plan and stability program.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intellectual Property Expenses</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.734375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:74%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">590,227</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">496,085</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our intellectual property expenses for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;">$590,227</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$496,085</font><font style="font-family:inherit;font-size:10pt;">&#32;for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">.  The change in intellectual property expenditures reflects the timing of filing costs associated with our patent base. At the end of the first half of 2018, we had been issued over </font><font style="font-family:inherit;font-size:10pt;">396</font><font style="font-family:inherit;font-size:10pt;">&#32;patents including </font><font style="font-family:inherit;font-size:10pt;">49</font><font style="font-family:inherit;font-size:10pt;">&#32;U.S. and </font><font style="font-family:inherit;font-size:10pt;">21</font><font style="font-family:inherit;font-size:10pt;">&#32;Canadian patents, as well as issuances in other jurisdictions.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We still expect that our intellectual property expenses will remain consistent in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research Collaborations</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.34375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:76%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research collaborations</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">227,728</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,952</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our research collaboration expenses for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;">$227,728</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$142,952</font><font style="font-family:inherit;font-size:10pt;">&#32;for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">. During the six month periods ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and 2017, our research collaborations included biomarker studies and studies investigating the interaction of the immune system and pelareorep. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We still expect that our research collaborations in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;will increase compared to 2017. We expect to complete our ongoing collaborative program carried over from 2017 and will continue to be selective in the types of new collaborations we enter into in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Research and Development Expenses</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.9296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:70%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">R&amp;D salaries and benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,300,870</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,059,249</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other R&amp;D expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">110,406</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122,992</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other research and development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,411,276</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,182,241</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Other Research and Development expenses for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;">$1,411,276</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$2,182,241</font><font style="font-family:inherit;font-size:10pt;">&#32;for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">. The change in our R&amp;D salaries and benefits was mainly due to severance payments to certain officers of the Company who were terminated during the second quarter of 2017. The change in our Other R&amp;D expenses was due to a decrease in meeting attendance and related travel expenses.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We now expect our Other R&amp;D expenses to remain consistent in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to 2017.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Foreign Exchange Gain</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.9296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:70%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange gain</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(284,501</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(47,200</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">Our foreign exchange gain for the six month period ending June 30, 2018 was </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">$284,501</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">$47,200</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#32;for the six month period ending June 30, 2017. The change in foreign exchange gain was primarily due to the fluctuation in the U.S. dollar exchange rate on the translation of U.S. currency received from our June 2018 public offering and the settlement of our contract receivable. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Based Payments</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:518px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:378px;"></td><td style="width:68px;"></td><td style="width:4px;"></td><td style="width:62px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">330,509</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">126,103</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, our non-cash share based payment expenses were </font><font style="font-family:inherit;font-size:10pt;">$330,509</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$126,103</font><font style="font-family:inherit;font-size:10pt;">&#32;for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">. We incurred share based payment expenses associated with the granting of options and share awards to officers and employees associated with our research and development activities and the vesting of previously granted options and share awards. In the second quarter of 2018, we also recognized a recovery of share based payment expenses due to the departure of the Chief Medical Officer and the forfeiture of unvested share awards and options. We granted 202,855 options and share awards in the six month period ending June 30, 2018 compared to 1,578 options and share awards in the six month period ending June 30, 2017.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Operating Expenses</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.9296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:70%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Public company related expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,565,730</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,454,935</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,428,940</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,076,690</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">40,984</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,724</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">365,701</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">163,494</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,401,355</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,744,843</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our operating expenses for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;were $</font><font style="font-family:inherit;font-size:10pt;">3,401,355</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to $</font><font style="font-family:inherit;font-size:10pt;">2,744,843</font><font style="font-family:inherit;font-size:10pt;">&#32;for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">. Public company related expenses include costs associated with investor relations, business development and financial advisory activities, legal and accounting fees, corporate insurance, director fees and transfer agent and other fees relating to our U.S. and Canadian stock listings. During the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, our public company related expenses were </font><font style="font-family:inherit;font-size:10pt;">$1,565,730</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$1,454,935</font><font style="font-family:inherit;font-size:10pt;">&#32;for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">. The change was due to an increase in expenses related to the Nasdaq listing, an increase in legal fees and costs related to the special meeting of shareholders held in February 2018 and an increase in travel expenses, partly offset by a decrease in business development activities.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office expenses include compensation costs (excluding share based payments), office rent, and other office related costs. During the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, we incurred office expenses of </font><font style="font-family:inherit;font-size:10pt;">$1,428,940</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$1,076,690</font><font style="font-family:inherit;font-size:10pt;">&#32;during the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">. The change was due to an investment in our business development department and an increase in office expenses related to the opening of our U.S. office.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, our non-cash share based payment expenses were </font><font style="font-family:inherit;font-size:10pt;">$365,701</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$163,494</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">. We incurred share based payment expenses associated with the granting of stock options to officers and employees and the vesting of previously granted options and share awards. We granted 119,903 options and share awards in the six month period ending June 30, 2018 compared to 28,684 options and share awards in the six month period ending June 30, 2017.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We still expect our operating expenses in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;to increase compared to 2017.    </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, we are committed to payments totaling approximately $</font><font style="font-family:inherit;font-size:10pt;">6,063,389</font><font style="font-family:inherit;font-size:10pt;">&#32;for activities related to our clinical trial, manufacturing and collaboration programs which are expected to occur over the next two years. We are committed to rental payments (excluding our portion of operating costs and rental taxes) under the terms of our office leases totaling $</font><font style="font-family:inherit;font-size:10pt;">1,183,174</font><font style="font-family:inherit;font-size:10pt;">&#32;for 2018 to 2021. All of these committed payments are considered to be part of our normal course of business.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s4DD69EE9D85B986E990F8116A0398E71"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Summary of Quarterly Results</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:647px;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:246px;"></td><td style="width:9px;"></td><td style="width:36px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:36px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:36px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:36px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:36px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:36px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:36px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:36px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="6" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td colspan="12" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td colspan="6" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mar</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dec</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Sept</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mar</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dec</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Sept</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,211</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,671</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,746</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,004</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,349</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,518</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,210</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,332</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted loss per common share</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,693</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,127</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,150</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,848</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,579</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,623</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,758</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,437</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1), (3)</sup></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,741</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,745</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,836</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,034</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,676</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,102</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,123</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,702</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term debt</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash dividends declared</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;padding-left:36px;"><div style="line-height:120%;text-align:left;font-size:8pt;text-indent:-36px;"><font style="font-family:inherit;font-size:8pt;">Included in total cash are cash and cash equivalents plus short-term investments.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The calculation of basic and diluted loss per common share for all periods has been adjusted retrospectively for the Share Consolidation. Included in net loss and loss per common share between June 2018 and July 2016 are quarterly share based payment expenses of </font><font style="font-family:inherit;font-size:8pt;">$157,092</font><font style="font-family:inherit;font-size:8pt;">, $539,118, $140,659, $148,447, $155,708, $133,889, $106,443 and $98,369, respectively.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><font style="font-family:inherit;font-size:8pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">We issued </font><font style="font-family:inherit;font-size:8pt;">590,500</font><font style="font-family:inherit;font-size:8pt;">&#32;pre-consolidation common shares (approximately 62,157 post-consolidation common shares) for net cash proceeds of </font><font style="font-family:inherit;font-size:8pt;">$0.5 million</font><font style="font-family:inherit;font-size:8pt;">&#32;and </font><font style="font-family:inherit;font-size:8pt;">1,532,435</font><font style="font-family:inherit;font-size:8pt;">&#32;post-consolidation common shares for net cash proceeds of </font><font style="font-family:inherit;font-size:8pt;">$10.2 million</font><font style="font-family:inherit;font-size:8pt;">&#32;in </font><font style="font-family:inherit;font-size:8pt;">2018</font><font style="font-family:inherit;font-size:8pt;">&#32;(</font><font style="font-family:inherit;font-size:8pt;">2017</font><font style="font-family:inherit;font-size:8pt;">&#32;- </font><font style="font-family:inherit;font-size:8pt;">20,547,500</font><font style="font-family:inherit;font-size:8pt;">&#32;pre-consolidation common shares (approximately 2,162,894 post-consolidation common shares) for net cash proceeds of $</font><font style="font-family:inherit;font-size:8pt;">12.8 million</font><font style="font-family:inherit;font-size:8pt;">).  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><font style="font-family:inherit;font-size:8pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">We have not declared or paid any dividends since incorporation.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div><a name="s24898810104A36C5B1FD8116A067C765"></a></div><div style="line-height:120%;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div><a name="sE8C9A0ACC1AD213E66DB8116A06DBBB2"></a></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">&#32;Financing Activities </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share Consolidation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 22, 2018, we completed a consolidation of our common shares on the basis of 9.5 pre-consolidation common shares for each one post-consolidation common share (the "Share Consolidation"). Fractional interests were rounded down to the nearest whole number of common shares. Outstanding stock options, restricted share units and performance share units were similarly adjusted by the consolidation ratio. Outstanding warrants were adjusted such that, following the Share Consolidation, 9.5 pre-consolidation warrants entitle the holder to purchase one post-consolidation common share until June 1, 2022.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Listing on the Nasdaq Capital Market</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 1, 2018, we announced that our common shares were approved for listing and commenced trading on the Nasdaq Capital Market. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Public offering</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 5, 2018, we closed a public offering whereby we sold 1,532,278 post-consolidation common shares at a purchase price of US$5.83 per share for gross proceeds of US$8,933,181. We incurred share issue costs of </font><font style="font-family:inherit;font-size:10pt;">$1,418,356</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Canadian "At-the-Market" equity distribution agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the six month period ending June 30, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, we sold </font><font style="font-family:inherit;font-size:10pt;">519,500</font><font style="font-family:inherit;font-size:10pt;">&#32;pre-consolidation common shares (approximately 54,684 post-consolidation common shares) for net proceeds of $</font><font style="font-family:inherit;font-size:10pt;">520,315</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Options</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the second quarter of 2018, we received cash proceeds of $23,910 with respect to the exercise of 71,000 pre-consolidation options (approximately 7,473 post-consolidation options) by a former employee.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Warrants</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the second quarter of 2018, we received cash proceeds of $1,417 with respect to the exercise of 1,500 warrants.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sA6CA09EAAE44EE877C588116A09D6CE5"></a></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">2017 Financing Activities </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Canadian "At-the-Market" equity distribution agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the six month period ending June 30, 2017, we sold 842,000 pre-consolidation common shares (approximately 88,631 post-consolidation common shares) for gross proceeds of $668,648. We incurred share issue costs of $109,121.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Public offering</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 1, 2017, pursuant to an underwritten public offering, 16,445,000 units were sold at a purchase price of $0.70 per unit for gross proceeds of $11,511,500. Each unit included one pre-consolidation common share (0.106 post-consolidation common share) and one common share purchase warrant. Following the Share Consolidation, 9.5 common share purchase warrants entitle the holder to purchase one common share in the capital of the Company until June 1, 2022, at an exercise price of approximately $9.025. The post-consolidation common share purchase warrants will be subject to acceleration if the volume weighted average price of the Company's common shares equals or exceeds $23.75 for 15 consecutive trading dates. We incurred share issue costs of $1,145,402.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Options</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the second quarter of 2017, we received cash proceeds of $295,350 with respect to the exercise of 686,500 pre-consolidation options (approximately 72,263 post-consolidation options) by former employees.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s8075C0B8DD1A04CC495A8116A0BEE7F9"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Liquidity</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, we had cash and cash equivalents and working capital positions as follows: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:79.1015625%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:66%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,<br>2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,<br>2017<br>$</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18,741,347</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,836,119</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Working capital position</font></div></td><td style="vertical-align:middle;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">16,396,435</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,587,340</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not have any debt other than trade accounts payable and we have potential contingent obligations relating to the completion of our research and development of REOLYSIN.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the costs associated with these activities. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#8217;s activity.&#160;&#160;Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares.&#160; Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital.&#160;&#160;There are no assurances that funds will be made available to us when required.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 4, 2018, we renewed our short form base shelf prospectus (the "Base Shelf") that qualifies for distribution of up to 150,000,000 of common shares, subscription receipts, warrants, or units (the "Securities") in either Canada, the US or both. Under a Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents or other intermediaries and also may sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Renewing our Base Shelf  provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in our company. Funds received as a result of using our Base Shelf would be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf will be effective until May 25, 2020. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We anticipate that the expected cash usage from our operations in 2018 will be between $14 - $16 million. We continue to manage our research and development plan with the objective of ensuring optimal use of our existing resources. Additional activities continue to be subject to adequate resources and we believe we will have sufficient cash resources to fund our presently planned operations to the end of 2018.  We also anticipate entering into new financing arrangements to fund our operations. Factors that will affect our anticipated cash usage in 2018, and for which additional funding might be required include, but are not limited to, expansion of our clinical trial program, the timing of patient enrollment in our approved clinical trials, the actual costs incurred to support each clinical trial, the number of treatments each patient will receive, the timing of R&amp;D activity with our clinical trial </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">research collaborations, the number, timing and costs of manufacturing runs required to conclude the validation process and supply product to our clinical trial program, and the level of collaborative activity undertaken.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are not subject to externally imposed capital requirements and there have been no changes in how we define or manage our capital in 2018.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s09788A32A585A38A6F0C81168CF5BBA0"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Financial Instruments and Other Instruments</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our financial instruments consist of cash and cash equivalents, other receivables and accounts payable.  As at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, there are no significant differences between the carrying values of these amounts and their estimated market values.  These financial instruments expose us to the following risks:</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Credit risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credit risk is the risk of financial loss if a counter-party to a financial instrument fails to meet its contractual obligations.  We are exposed to credit risk on our cash and cash equivalents and contract receivable in the event of non-performance by counterparties, but we do not anticipate such non-performance. Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents and contract receivable.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We mitigate our exposure to credit risk by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada. For our foreign domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable or payroll.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest rate risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in market interest rates.  We are exposed to interest rate risk through our cash and cash equivalents and our portfolio of short-term investments.  We mitigate this risk through our investment policy that only allows investment of excess cash resources in investment grade vehicles while matching maturities with our operational requirements.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the investments held.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Currency risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Currency risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. In the normal course of our operations, we are exposed to currency risk from the purchase of goods and services primarily in the U.S., the U.K. and the European Union. In addition, we are exposed to currency risk to the extent cash is held in foreign currencies from either the purchase of foreign currencies or when we receive foreign currency proceeds from operating and financing activities.  As well, we are exposed to currency risk related to our regional licensing agreement. The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;by approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$78,308</font><font style="font-family:inherit;font-size:10pt;">. The impact of a $0.10 increase in the value of the British pound against the Canadian dollar would have increased our net loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;by approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$15,848</font><font style="font-family:inherit;font-size:10pt;">. The impact of a $0.10 increase in the value of the Euro against the Canadian dollar would have increased our net loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;by approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$4,658</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We mitigate our foreign exchange risk  by maintaining sufficient foreign currencies, through the purchase of foreign currencies or receiving foreign currencies from financing activities, to settle our foreign accounts payable.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balances in foreign currencies at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.5703125%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:63%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">US</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">dollars <br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">British pounds</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#163;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Euro</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8364;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,698,664</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,212</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,347</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(916,806</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,060</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,781,858</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,152</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,347</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities. We manage liquidity risk through the management of our capital structure as outlined in Note 10 of our interim consolidated financial statements.  Accounts payable are all due within the current operating period.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s6B328E6A76E6FFE87DED8116A1124EF1"></a></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Other MD&amp;A Requirements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">16,531,956</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares outstanding at </font><font style="font-family:inherit;font-size:10pt;">August&#160;2, 2018</font><font style="font-family:inherit;font-size:10pt;">.  If all of our options, restricted share units and performance share units (</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1,153,080</font><font style="font-family:inherit;font-size:10pt;">) and common share purchase warrants (</font><font style="font-family:inherit;font-size:10pt;">1,730,894</font><font style="font-family:inherit;font-size:10pt;">) were exercised or were to vest, we would have </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">19,415,930</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares outstanding.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;annual report on Form 20-F is available on www.sedar.com.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s5C4204B115EC57BF7F9B8116A1432E26"></a></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Disclosure Controls and Procedures</font><font style="font-family:inherit;font-size:12pt;">&#32;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were no changes in our internal controls over financial reporting during the quarter ended June 30, 2018 that materially affected or are reasonably likely to materially affect, our internal controls over financial reporting.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>ex993-q22018certificationx.htm
<DESCRIPTION>Q2 2018 CERTIFICATION CEO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s1FE4FA63BCE61CEAFB398116A3DEC1F3"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">FORM&#160;52&#8209;109F2</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">CERTIFICATION OF INTERIM FILINGS <br>FULL CERTIFICATE</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">I, Matthew Coffey, President and CEO of Oncolytics Biotech Inc., certify the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Review:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;I have reviewed the interim financial report and interim MD&amp;A (together, the &#8220;interim filings&#8221;) of Oncolytics Biotech Inc. (the &#8220;issuer&#8221;) for the interim period ended June 30, 2018.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">No misrepresentations:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Fair presentation:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Responsibility:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;The issuer&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (DC&amp;P) and internal control over financial reporting (ICFR), as those terms are defined in </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">National Instrument&#160;52&#8209;109 Certification of Disclosure in Issuers&#8217; Annual and Interim Filings</font><font style="font-family:inherit;font-size:11pt;">, for the issuer.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Design:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;Subject to the limitations, if any, described in paragraphs&#160;5.2 and 5.3, the issuer&#8217;s other certifying officer(s) and I have, as at the end of the period covered by the interim filings:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(a)</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:justify;font-size:11pt;text-indent:-48px;"><font style="font-family:inherit;font-size:11pt;">designed DC&amp;P, or caused it to be designed under our supervision, to provide reasonable assurance that:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;">(i)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:11pt;text-indent:-96px;"><font style="font-family:inherit;font-size:11pt;">material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;">(ii)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:11pt;text-indent:-96px;"><font style="font-family:inherit;font-size:11pt;">information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(b)</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:justify;font-size:11pt;text-indent:-48px;"><font style="font-family:inherit;font-size:11pt;">designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer&#8217;s GAAP.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">5.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Control framework:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;The control framework the issuer&#8217;s other certifying officer and I used to design the issuer&#8217;s ICFR is the Internal Control -- Integrated Framework (2013) published by The Committee of Sponsoring Organizations of the Treadway Commission (COSO).</font></div></td></tr></table><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">5.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">ICFR &#8209; material weakness relating to design:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;N/A.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">5.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Limitation on scope of design:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;N/A.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Reporting changes in ICFR:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;The issuer has disclosed in its interim MD&amp;A any change in the issuer&#8217;s ICFR that occurred during the period beginning on January 1, 2018 and ended on June 30, 2018 that has materially affected, or is reasonably likely to materially affect, the issuer&#8217;s ICFR.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date: &#160;&#160;&#160;&#160;August 3, 2018&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:47%;"></td><td style="width:6%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">/s/ Matthew Coffey</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Matthew Coffey Ph.D., M.B.A.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">President and CEO</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>5
<FILENAME>ex994-q22018certificationx.htm
<DESCRIPTION>Q2 2018 CERTIFICATION CFO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s2767B378E24D4DFB2D9B8116A48611E1"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">FORM&#160;52&#8209;109F2</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">CERTIFICATION OF INTERIM FILINGS <br>FULL CERTIFICATE</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">I, Kirk Look, CFO of Oncolytics Biotech Inc., certify the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Review:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;I have reviewed the interim financial report and interim MD&amp;A (together, the &#8220;interim filings&#8221;) of Oncolytics Biotech Inc. (the &#8220;issuer&#8221;) for the interim period ended June 30, 2018.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">No misrepresentations:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Fair presentation:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Responsibility:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;The issuer&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (DC&amp;P) and internal control over financial reporting (ICFR), as those terms are defined in </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">National Instrument&#160;52&#8209;109 Certification of Disclosure in Issuers&#8217; Annual and Interim Filings</font><font style="font-family:inherit;font-size:11pt;">, for the issuer.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Design:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;Subject to the limitations, if any, described in paragraphs&#160;5.2 and 5.3, the issuer&#8217;s other certifying officer(s) and I have, as at the end of the period covered by the interim filings:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(a)</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:justify;font-size:11pt;text-indent:-48px;"><font style="font-family:inherit;font-size:11pt;">designed DC&amp;P, or caused it to be designed under our supervision, to provide reasonable assurance that:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;">(i)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:11pt;text-indent:-96px;"><font style="font-family:inherit;font-size:11pt;">material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;">(ii)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:11pt;text-indent:-96px;"><font style="font-family:inherit;font-size:11pt;">information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(b)</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:justify;font-size:11pt;text-indent:-48px;"><font style="font-family:inherit;font-size:11pt;">designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer&#8217;s GAAP.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">5.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Control framework:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;The control framework the issuer&#8217;s other certifying officer and I used to design the issuer&#8217;s ICFR is the Internal Control -- Integrated Framework (2013) published by The Committee of Sponsoring Organizations of the Treadway Commission (COSO).</font></div></td></tr></table><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">5.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">ICFR &#8209; material weakness relating to design:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;N/A. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">5.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Limitation on scope of design:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;N/A.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Reporting changes in ICFR:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;The issuer has disclosed in its interim MD&amp;A any change in the issuer&#8217;s ICFR that occurred during the period beginning on January 1, 2018 and ended on June 30, 2018 that has materially affected, or is reasonably likely to materially affect, the issuer&#8217;s ICFR.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date: &#160;&#160;&#160;&#160;August 3, 2018&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:47%;"></td><td style="width:6%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">/s/ Kirk Look</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Kirk Look, CA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">CFO</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>oncolyticslogobluea02.jpg
<TEXT>
begin 644 oncolyticslogobluea02.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP"$  $! 0(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(!
M 0$! @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" O_  !$(!H\/  ,!(@ "$0$#$0'_Q  ?  $
M 00# 0$!            ! $" P4)"@L(!P;_Q !W$  ! @,#" <$ PD(# H%
M A<  0(#! 4&$2$'$C%!46%Q\ @3@9&AL=$)"L'A%"+Q%1HR-U=V=[6V%B,X
M0E)REM49,S0V5F)T=967LK,7)"4G<X*2TM/6-4-3M]08)BA$1564HN)&1U1G
MA<)C96:3M&2&IL7&_\0 ' $!  (" P$               <( 08"! 4#_\0
M6!$!  (! @(%!0@+#0<#! (#  $" P01!2$&!Q(Q01,B46%Q(S(U0G)S@;,4
M%S-24V)TD9.AL14D-$-4@I2RP<+1TM1C@Y*BM-/P%J/A1%7#\25DA*1%_]H
M# ,!  (1 Q$ /P#O\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                    "EXO!NJ"GAW"[?Y>@8W]2H*"Y#&XJ"EZ;A>)M#*H
M!2]#$6W\)"_FY1?S<HO07H9W]7[&.?\ Y'_R7\W*+^;E%Z"]!OZOV'/_ ,C_
M .2\J4O0K>8FWJED *7H(M J"F&X7&=Q4%+M_D+N/@98W]2H*7[A>&=U0
M
M
M
M
M
M
M
M
M
M                                                    *7@W5!07
M+M&[&ZMY2\7)L**Y-IC<YK@8UB)J\KRQ7KJ^*> W_P#/_(99;N;U*\[3!G+M
M[N? 8[5&T^G]1LRJ].5*=8GV8\_88KA>-ADZS<OD.LW>)CO*9Z&1?G+RJ_84
MO7[$N\2Q7IW&/KDY2[S,;1Z!GQVJ4[5YX&#K>/A\!UBZD\53T,FS/<+DV&#.
M?J3GB,Y^SP#.W_F\,]R;!<FPP9S]G@,Y^SP!M_YO#/<FP7)L,&<_9X#.?L\
M;?\ F\,]R;!=SH\C!G/V> SG[/ &W_F\,]W-ZE<=JD;/=L\5*];Q\/B@8V2+
MUV]^(SEW>*>"&!(O."^5Q>V(BI?\#&WJ9V9NL79XE>LW+X&+/3:5OYN,[,,O
M6(51Z;N_[##>@N,;"0BE+N;U,";E4K>NWOQ,;3Z?U&R04,.>O*KY:_B7)$37
MY7&9&2_<+RB/3:5N39X#=CFJ"EW. ,[FZH*7E0SN
M
M
M
M
M
M
M
M
M
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M HB"\1(J!>#(
M
M
M
M
M
M
M
M
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M 1TPT<\[4,C8FA%OO\!#&S(BE2V\8\J(G<7 I>5,L@
M
M
M
M
M
M
M
M
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M@ 99
M
M
M
M
M
M
M
M
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M^1E:^_48[O6,@+;BZ\S$@ #(
M
M
M
M
M
M
M
M
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MNN^XS7HN\P(H3#1MUX_8<9CZ!(0J8FOON37@7W;+NXSNPN!1%*F60
M
M
M
M
M
M
M
M
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M6];C,8F-QFTE;R.WZO#GGR,S7(O?P,3.WL%X+;^=A5%.1NJ
M
M
M
M
M
M
M
M
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MCD;=FW)>BJO5! GJVX-_(_\ W]1_9FABO6CQV/\ Z[\^GTL__@=O&E>\_P!
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M7JW1BG.'$D-?>FKE PSL?M+T0CW%[7ZEY2XXSR&5'(I4L71@OCP+D4S$[BH
M,@
M
M
M
M
M
M
M
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MM9=I[ML5-]I]62^.4:\:ZW.%Z;>N"<FMR1X88[.+?GRG-DVCZ<=,D.^5E_\
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MS'/>&&="I1<?D#,2PJ #+(
M
M
M
M
M
M
M
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M9GUH;XGQG5ZV_E-7J,NHMX>4M,UK\BGO*1ZJ5K$>A;F(7(5!Z;S
M         MSD!NN!3.07[O(QNQNJ"E^[R*9R<!N;PN!;GIM+KS+(
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MRSL=FZ=W/.@SD<JUUW"_PY[DP.,QXQWL,R+\BXI@I1%,UG=CN_L7  RR
M
M
M
M
M
M
M
M
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MK6E8]E:Q$>WT]\H2U>LRY\ELN?+DS9+SO;)DO-[S[;6F9Y>'HCEW  .RZX
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M9JJWRNYT(8IJ72/_ &]&S'^4,;'W?^M1^I+KMR7'J8.N;41]UT.&WS>6^/\
MK5R/*U'4?IIW\EK\]/1&3%CR1'M[-L>[R<TF8:_@O8[^:]KO)>XRH_G4>HK;
MKHM9-K3Y_P"Z/)[8>NK%6][ZK96B3L15P^OGQY%T1(B7(K7M<U[51'(Y'(BG
MQ'E ]BET:K0Y[HF3.3H\=]Z?2K-U:M46(V]J-18<O#GXU.8K;KVJE/OO55=G
M(MQ[NEZX]);;RVDU&/YNV/+$?\4X9_4UW5]2&MKOY#6Z7+Z(RTRX9G_AC-&_
MT[>MYXN?SH]0C^;N>^\[HN4GW:C)9/=8^RMN+<6;>MZPH%192K32R;&Q(T27
MIDTC4_E0T5UV&.DXZ<J/NU^5FFI$BV3MC8FU<-F<YL"<6IV8G7-_BL8V8@5.
M4B1EP;<Z9EX5][D>U+D-GT763PC-,1]E>2F?#-CR8_SW[-L?_/LU/7=5W&\&
M\_8D9JQ\;!DQY-_93M1D_P"3_P">NH#[XRO>RWZ05ATBQ*YDKM/%E8-ZOJ%"
M@0+34]L.Y;HL2:L_&J+8$-UV"3*0(C<&Q&,<N:?!M0DYB3C.EIN!&E)EJJCI
M>;@Q):8:J+<J.@1VPHJ7*BHOU,%P-PTO$-/GKVL&;%FK]]BR4R1^>DS#2];P
M_4::W9U&#-@M][FQ7QSR]$7K&_T,(,:O5-2IMOP+VK@=N)=/=4 &0
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M><#,8"K77:=&/CHP\O'$XS'C'?\ M89T4J6Z>=?.DK>9B6%0 99
M
M
M
M
M
M
M
M
M        4O**EXF01-IC>^[#L3GG87/?==V\\^=QBW\\W[3CW^'L($0QO?=S
MSV\W5>]$Y7G9P(Z7Z5QV=O/'6IR%='%=%^I.="!5N\>>> 5;L575K[".JJO#
MCI6_GLW@W'+G8ZMFWY:OF6/==Q7G#ASCHJY^K7=@FK[-Y@<MV.OG#T\;P#W7
M7JNSE-/<1W.UK]EVGMN[^ <[6NS1LV=Y%B/T>"<\IH J]^WNTIBMQ&<_';Y<
M,/CW%KW8Z>[X;$V]FLB1(EZ8[]WAI[-/8!?$=I^&CE%UZ;R(YW!-7'T3Q4M>
M_;W>7V$6)%X?9BBJ!=$B8;O7Q1/@1'Q-_;LW<^)8^)AS>J[",^)M[$\MU^_0
M@%7OPO7CSNW=A$?%OO1+\+]=W8OH8XL7#M^'-_>0HD33Y7Z-Z@9(D3QV=FC9
M\%XD1[]*<>"<ZC&]_P!JZ^?(B1(UVOLU^NC3M ROBHF_?SMU)RD%\6^]$NN7
M7Q71NX)KTF.)$OW)QNY3=W$5[]2:]"(F*ZD1$3'L3$#(L39KP[-7#LU'X3T@
MNDC8K)=9Z8M1;RT-/L]1X"K#9%FWJZ8G9A$5S).ER$+/FZE/1+KF2TI"B/2_
M/BK"A7Q$XI?:,^VYL/D@6=LO8U)*W>4.$CX$>3EYA76;LU'NNOKU2E5<DU.P
MEQ6B4V(LPCDNGYB3:YK(O2PZ1?2?MUE:M%&M1;ZT$Y7JF_.9+,BN2#3J7+.<
MKDD:/385TI39-E]R0I>&CXEV?,18\9715DOHGU;:G7]G-J>UI=+/.)F/=LT?
M[.EO>UGPR7C;:8FM;Q*+.F/6CI.']O!INSJ]9'*:Q/N&&W^UO7WUH\<6.>UR
MF+7QSLYCO: >WRMOE"6>LUDM2=R?V-BI$EHU6ZQL.VE=EW(K'I$G(#WP[.R<
M9BHGT2F/=4',54F:C<]9:%U]HJNB/?$>]SXD1[HD1[U5[XD1ZJY\2(]ZN>^(
M]RJ]\1[G/>Y5<]7.55*9B%Z%A>#\"TN@Q>1TV&F*O+M3'O[SW=K)>?.O/KM/
M+NB(C:%:>-<>U?$<LYM7FMEMO/9K,[8\<;[]G'CC:M*^J(WGOM-IWE8C"\ ]
MAY       7E%5 *@DTFDSD_-09&1EIF=G9F(D.6DY.!%FIN9>MR(R7EH#(D>
M,[_HV.N_C7)B<QO1B]A-EWR@_1YZL4N5R;T*-F/6>MBL2'58D%[;\^4LS)YU
M4B.1%:YK:BZDPHC57JH[U:YJ>9Q'C.ETE>WJ<^/#7P[=HB;?(I[^\^JM9GU/
M4X7P35ZV_D])ILN>W+><=)FM=^[MW]Y2/7>U8];AF<JZC^]R;Y*[4VQGFTRR
M5G*W::?5S&K*4*ESM4BP^L=FL='^APHK)9BKAULR^#!;BKHC6HJG=NZ-_N^6
M1.R"0)NU_P!ULIE6AYKW)6XZTJSS(B*B_O5$I,2#%CM:YM\-T]4(V<U7,C08
MC<#FKR?Y.*!96G0J19BB4BSE+@-S8-/H=.E*5)PTNN54@24&!#55S4SW.17O
M7ZSU55QB_B_6_I<>]='@R:BW=V\D^1Q>V(VMDM'JM7'/K2QP;J5U>3:VNU&/
M35[YQ8H\ME]DVWKCK[:VR^R'1ZR">[ZY=K5]3,6F90<G-/B(U[DK\]]T:TC%
MQ5B42C)-.@QKOP4FYN!"5<'167+=S/Y#?=Q<CM"; F+:5VU5O)UB(L:72999
M:B/<B8HV4I3HU5S<ZZ](M;>U[4S70T1SD.PY#A(FA.>SE.TS)#W(B?/9H(VX
MIUD<6U.\1GC3TGXFFKY/_P!R9MECZ,D>K9*7"NJ_@VEVF=-.IO'Q]5;RO_MQ
M%<,_3CW];Y?R,]#')3D]A-AV,R>61L^]F;_QJ4HLI&J+WMN3K7U*<AS4]URY
MJ*^*R.QSU2]=)]-O:KESGO<]VU[E<[O>JJ2$AW[5YYQO,C8>Y$YYUFDY]1DR
MVFV6]\EI[[7M:]I]MK3,_K;Y@T^/%6*8L=,=([JXZUI6/96L1'ZD1(>Q+^SU
M[O,RI#T7W7<]G:24;M7QNX\_$N1B:D\.?(^+[(R,3:52&FQ5XZ/EXDQ(:Z;D
MT>/.HN1F_GAYZ@(:0MR=_P .;B_J^414YW^!+2'Q7@MW9=YER0=RKI4"'U>]
M<>!7,VKY$U)=4T-^PN2 MVB[B!!S4VE<Q/Y2&QZCAW(.HYN0#7=6G\I"F:FU
M#9=1S<@ZCAW(!K,U-I3J]ZFQ^CKL\2WJ%_D^.ZX#7+#W]Z*OJGS*+"W)WDY8
M%VI>>>S2A187'GGG #7K#W*G/;S<45B;2<Z&NWX+V=A18:[/$#7NA[[^>[XX
M[#&L+:BISH],#8N9M3GL\M)9F)PYYT<-0&O2'<M[7*U4T*BW+WHJ*G9=JN4_
M%\JO1TL);F#$E[9V,LQ:F'%14B+6Z+(3TPY%2[^[8D%)Y,-39E$2Y%U(?NJP
ME79]F!C6'V>/##'LW<#Z8LMZ6BU+6I:.ZU)FMH]DQM,/GEQ4O6:7K6]9[ZWK
M%JS[8M$Q/YG YER]WMR#6H2+'L[#M'D^GHB.<U:%4UJ-)ZQ;[E?1ZVDVV'!:
MEW[Q(3<@BW7YZ*Y57AFR\>[CY6[/I'F;#6ALU;Z3AYSH<G%?$LO7G0VWKC*S
M[YFEQHKDN1D&5JL5[UP^KA?W>%A<%\.5X&)\)/Y-U^WGGRW+AG6'Q;2[1&IG
M-2/B:F(S1/J[<^ZQ]&2(]32.*]6O!]7O-M)7!>?CZ6?(3_P5CR._KG',^MY<
MF6SHSY0\F\TLG;NQ=HK*QD>L-KZQ3(\O)Q7HMV;+U)G6TR9=KS9:<C.1+E5$
M14/PQC[]G%,4[%/5WKE DJC)QJ?49.4J,A'ANAQY&?EH,[)QH3KLZ'%E9F'%
M@1(;KDSF.AJUUV**<1?20]AOD"R@?2)J2L],9/ZS&O<E3L/%AT^46(JJN='L
M],,C42(F-R0Y:#3X:7(N*I<LD\)ZX<-^S76Z:^*>6^3!/E*>V<=NS>L>RV2?
M:B[C'4EGKO;0:JF:.<QBU$>3R>R,M.U2\_*KBCQW= $'/ITFO=Y,L-DOI$_8
M6=I.4JE0U<]DK)JVAVG;#_"1%I%0BK)3L1C?JK]SZDZ8CON2!(7+<W@TMWD]
MM!9:I1J-:6BU:S]7EW.9&IM:I\S39YCF+<Z^7FX4)[T8N"NAH]C5UZ"4.%](
M-%K:]K2ZC'FY;S6MMLE8_&QVVR5_G5A$O&.CNNT%NSJ]-EP\]HO:N^.WR<M=
M\=O96TR_E@6-7 NO/9>*J     %KFWEP Q]7SNV;\#E%Z!WM;,I^0J-+4V3F
MOW5V%;$;](L779F,Z5EH=Z)$?9VHW19F@3.:GU6061Z9$=<LQ3HMS5;Q?%BL
M13S^(\+T^JQ6PZC%3+CMWUO&^T^FL]];1X6K,6CPF'>X;Q/4:/+7/I<U\&6O
M=>D[;QXUM'.MZSXTM$UMXP]*3H2^T9R:9>*8L>Q]5^CUZ5EVQ:O8^K+"E;24
MG!.LB_1FO=#J5.:]5:RJ4U\>57#KTEGN:QWWLV)>FY=?QVX[4\#RC+&VRJ]G
M*I)5R@5.?HM9ID=LS3ZI2YJ-)3TG'8M[8DO,P'LB,5=#VWJR(U59%8^&YS%[
M9/LZ?>#I2HND;(9>'P*=/.ZN6DLHTK+M@TV;>JI#8VUE.EVI#ID5V&=6I"']
M!<]5?.R<FS/F&0'TLZKLVF[6?0=K48.<VPSSSXX_%VV\M6/"(CRD1MROM-UC
M.AW6U@U78T_$>QIM1.U:YXY:?+/=YV_W&\^N9QS.\Q:F]:.UDR+=O2]-6C9]
MJ=I.AQ;^&'/S/Y2CUF5GI:7G9&:EYR3FX,.9E)N4CPIF5FY:,U'P9B6F(+GP
M8\"*U<Z'&A/=#B-T.P5#<L?K1<=FCLYP4B28VY>A,L3OW<X]+>,?==WW^MW-
MY+9$T\+_ +.<#2PXVK1N]+^;L"8UR<4V:TX<[##+=MB8)HNT8:.W@NA>\F,?
M?\44T3(G/P7>361/+1?S\D W+(FC'_[GG1VX$R'%T\HO/EW&G9$ONV[=N.I/
M@N@E,B?9QT7>6\#=,?H5-V&C[/B2&/T\]B)JPU:#4LB:,>WX*2V/TW>?.K0H
M&V8Y-MV%Z?;]MQ*8_O\ AWZ/(U<.)C?CRER^.O0N)(:_7\-6V[3JN5/@!MFO
MOW+]GGX:#.UU^&OUQ^SN-<Q]_'4J? DM?PO3GS[@)S7+?BNC%%Y\>*F1,-&K
M'G=MV:4P(K77X+IYN7SN]3.UV"(NGSX 2VNSBJMON36FO;QYX$9=NS2FW?P^
M)(:Y%1.SP R0XFKGGX=QG(BM7;BGBFI#+#B7X:]G//@&4B&Z[#?Y\_'0950P
M*9&NU*<)C;G##*"W!,>TJBG/<5
M
M
M
M
M
M
M
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M[TPNUZ22UR*!F8Z]/#P#4N[>>?$PKACWDA%13A/+V?L)7 I>5.9$@
M
M
M
M
M
M
M
M
M   %$WE+\2US[M5^A._G$QNPL<^];D[>>'AO+0U+C%$?=@B<W<W;3,,K8CK\
M$QV\/M[2V_5J33JO^7.HHB78)KTKLPU<Z,2Q[[DNNO\ DN/=K^)@4>_4B]WC
MSJ,6V[5XKOW)?\2NY%QTJNQ%\;]M^@P.7N3F[G&\R"K>N/9]A&>Z_P ;MZZN
MS[2Z(Z]=W.'/S(KWX;K^>S7\@*.>F*]VKGFXBO=MYW(FTK$?C?W?/?PQU$1[
M_2[;M3MU@4B/QT\IJYT\-$-S]?<G.O8FHJ]Z8[$T=FCNT)=O(<6)SLWKOV;
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M+=]=XYJY\;X!J^'99PZO#;%;XMN_'DC[['DCS;QZ=IWKW6B+<EP /8>.
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MV'4'=;/45J-ZSZ1(->LMW+Z559><EY>;DX\":E)J!"F9::EHT./+S$O'8V)
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M"QUV'CQ7F\S*<8Y<A4! <@
M
M
M
M
M
M
M
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M*!*4S0W7\\\]I@8MZ(7(MRW[</F<;1N,^":RXMTW+P+CE
M
M
M
M
M
M
M
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MR A]7Q[D^'V;2G5KS>2\U-W/:,QN[GM A]7N[OE<6K#3^2I.ZM-OC>46'O\
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MV<W&9CKSC/*=Q>"U.WM+CD1(
M
M
M
M
M
M
M
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M;N=5_=@O#09W)>@$G@5,;'7\ZTY[2Y$N.-8VY?F]@N !R
M
M
M
M
M
M
M
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MYU#TO3GGM/IOH==+"TV16WM'MW9A^='D(BRU4I<2(Z')UZAS3F)4J+.HV_\
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MM*&%2^&[3?XG&WI]'[&&5"I2\J<@
M
M
M
M
M
M
M
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MBQ33AO33Z+=K BJV_CY=W/ Q.9=IYX\W<-*3G-1;_!?CN\$,*I=IV:?7G1I
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M .3(
M
M
M
M
M
M
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M4%J+Y;"XR
M
M
M
M
M
M
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M1<G;HOOU<;](!C-2:.?#?KX$R'#U)L[MB^EV"%6,7?J\T^Q$V$EC-7?SY[-
M%6,U:MO;HW;]V@E,;?N3G1Z]Q1K+TPV^7/ DHFI$ M:EV"78<\Z3.C+K[L=^
MCGAK#6HB+NTKZ=F@O1BKP3SVKMV@43'!-&%Z[?ENV&9$N[>/*\ZB[!,$YWWE
M%79BNO=CAX@5<NV[ANW_ "+FLSL5PV)SMYN+F0[KE7G S7@$2X7A&JNI43G1
MSP,J-NY3GG>8F?SBB0]N/9A\RY%1,.=!787&-O3^;T"A4 Y
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M= D2&K@G!/(JBW+Q\[KKNTP0EQNV8=O.OL,Z@2%"*4:Y%T%;S$2*@ R
M
M
M
M
M
M
M
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MF(SUB1IB/&>^+&CQHCL7QHT5SHL5ZXN>YSEQ4QEJ-N+BVU8VC93;?T]X #(
M&)[KL=2=NC'0F/A>8F1]B] WH@U;+?E-H-AJ>L66D(\1:C:6JPVJK:/9N1<Q
M]3G57\%)B,US)&G,<K>MJ$U+MO:Q(CF>DMD^L%2;,42DV=H,E"IM$H5/E*52
MI" B)"E)"2A-@2\)JHB9SD8W.BQ%3.BQG1(KOK1%4XE/8H]!+_@@R7P*W7)/
MJ+=90H,G6JZD6'FS-)I&8L:@V=7^-#=+P(WW2J4-USFU*;= B-1TG>_F@8W#
M<FGA=YX]B%6^L;I/]GZV<6*V^ETLVQX]O>Y,D<LF7T3$SYM)[NQ7M1MVY6VZ
ML>B?[G:&,N6NVKUD5R9=X\['CVWQ8>?.)B)[>2.4]NW9GWE=LC&KIUXW7W)<
MGK=I["6UFA.-ZZ_M4LAMW8W)<GRYP)T"'M[=6NZ[OU["/$E)$%MURIP3?]O@
MA-AL[4O[U75P3:8X355>>WRT=I/A0^S5V>JKH S0F8^/:B8KP30;&&S"[5AS
M\]N!C8R["[&[NV?/:MY-AM[M''Y;M8&2&S;AMU8;.)/ALPWW8;-W9K\5,<)B
M=W>JZ^=6HFPVZ]V.C1L]0*PV_/CNWJNC<3F,5..K#P^*J6,37V[,-*8;5\B6
MQEW%4PT:U\D\<;P+F-[UT\^";25#9H1.U=ZX]ZE&LP5.=GV$I$T(EU_=QYT@
M$2[!/LU?89FMNOQX\2C6W)=OQ79?SA<9&)G+L1-6WB!5K;]R:D^)GW(4W<\^
M9:B7X(G'XW_ ,Q"[<G!5U\^>HSL9<58RXJJ\H&%54N:R_3V%S8=W'GGFXR7;
M,#COOW"FA, F\JB%3,1L  ,@
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MK@412IEF)
M
M
M
M
M
M
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M^DX=_L<9E33SX(7@',B/S@ #(
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MN.-HW@9DUEQ;\RXS$L0  RR
M
M
M
M
M
M
M
M    !1%"EJZ/#88EC=B?^$NZY?F8XBW(7)K7:O/.@QQEP1.=WCX8F8984T;W
M+X=FCXED==%V].>VZ\R:.Q+M^U>.XP.5%6_^2BZ-O9J2_2!C<MR*N"JGP^?B
M18F"7)NXWK?CQ\,<=1F=J3YZ/1?':87+>J;DOX?;Y(!%B+J3G4E_;CCA<08C
MM?=MNU?._2EQ*B+@J[51/A<0XB;D3?X<IJ AQ78;UONW;KOBG'408JHG!$\;
MD3OW=I)BNQNYW=V*[MY C/U]N.[1Q3&] (D5_A==JQUZ-5^L@Q5NPV)CMO\
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MXHA4Y00
M!;HX%P#$K'(BIRG/P,&A;E[.=IG1+MEV):YE^///.HX]WL_8RP/:BZC FG-6
M^^_!>>>TDHICB,PYVWG(8E1%P\".J7+=LT=N-RZM7P)"+KUW8\-'?N,3VWI>
MFGY\]VH".],45-F.'.KM(\1B:4W)V?+[2:BZ]5]R[UV_!2,J:MMZ^./CV*!
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M4B\J8X:WIW>GPO[2^\XUC85 !R
M
M
M
M
M
M
M
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M-7%9X*7K?CL3[=_ VC&ZMF'%=7K?Z$6"RZY=F''"]5NVZN)L(3?#'M7TU;\
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M.&TD,:B:$3F\"],"Z&E^E.'/EN+;KUNX7\%PY[C/H.-I\#=7@4:EQ5"IF(
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M#)"75L\M7=H7:9==_.DPM6Y>Q? D''Q8F  ')D
M
M
M
M
M
M
M
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M2XNAXK?Q\_LXB9&2&VY,>?D7IP**I<<:_M8  <F0
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MBWMK.UH]<1+T>$<1MI-7IM53OP9L>7;NWBMHF:SZKUWK/IB7K$PEXINUHO\
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MIF8N"+N&XN12I1-?'X(5#$2  ,@
M
M
M
M
M
M
M
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MIH:FJ[Y\.W$E(B(@!RZN;M9(1,.XQPT1;S*<9YSZC<0J <@
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M(U=#D7@J%YD                           !2\J     I>!4
M                       "\I>!4%+Q>!4%%<FU#"D6_0M_#'ROX@9P8<]=
MB]R^=UWP+U?AH6_@H%X,*O78MW#[0V*E]RJB+=HO0#,"EZ"\"H   I>5
M                              I>+T J"EY8^*B(N*)Q4#(#"UZK\DO^
M'-Y5'KK1>Y>= &4&)7+J\E]#&Z+=I5$XX;-NW'E )(+&O14TH77@5!2\J
M
M     "\7@       7@                               I>!4
M  I>!4                                     !2\J
M7@                                         "EX%04O%X%08'Q41?
MPD[TT]Y7/7>J;D7T[P,P+$?N7N7T*.?L1>Y?0#(# L14TX<4N3RP+V1$70J+
MVH!D O*7@5 O*7@5                            I>!4"\I>!4&)T5$N
MQ2^_1>@:]=?DO.@#*"W.3?W+Z%BN7?=P7GG:!E!'6-=IN39JO,R.1=:=Z 7
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M9
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MK%5L2&]KFKB;HKE,;<IC:8Y3'H6=B8F(F.<3SB8[ICU  ,,@
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MB8Y;3$]T^I(U;Q:(FLQ,3$3$Q.\3$]TQ,<IB?"85 !AR
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M_P 4??8.3C\E-N?]+6=_\4Z. 'VKN#?@,G](S?YS[;'&_P"4X_Z/@_R.\?\
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MC\E-N?\ 2UG?_%.CAMXKY@M%]J[@WX#)_2,W^=4O[;'&_P"4X_Z/@_R.\?\
M?8.3C\E-N?\ 2UG?_%'WV#DX_)3;G_2UG?\ Q3HX ?:NX-^ R?TC-_G/ML<;
M_E./^CX/\CO%1_>Q<G#(<2(N2BW2I#AQ(BI]UK.XI#8YZI_;=:-N.TEDYMG"
MM'0*)7X$&)+0:W2*75X,O&<QT6!"JDA+S\.#$<SZCHD)DPD-ZM^JKFJK?JJA
MX[%0_N:9_P FF?\ <1#UYNC!^+>P/YDV2_9VFD8]9/131<-QZ2VDQVI.6^6+
M]K)>^\4BDQ[^9V]]/<E?JNZ7Z[B=]7&LRUR1BKBFG9QX\>TVF^_O*UW[H[]W
M[J ")TP@                        *9R&-Z[].A-:Z\$TKMX 92EYQD],
MOVN.0W(<D:2M;:^7G[1PVWMLA9=K:[:.];\ULU*RL3Z-2K\%SJM-R;E8J1(4
M*,U#JS=*OWHC*G:%TS(9*;-TC)Y3'9[(-9J[(%J;5.8K<U(K84>&EG*?$OSG
M=6LE6$3ZMT5JWFV<%Z$<2U^UL6":8I[LV;W/'MZ:[QV[QZ\=+QZ6F<>Z?<+X
M=VJYM1&3-7E.#!MER[_>VB)BF.?5DO1WJK36LIE&E(M0JU1D:5(04OC3U2FY
M:1DH6E?WR:FXD&79@BK]:(F".6[!3BCRZ>W8Z,5@G1X$UE(E+2U" KVNIMB9
M*<M1'ZQFF$Z<D87W)EXG^55& V_#/OP/.7RU])C*'E)G7U"WUM;36OF7*Y46
MO5><GI>$CG9W5R\C$B_09: QURPX4&69#A(B-AL:B(A^+M3!$U)H34FY$T)V
M=F!*'#.IS#&TZO5Y+SRWI@K&.L>KMW[=K1ZXI2?1LB;BG7=GMO&BT>/''=%]
M1:<EO;Y/'Y.M9V\)O>/:[KN6#WL2S$!\:#8+)+7JJU6N2!4+65ZGT-K7XHUT
M2E4F#6XD2&MV=<VJP7YJ_61KL$XW,I'O072"JU[:#1LGEDX=ZYCH%'J%=CW9
MR*F>^KU)83HB-3-5S8+6*JJJ,2Y$.N-FH+D-VTG5YPC#MMHZ7GTYK7R[^N:W
MM-/HBL0T36=9/&\\SVM=?'$]U<-,>';U1:E8O^>TSZW+?;+V[_2KK3W/=E7G
MJ6URXLH5"LU36)BN#;Z3-/:GUKOJOSKD:B*U4O/P.M>U*Z1U3ZSZ9EMRCOZU
MC6/2%:*-)WM;H1OT"'*]6NUT/,>[^,Y3X,N0K<>]AZ/Z''[S1Z6NWHT^*/UQ
M1K^;I%Q#)]TUVKOW^^U&:>_VW_5W>B(?8?\ 9"\O/Y9\J'].+0__ !Q?"]H?
ME[8YKVY9\J&<QR.:JVVK[D1S5O15:^=<UR7I^"YJM70J*F!\<@[7[EZ;^3X/
MT./_ "NK^ZNJ_E.H_39/\SD0HGM<.DU35OE<MUOT^NL14F*E*5!JN5BLO6'4
M:?.,5+E_ 5JPT=<_-SVM<GT-8SW@;I5T5$:N466K+41J*VOV5L]/J]$1J?7=
M E)!][KOK.:YBJJN5%2_#AI*7(=+-T;X?DW[>BTEM_3IL6_Y^SN[N'I/Q+',
M337ZRNW=$:C+M^;M[3],;.S5DW]Z<RUTWJF6CL7D_M+!1S>NC2\.LT"<>U%^
MLD-TM/3<FQST6Y,^6B(U4:J(N*+R49(/>N,G$^Z%"MSDRME9ESE8R)-V?J%(
MM5*L<N#HT2%,K9V<AP4_#S(,.=CL1<QK8SDSG=&VX7(>#J^KCA&;?]ZQCF>Z
MV&^3'M[*Q;R?YZ2V#0]9G&\&W[]G+$?%SX\>3?VVFOE/S7AZ@^0?VSO1KRB/
MEY:B94Z%3ZE,N1D*DVJ29LE45B*E_5LA5Z!)08[FK@KI>/%A._"9$<VYR\F5
M'K,K/2\*;DYF#-RLPQ'P)F5C0YB6C,553/@S$%SX,5MZ*E\-[TPNOOO/'#BM
M16YJHCFK=>UR(YJ\6JBM7@J'TED Z9>5;)7--F\GMO[4655KF*^4I]4COI,=
M(:WPV3=%FUF:1-P6+BD&8DHD%5TPU1$NTCB?4YCYSH]7>L^%-12+Q/\ O,<5
MFOZ.S?>%]=^2)B-;HJVCQR::\UF/7Y++-HM/^]J]<&_FY1>=%SHJ^]+6^H[I
M:GY7;'4RV4DU6LBVALNL.SMH6MNN6-'I<7K*%4(B.^N])5:,VY%;"@9RHJ=I
M3H>>U%R)9<H<.%86VLD^N.AK$BV3K:?<.U4NB8O3[DSKT=.MAM5'18])CU&6
MAHYJ/CM=>U(PXUT,XCH(FV;3VMBCOS8O=<41Z;6KSI'H\I6F_@EG@/3KAG$=
MJZ?4UKEGNP9O<LN_HK6T[7GYNUW(@"U')M[]/:,Y-IJS;EP
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M(M,QRWB$P\&Z1:+B%.WI-1CS1'OJQ.V2GR\=MKT]'G5B)\)E_5@I>A4\A[0
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M"ID
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M]/M^QPO6WY\JZ/->>_GRTUYGQ[O(S,_[+\'#M4 QM??X;/0R$'+
M             #J>>]?_ (N<DWZ0JK^R%0.CD=XWWK_\7.2;](55_9"H'1R+
M2=5OP/A^<S_6W5+ZV_AK-\SI_JX  2(C,.R[[K%^/JV/Z+*A^TMGSK1'9=]U
MB_'U;']%E0_:6SYJ/3SX(UWS/]ZK<>K_ .&>'_/Q_5L[^8 *BKG@
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MZ;Z/BU/<;>3U%8WR:;),>4IZ;5VY9,>_+MU]7;K29B'[X"B*5-5;B
M              +7Z%X+Y'ET>V:_A1Y:?SM7]5TX]1=^A>"^1Y='MFOX4>6G
M\[5_5=.)=ZG/X?J?R2?KL2&.NWX/TGY9'U&9QD  L6K,%KO@OP+BUWP7X&)[
MI8GNEZ,WNVG\%FS?YV6Y_:"9.>PX$_=M/X+-F_SLMS^T$R<]A3GI;\*<0_*]
M1]99=OH9\$<-_(M/]54 !KS9@                     (DS*MBL=#B-:]C
MVN8]CVH]CFN:J.:YCKVO:YJJUS7(K7-P5%15OE@#S2_;B>SI?D%RL3$W1)1[
M,GEOGSE?LG$8Q>HI4XL5(E<LJYZ(C6NI4Q&;-2#-+Z/.2J(Z)$E9KJ^&-#U2
MO:7]!FD](')37["SG4RU91GW7L?5HK+_ +D6ID(41:;'>Y/K))32O?3JHQMZ
MQ)":C*UKHD.%=Y;%MK&U:S=9JMGJ](1Z76Z'49NDU:G3+<R/)5"0COEYN6BM
MQ^M"C0W(CD561&9L6&YT-['NM+U==*/W0T<8\MM]5IHKCR;^^R4[L>7US:([
M-YY^?6;3M%H5'ZS.B7[FZZ<N*NVDU<VR8MH\W'D[\F'U169[5(^\M$1OV+;?
MS@*(5)#1N%%T>N@J .^K[MO[1#]WMA(N1NTT[UEK,G$E#?9Z+,15='K%A>L9
M E6-5ZJ^+'LO,1(=+C(U;H=,C4>YJ(U57L[I$0\C;HF=):T61W*'9?*-9>*K
M*K9NHPYITJKW,@56FQ46!5:+.7*F=*5:GQ(\G&2]%8L1D9CF18,.(SU7NCIE
MWL]E-L39JWMEII)NA6HI4K59&)>G60DC-NF)*9:B)U<[3YIL>1G82HCH<S+Q
M6*F!63K-Z,?8>K^RL5=M/JYFT[1RQY^_)7U1?[I6/3VZQ&U%J>JCI7]FZ/[$
MS6WU.CK6L;SSR:?NQW]<X_N=O5Y.9F9N_;P 1DE<             "BJ5+7+
M@!_"Y3,H]&LC9ZMVHM#/0J90[/4N=K%6GXRHD.4I]/@/F9J,NMSFPH;NKAMO
M?%B*R&QKGO1J^5IT_>F36,O&56TN42JI&@2T_'21L[2XKKTHMEY!T2%1J:U+
MU:V-U*NG)]681*C-S3[W?A+V6O>;O:'JULGT>K+U#ZT5LC7\I,26B+]6%?#G
M;.V7CJQ]U\9R0J_4I=Z80FT=')=&0Z;#6W+?SSSN+%=571CR&"=?EKMEU-=L
M,3'.F#O[7JG-.UOFXI,3YTPK+UO=*_LC45X=AMOATMNUGF)Y7U.TQV?7&&LS
M7YRUXF/,B60 $O(9"BJ'+<87/OVW;L<-.")BJ[$3%="(8F6)E]E= CH<UW+S
ME1LWDZH:1(,.H1EG:_56L5T.@V9D'0XE8JT5V#6OAP7,E)!KG-2/5)R2EVJK
MHK47U1,D&2NB6'LQ0;(6:D8=-H%FZ7)4>DR,)$1LO)2,!L&"URIC$C/1O6S$
M9U[YB8?%C/5SWJJ\+/L#O9Q+D4R7LM1:20^C91,H\O)5:LLCPU;-T*@(SKZ#
M9I4=]>#&APHRU.KPE;#B-J<VLK':JR$-&<]C$N^R[GR*N]8_2G[/U?D<5M]+
MI9FE-I\W)E[LF7ERF/B4GGYL3:/?S"V?5?T2_<[1>7S5VU>KBM[[QM;%A[\>
M+TQ//MY([^U,5F/<X7@ CI)P     '#Y[>W^"=E;_P BLY^V% .8,X?/;V_P
M3LK?^16<_;"@'N=&/A+A_P"6Z7Z^CP.E?P7Q'\AU?U&1YF:Z5*%5TJ4+F*/
M                                  [X/NJGXG<H'Z2HO[,T8[1YU</=
M5/Q.Y0/TE1?V9HQVCRHW3WX8U_SL?5T7,ZN_@7A_S,_67  :@W0        /
MS7+)_>E:;\WJY^J9P_2C\URR?WI6F_-ZN?JF</K@]_3Y5?VP^.H^YW^1;^K+
MQ^=O%?,#;Q7S!>-04  $2H?W-,_Y-,_[B(>O-T8/Q;V!_,JR7[.TT\AFH?W-
M,_Y-,_[B(>O-T8/Q;V!_,JR7[.TTA/KG^Y:#YS4?U<2>>H_[IK_DX?VY'[J
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M)$>Y5<^(]ZJY[XCG*KGO>Y5<][U5SG*KG*KE52\ D6(V1F  R
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MXIOGKCM>NIQUB*VK2(W\O6-JTMSB(O6(I:TQ7LUG:;<^B*5+6:$+B)4R@
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M4E-T)P -2]5[//GL)%_/88H6OLNX<H7II^SGGB8VYL2O !ED
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M:/57_?V&OFVG_P"IQ5^/Z\M(^Z1\:/=(W\_L<B0+6+@7$8I9
M      !U//>O_P 7.2;](55_9"H'1R.\;[U_^+G)-^D*J_LA4#HY%I.JWX'P
M_.9_K;JE];?PUF^9T_U<  )$1F'9=]UB_'U;']%E0_:6SYUHCLN^ZQ?CZMC^
MBRH?M+9\U'IY\$:[YG^]5N/5_P##/#_GX_JV=_, %15SP
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MMI_!9LW^=EN?V@F3GL*<]+?A3B'Y7J/K++M]#/@CAOY%I_JJ@ ->;,
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MK8U.6N^ET=JWMO'++GY3CQ<^4Q&W;R1Z(K68VR0^OVLNN6^_NQYW&0 K$MB
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M?:/U?\OP?H\CR<NL3^4WO'6)_*;WGK&_V.SH_P#Y#,CW^K.QG]3#^QV='_\
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M,'XM[ _F59+]G::0GUS_ '+0?.:C^KB3SU'_ '37_)P_MR/W4 $!K#@
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M/:/^KCUI.K3_ !O^T[U*YB;_ /M.]3H3URZC^18?TM_\KT/M':;^7Y_T./\
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M[N>&HDK@AA@ZUY[C,J7W)O#,LS$P\.XO*(5.-?'VRP  Y
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M;3,S,[S,SO,S/?,S/.92]2L5B*UB(B(VB(B(B(CNB(CE$1Z(6YI< <7(
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M\[+<_M!,G/84YZ6_"G$/RO4?667;Z&?!'#?R+3_55  :\V8
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MS0G!/(K=UP?"6'\CQ_79UH.I7X+S_EV3ZC3K@ 10F
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M M)H,<8M)I\>&NW/LU\^^WC?).][SZ[VF5,WG[2F;S@7 \QZRB)<5
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MS,_N4+0FGG6JZU72J[5[LP!$2:@
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M.JE2BH5,1W  #(
M                          %J%Q37W?$Q/=+$^'_G@POT\[C%$2]#-$3%
M%XH8W<]RB.Z&49NA%X^IAB)BBZ4QPNW]Q(NP1?\ &\\#'%U<ZT,B(]/!4\55
M/)+D,435Q^!)BI@XC1-7;Y 0(J8.($6_;KO\<$-A$T.YV$")Z>5X&OB7WKP\
MENYV:S5QK_!/#G!=&TVT32G/\8UL9/)?,#6Q;_K)M]._5SB:R-?X^:7>&[ V
MD5->[Y?$UL7_ +H&JBHFC<OF:J+I\]]]YMXNA.*_$U470G%-.K'X :^*FG'5
M?VKI\NP_/,J% 95;.6AI<3^UU&@UN1?@J_5FJ9-0M"*V^_/NNSFJM_X2)BGZ
M-$;<O?X7W=VHULS 2*QT)=$5KX5UU]_6PUAW7:[\[1KT:SE2_9F+1WQ,3^:=
MW&]>U$UGNF)C\\;/)R@PGL1C(C58]C&->U=+7L:C7M75>UR*U=Z+M))_:Y3Z
M2DA:BTLBB(B25HJ_)HF9U=WT2L3TNB=7?^]W)#NS,<R[-U'\47BQ7[5:V^^B
M)_/S4%RXYI:U9[ZVM7\TS  #Z/F&&*S.16_RFJW_ +2*WXF8L<N+5WF)[AZ;
MW0"M$M6R'9(*FY55T]DXLA,/O1B*CG4>5:J*UGU6JBM5%:FA4NPQ1/L2&F*<
M,>*<Z#C2]D+64GNC7D@BHYCD@V69(JK$6Y%IU0G9%6K?_P"L8LOF1%T*]'78
M8)R6M7%.WS*5<9Q]C6:NFVW8U.>NWJKEO$?L7MX)E[>BT=]]^WI=/;?T]K#2
M?[6TAZ$YU&S@K>B\$7GN-7!71Q-G T+P5.[G0>:]-M(;EN3CSYFPAKI7_&3T
M-="7#@OFJ7<ZC8P]?%/,#90]7"[SYNTDYBZ[M6[9\N.C8086E.*^'VFPAIHW
MW?% )</7P\<W3?PP^1/8JW]B>%R\^.!"A[.'=FW7DV%JX+Y(!-AZ5X&5B_63
M^:8H>E>'Q+VIBQ?D!*_E</B=7CWJ1?\ F9L'^DB%^H:B=HA-/8O@=7CWJ-/^
M9BP?Z2(/Z@J7H;=T#^&-!\]_<NTOK%^!.(_,Q]91T1@ 6Z4S "BJ!4']_8K)
M3:.T5.M/5:)2IBIR5C:3 KMI8DHG6OI5%F)^#3$JD:"BK%=(P)R8@PYR/#8Y
MDG#B-F)GJX%\1/SMK\;N=7*:MY\ZY:S-HB8F:S$6B)B9K,Q$Q$[=T[3$\_"8
MGNF'.V.U8K,UF(O&])F)B+1$S69K/=,1,3&\>,3'@R@ ^C@P*U4QV+AIOPT8
M\[CLF>P:]L _)'6I;)/E#J2KDQM%/W46JSL9RP[!UV=B79RO=?U-F*Q,/:E1
MAWI I,_$^ZS&PX,Q4G.ZW1A=#2['&_"Y<4NQP5-:+K39?I/(XUP7!K]/DTV>
MN]+QRF/?4M'O<E)GNM2><>$QO68FLS$^MP+C>HX=JL>JTUMKTGG69GL9*3MV
ML>2/&EH[_&)VM68FL3'LFP9ED1K'L<CV/1KF/:Y'->UR7M<US;VN:Y+E:YJJ
MCDN5%N5"2=.OW?#VPWTUE)R 93JI?.P(;)/)G:6H1TOG)>$W][L55)F,^]TY
M+PTNLS,.<JS,JW[CO5L:7D&S'</:^_P\RI/2#@.;AVIOILT;[>=CR1&U<N.?
M>WK[=MK1WUM$UGG"Y?1KI%I^*:6FJP3RGS<F.9\[#EB([6.WLWWK;:(O68M'
M*64 'B/?             '4\]Z__ !<Y)OTA57]D*@='([QOO7_XN<DWZ0JK
M^R%0.CD6DZK?@?#\YG^MNJ7UM_#6;YG3_5P  D1&8=EWW6+\?5L?T65#]I;/
MG6B.R[[K%^/JV/Z+*A^TMGS4>GGP1KOF?[U6X]7_ ,,\/^?C^K9W\P 5%7/
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M7BT1,3$Q,1,3$Q,3$]TQ,<IB8\855FLQ,Q:)K,3,3$QM,3'*8F)YQ,>,3$3
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M9K:)BT3,3$\IB8Y3$QZ8GDN?2\6B+5F)K:(F)CG$Q,;Q,3XQ,<X  <7(
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M/L32QH,%MM1JZSY28GGCTV^UO9.:8G''XD9.[S9?F3.=O;O,A:UMQ<61A6"
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M1YGWL"?X5N3+A:;]G*@>F"S0G!/(K=UP?"6'\CQ_79UH.I7X+S_EV3ZC3K@
M10F                         /S7+)_>E:;\WJY^J9P_2C\URR?WI6F_-
MZN?JF</K@]_3Y5?VP^.H^YW^1;^K+Q^=O%?,#;Q7S!>-04  $2H?W-,_Y-,_
M[B(>O-T8/Q;V!_,JR7[.TT\AFH?W-,_Y-,_[B(>O-T8/Q;V!_,JR7[.TTA/K
MG^Y:#YS4?U<2>>H_[IK_ ).']N1^Z@ @-8<              #$K[EU=^CL
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M%#:F#60X4-K&-30UJ(;TP0]*\7>?J9RDDSOSGOE?.(B(B(Y1'*(]0 ##(
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MOOV<&>WWN');T]U+3W/+\E?P6)_B-X?@IHYT$LC2Z8-_FHG<B8DDN[50BO=
M #+D$6<6Z%%79!C+NPAN4E$2>8KH,9K457.@1VM:FESG0GM:U-N<Y42[6JH8
MEFO?'MAZC?16I+9')ID\DVL?#;+V(LI#1D2_K&I]PY)]S\Y$6^]ZKBE]UQ]"
M0ET?S5^)^99(H+H=DK*0WHK7LLI9=CVK^$Q[+.TYKV.WM<BM7>EVH_3V)H_F
MJ4?U5M\F2?3>\_GM,K\:6O9Q8Z^C'2/S5B$N'I7P[DT<#:PL+_YIK8>ONX7Z
MTWFSAZ^#?@?!]VSA:EYT&RA)HW)Y)\S6P]"<5-HS3V+Y(!.A)@G!390]/8GC
M<:Z%H3^:ILX>W<GFG.($Z$FCG63&+A_UOB0X>KL\U)T-,&\0)T/2O=X7DEGX
M*\5(L+T_V24S1V_$"0S\)W.PR7X.XH8(6E>=?/V&94^JO\X$,T/0G!/B96KC
MV)YF-B?#R0R,3%>*>0&9=14
M                                          Q1/*[Q,3N?(RQ/3S4Q
MKZ>8&#^*NY;_ !,,;0F[Y&1/XW#XJ61OP0,3TO1=Y$BZ$XDU_P /@0XFCM0"
M#$;B[O($1-'#X*;&)I7AZFOB)@G!$[[T U\34O.A%\S7Q4Q5-B+SXFPB>O\
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MB8G:5QN'<1PZO!CU&GO&3#EKVJ6CT=TQ,=\6K.];5GG6T3$QO"\ '4=T
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M2*5CQG;OM;TWO:9M>=N=IF0 '1>B
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MB%L^JGCTZSA=<5[;Y=';['MOWSCV[6"9]E)\G'S>_BR  CM)H
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MF5S<.*N.E,=*Q2E*UI2M8VK6E8B*UK'A$1$1$>$  /F^@
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M;V!_,JR7[.TTA/KG^Y:#YS4?U<2>>H_[IK_DX?VY'[J " UAP
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MCMUC^+RQ&V3'/CO6^\1OWUVM'*890412IX[W
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MG;Z>2&2'I7C\#&WT\D,D/2O'X 9@
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M#%NZ6+=TO0!]@;_!EL=_GBV?[33YS/M7GLYQ.%_V!B__ $,ECE__ &S;-/\
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M^BRH?M+9\U'IY\$:[YG^]5N/5_\ #/#_ )^/ZMG?S !45<\
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MX4XA^5ZCZRR[?0SX(X;^1:?ZJH #7FS
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M:QX+>=5_!8T?"<%IKMDU?[YR3X[7B(Q1OZ(Q168CPFUI\97  T)(@
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M7L5'L>U',>U45CVN2]KF/2]KVN145KFK<J*BHJHIG:Z\TIO:X
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M+5]"X,  #(
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MSTM^%.(?E>H^LLNWT,^".&_D6G^JJ  UYLP
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M?]ZR_%+DY_2,_P#9JI&W] OA?0_.6^JR-*ZQ?@3B'S5?K<;HG:^_X%2FOO\
M@5+<1W0IE3N  9<G,;[ G^%;DRX6F_9RH'I@LT)P3R/,^]@3_"MR9<+3?LY4
M#TP6:$X)Y%;NN#X2P_D>/Z[.M!U*_!>?\NR?4:=< "*$P
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M4NF['"YOMSS:C+??QVK%,<?KI957KCU7;XO%/##I<5-O#>TWRS/T^4B/HAE
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MK:/3%JS,3'LEE !\WU
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M01++"Y\.?(S)^$G:G:8(&OL\C,JW7<3$C.OIYEQ;<B\["J"O<PJ #+(
M
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MM$=EWW6+\?5L?T65#]I;/FH]//@C7?,_WJMQZO\ X9X?\_']6SOY@ J*N>
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M4X7PZL>&ATOYYP4F?US( #PVP
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M?\5L=?[D+$=1N./(\1OXSET]?HK3+/[;RO !"R>
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M?P6;-_G9;G]H)DY["G/2WX4XA^5ZCZRR[?0SX(X;^1:?ZJH #7FS
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MTN'28(VQX:12N_?:>^U[;=]KVF;VGQM,@ //>D
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MLQ M;D[M%*5VF.5D.<@MOEZI1YQS<Y:?6Z7&NFZ9/,5'(D*.SJX[6K&E(LQ
M5L5WU"CK^?D0SGP7Q7MCR4MCR4F:VI>LUM68[XFL[3$^U.6GU&/+2N3%>N3'
M>(M2]+1:EHGQK:-XF/8N !\GV
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MP[K^/KH,IQB.]@ !R
M                             "\H[0%+7K<G Q:/_/4,.M5VJ8(KM7'T
MT<?#$SH1U5<Y.=-Z_9MUF11VO<B>2D76[L3Y)S@2472NV_@1FHG>J^&.&[E
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M57_&^"\\=P$A5P7L\CJ]^]2X9&+!?I'@_J"I>IV@7:%V*OEL^/@=7[WJ=/\
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MUM-J4_3XN>C4=UDC-QI5^<C'/8CLZ"N<C'N8BX-<YJ(JSIU+Y/A&OKTMH_\
M]B)G]GYU?>O/%SX9?U:RO_33']OYFG !.B 0Q/3%.>;]1E,,3T^)B6)>F][!
MZJNF^B=D<B/S,Z'1JY+*D-<$;)VPM'*PT5+U7/6%"AN>BW+G+G7(BH<O!P*>
M[<VR95.BY9F4:Z]UG[26QHCTN:F:]E6^Z>;]5J*[ZE4:[.<KG?6NSKD1K>>L
MIMTHQ]CB6OK_ /W-3,>RV6]H_5,+O]$<T7X5PZT?R+2Q/MKAI6?UQ( #P6Q
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M^L/U&9/<>(T\8RZ>_P#QTRQ^:.Q^MLP$!"B>0
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MG\%FS?YV6Y_:"9.>PISTM^%.(?E>H^LLNWT,^".&_D6G^JJ  UYLP
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MI?L_-7;4ZNL>3B8YXM-OO7V6S3MDM^)&..4]J%6)<A< 16EX
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M;IIGV>6IO^IZA4);T1=W/.XR&& OU&WZ;DO3>B8F8IHO
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MM#.[+#7%>ST,FOM^'/V&!<%O[%^"]BDE-!QWYL2J #D
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M?TE+K?=5FOC/P731OO;!;+@OZII>;5COG^+O3Z/#;9D !H:0P
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MGL*<]+?A3B'Y7J/K++M]#/@CAOY%I_JJ@ ->;,
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MZ*9QSMJ-1VL6"8^+.WGY?1[G6?-_'FG*8W;]U==%8XIKXC)&^FTT5S:B/O\
MG[GB]F2T3VOQ*WVF)V<J= HLK39.4I\C+PI22D9:7DY.5EV)"@2LK*PF0)>6
M@0FW)#@P(,-D*$Q$N:QC4U*;LHC40J51F>^9[YG>97!B-N41M$<HB/   9
M                                 .J_[UE^*7)S^D9_[-5([4!U7_>L
MOQ2Y.?TC/_9JI&W] OA?0_.6^JR-*ZQ?@3B'S5?K<;HG:^_X%2FOO^!4MQ'=
M"F5.X !ER<QOL"?X5N3+A:;]G*@>F"S0G!/(\S[V!/\ "MR9<+3?LY4#TP6:
M$X)Y%;NN#X2P_D>/Z[.M!U*_!>?\NR?4:=< "*$P
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M=H]%J6FL_KA?/1ZJN?#BS4YTS8Z9:3^+DK%Z_JF  'P=D
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M^!@:MY=#P6[FZ[UU&+?_ ",Z<]I4M73W<\]A<98C_P _L  &0
M                                                       "BE2V
M\&Y@G/%2.W;M6_Y]J%\5=6WE>&&A2Q<$P[#%9W@88RZ$VW%JKBJ[$N]?AP*(
MMZJNI+]V!:Y;DO[?CYZC++$]?K*MVCQ75VH8G:DV7^A=J2[3BJ]WKH,%^O?A
MPU_$,,+]*\/6_P"1">F";^<.[227OP7'%?CY<KK(,5WAV:='@!%B+N^&]<=R
M;2"]]V.Q%O\ ->[ E1%3%=7.G9RI B+HOUW*OCX:OF!"BKI[N%^F[SOUD&(_
M3AH3CJQ[46XE1%^*^GK\C7Q-6_%>S'QON5 (,9W<JW=B<KAN-<Y>[%5V\W>A
M,C+I[NU?*[1YFMC+IV:$Q71MXX< -?$=HT:;^Q-'@A"<NE;]7=K7S)<14Q3A
MXX7<Z^PU\1?%=&Y-._5WX8 18CV-1%B/;#AIC$B/5&LAPTQB1'N7\%D-B.>]
MRX-:U57 \O/I89576YRH90K8*JJRT=LK0U. CKT6'*1ZG,-DX*8JJ,@RK(,)
MB*J_48W%=*^B1[07+$E@<BN4ZU38C84Q3K'U>!(*JW*^I5:7=2)"'#7"Z*L:
M>SH*HMZ/AHZ^]#S.$AN1$15SE2Y%>JWJ]4TN55TYRWN55TJN\G3J;T'+6ZJ8
M[YQ:>L^S?)EC]>'\ROG7AQ#GH-)$]WE=1>/;-<>.?U9F8 $Z("  !8\[N_NV
MN3!:7D9M):6(Q$B6LMU/)!>K$:_Z'9NGRE+1B.OSG0G342/%;?AGN>J:SI#1
MGHU%<N.:BNNW)B>DM[+').MC.CYDIHL2$D*:BV3DZW.W-1JQ)NTKXM>5[VXW
M1/HM0E(;T7ZW[U<ZY?JMBGK<UGD^'8\43SU&HI7;\3'6V2?HB\8_SPEWJ8T/
ME.*9<TQRT^EO,3^/EM7'6/;-)R?FER$LQ31IN\K_ #T&S@I<B]V'A=O-?#3%
M,+[D7G??=@;."W!$QVKMN39VE;5HVPETN5-RHF'#1WX\3:0,=6WQ^.XUL)-&
MW%>U<$7=CH-K"3!;M5R)NOV=H$Z%H;PO[M!L8+<%VHB>OR-?#;JNV)IUZ5^W
ML-E#T+LON^5WAP F0TN3R7AJXW^&!/A)HNU:N"?,B0T30FA.W7Z:B="1<5V<
M]N'H!*8N"X;?%<._43$7#1K3PN]/ BL3!,-GGB2TU=J_!._8!G<NG@G.Y20U
M/JHFG1Y_ C__ *2Z-R:[^'H24U;U];OL OTN7#4J'5]]ZH_$W8/](\+]05([
M04+%56[XG5]]ZH_$W8/](\+]05(VWH%\+Z#Y[^Y=IG6)\"\0^9K]9C=$$ %N
MU,@HNA2I1="@=H+W5'\=.43]&2?M133OGG0P]U1_'3E$_1DG[44T[YY5OK2^
M%\OS.G^KA;/JC^!<7SVH^L  1VDT       !8]MZ>/=SV:3I0>\'>Q[;28U5
MR^9,:6J4V8>^<RF6;I\%.KI\P]56-;6G2\.Y(<E,.N6TLM"AYLM,*M;;="C3
MZP^[$0*A(09F#&EYB%#CP(\.)!C08T-D:#&@Q6.AQ8,6$]',B0HK'*R)#>BM
M>QRM<U6JI[W1SI#GX;J:ZC#.\>]RXIG:N7'OO-+>B?&MMMZVB)YQO$ZYTHZ-
M8.*Z6^FSQM/OL.6(B;8<L1YMZ]V\>%Z[Q%J[QO$[3'C>-<B\\_$N.P+[<?V1
M,?(;:-^4"PM/B1,DMIY[-27@-?$2PU=FWNB+0YA;EZNA3SU<ZSTT]V; =G4:
M,J1(,E$F^ONUZ+SSY%MN#<7P:[3X]3I[=K'DCN^-2T<K4O'A>L\ICZ8F8F)F
MF_&N#9]!J<FEU-.SDQSW_%O6?>Y*3\:EXYUGZ)B+1,1> #U'E,<1MZ77(MZ*
MERZ%1<%14UIM.[)[OG[8-U?@TO()E.JM]=DX#93)M:*H1OWRMR,O#<K;)5&;
MC/OB5B1@,5*#&B+GU*0A_<YSHD]+2_TGI/DF1J<Q)3$O.2<Q'E)N4CP9F5FI
M:*^!,RLS+Q&QH$S+QX2MB0)B!&8R-!C0U1\**QKV*CD137NDO1S!Q/37P9N5
MN=L66(WMBR;<KQW;Q/=>N\1:N\<IVF-CZ+])L_"M574X9F:^]S8IG:N;%OSI
M/?M,=]+;3-;;3SC>)]D*%K[#*=?SV'?M=)3+K9AMB;:3L*!E:LK(0UGG17-8
MEM*-+HV"VTLBQ$:S[H0;X<.T4BS&%,/;4H#5E)I[97L -=?]A4GBW"LVBSY-
M-GKV<F.=OQ;5^+>D_&I:.=9^B=IB8BY/!N,8-?IL>JTU^WBR1O'=VJVCWU+Q
MSVO2>5H^F)FLQ,]3_P!Z_P#Q<Y)OTA57]D*@='([QOO7_P"+G)-^D*J_LA4#
MHY%D^JWX'P_.9_K;JO\ 6W\-9OF=/]7  "1$9AV7?=8OQ]6Q_194/VEL^=:(
M[+ONL7X^K8_HLJ'[2V?-1Z>?!&N^9_O5;CU?_#/#_GX_JV=_, %15SP
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M3H+SM&>(SX8F?XS''9R5CTS;'M;V8I<\@+6Z$+B %C@
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MPYJY*4R4F+4O6MZ6CNM6T1-;1ZIB8F/4  ^;Z
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M21I7^UP_YK/]A"27BC_']J@5.X !ER8H_P" _P#F.\E/7NZ./XO;"?F99?\
M4<@>0C'_  '_ ,UWDIZ]W1Q_%[83\S;+_J.0(2ZY_N7#_EZC^KA3QU&_=>(_
M-Z;^MF?LX ($6(                                      ZK_O67XI
M<G/Z1G_LU4CM0'5?]ZR_%+DY_2,_]FJD;?T"^%]#\Y;ZK(TKK%^!.(?-5^MQ
MNB=K[_@5*:^_X%2W$=T*94[@ &7)S&^P)_A6Y,N%IOV<J!Z8+-"<$\CS/O8$
M_P *W)EPM-^SE0/3!9H3@GD5NZX/A+#^1X_KLZT'4K\%Y_R[)]1IUP (H3
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M?)[$SCCUX[>AG !'23@
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M///>7&&$NF_G9X:C(B<[SC$^ N !R
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M8VOFBVHO_OI[5-_7Y*,<?0IWUE\5^RN,ZN8G>F":Z:G/>(C#&V3;_?3EGDJ
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MYT,/=4?QTY1/T9)^U%-.^>5;ZTOA?+\SI_JX6SZH_@7%\]J/K  $=I-
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MF%VN \:P\0TF'5X)WIEKO-=]YQWCE?';\:EMX]$QM:/-F)7  \I[
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M6Y,N%IOV<J!Z8+-"<$\BMW7!\)8?R/']=G6@ZE?@O/\ EV3ZC3K@ 10F
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M4Q,<XF.^%0 8<@
M              !Q/^VTR%P;?=&;*G(N@LBSE H3[:4R(]53Z+.60B-K,689
M<MRN^Y<"I0+E145(ZWZ$/,,AN1414T+<J<%2]/0]>?I'T)M5R?6\I;H:1FU&
MQEJ)!T%[D8R*DY0I^76&YZJU&-B)$S7.541$55541#R%);^UL_FM_P!E"P?4
MUJK6TNLPSW8\^.]?5Y6DQ/T>Y;^W=6WKOTD5UFBS1&TY=/DQVGT^1R1,>V?=
M9CV1$,X )E0B$&9_ >FUCO\ 97FXG$2/BUW\UW#\%3$L2]>CHPVC?6,FV3VK
M1,[/JEA[)5)^>C$?GSU I\R[/2&JL1V=$7.1BJQ%P:JHA^YGRCT#TFDR'Y&D
MG559U,E&3I)M55BJLTED*1](55A?O:JL7/O6']1?XGU;CZN*1:ZL5SYJQW1E
MR1&W=M%YB-E]N'WFV#!:=][8<<SOW[S2LSOZP '5=L
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M\.<> AX.NVZ.[Q#*2N&/9SP)&HP+B7PW:ETW;/'A\3$L,J+L*EJJB:BXR
M
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M/=4?QTY1/T9)^U%-.^>5;ZTOA?+\SI_JX6SZH_@7%\]J/K  $=I-
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MF)F)A;C0:_#JL-,^GR5RX<E>U2])WB8_LF)Y6K.TUF)B8B8F%P .J[8
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MZS'6/+X-]I]$Y<43SMBM.WC,TF8K?OK:W[0"W/0N-,;R
M %CG<]X!ZX8'![[:#VL=/Z/5CUH=G)J4G,K%JY&.RSD@[,F6V=DHB+ BVMJT
MOG*C84JY7MHLI,-5E5J4/&'%DY.=8O\ :>U:]KQ8_HXT%U/EUE+293ZO*/?9
MZR,..BMDH<6&]L&O6F6$[K9&B0XJ)U,"^'.UF(U9>11L)LS.2WG&9:LM%I\H
MEJZU;6V-5F*W:2T$XZ=JE1F,U'1(ER0X4&#"8B0I62E(+8<K(R4!K8$I*PH<
M&$U&LO65.K_H';6WIK-72:Z.D]JE+1SU-H[HV_ Q,>=;NO[RN\=J:Q#UC]8=
M=#2^BT=XMK;Q-<F2O.-+68[]XY>7F/>5^)[^VT]F+?P%8K4Y4YV<J-2FYB?J
M%0FIB=GYZ<C/F)N<G)N*Z8FIN:CQ%<^-,S$>)$C1HKU5T2(]SETD%$N*@LE6
ML1RCPY?1Z/H5=\=YYS/.9GG,[^F>\ **IR%3[O\ 9J="R?R]98;+V"@PXB45
MTQ]V;83S+T;3[)TR+"B5:)GYKFMCSR/A4F0:Y+HD[/P;_P![9$<SX+<F<J(B
M*Y5PN:BN5<=#6M17.<JX(UJ*Y55$3%;CT=?8,>SBB9$,EC*_:6027RBY1(4I
M6*_"BL:DU0Z*UCHM!LRYV+H<:6@QGU"JPOJ*VJ3D26B-<Z12([2^G/26O#M%
M>U9C[(S;XM/'CVYCSLFWHQ1YV_=VII6=NTW?H!T7GBFOI2U9^QL.V;4V\)I6
M8[.+?TY;>;MW]CMVCWL[<X=G+/R5+D).F4^6A2DA3Y67D9*4@L1D&5E)2"R7
MEI>$S^+"@0(<.%#1-#6)?CB;TL8EQ>5,F=^<\YGGO/>N1$1$1$1M$<HB.Z(]
M$  ,,@            "U^A>"^1Y='MFOX4>6G\[5_5=./47?H7@OD>71[9K^
M%'EI_.U?U73B7>IS^'ZG\DGZ[$ACKM^#])^61]1F<9  +%JS!:[X+\"XM=\%
M^!B>Z6)[I>C-[MI_!9LW^=EN?V@F3GL.!/W;3^"S9O\ .RW/[03)SV%.>EOP
MIQ#\KU'UEEV^AGP1PW\BT_U50 &O-F
M        _/<K?]ZMI?S?K7ZMFC]"/SW*W_>K:7\WZU^K9H^N#W]/E5_;#Y9_
M>7^3;]DO'HE?[7#_ )K/]A"21I7^UP_YK/\ 80DEXH_Q_:H%3N  9<F*/^ _
M^:[R4]>[HX_B]L)^9ME_U'('D(Q_P'_S7>2GKW=''\7MA/S-LO\ J.0(2ZY_
MN7#_ )>H_JX4\=1OW7B/S>F_K9G[. "!%B
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M,'XM[ _F59+]G::0GUS_ '+0?.:C^KB3SU'_ '37_)P_MR/W4 $!K#@
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M.QL2#'@1H3G0XT"+#<V)"BPW.9$8Y',<YJHILD5%T$!+&Q*H
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M/*8GN,66MZUO2U;TM$6K:LQ:MJS&\6K,;Q,3'.)CE,+@ <',
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M #D
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MN^ZQ?CZMC^BRH?M+9\U'IY\$:[YG^]5N/5_\,\/^?C^K9W\P 5%7/
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M!DOBRXY[5,E)VM6?V3$QRFL[UM$S%HF)F'J0^SY]J=DMZ1-)2+96I-I5JI6
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M!/W;3^"S9O\ .RW/[03)SV%.>EOPIQ#\KU'UEEV^AGP1PW\BT_U50 &O-F
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M0/3!9H3@GD5NZX/A+#^1X_KLZT'4K\%Y_P NR?4:=< "*$P
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M-ZK@NF[88(;[TYYYXF3'4)C<9T*EC%O0JBH8K/YV%P .3(
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M .I!]\']$[\IZ_T3M?\ U(>:KCM48[5'VG^&_AM9^DP_Z<^W5Q7\!H/T>?\
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MZ]W1Q_%[83\S;+_J.0(2ZY_N7#_EZC^KA3QU&_=>(_-Z;^MF?LX ($6(
M                                  ZK_O67XI<G/Z1G_LU4CM0'5?\
M>LOQ2Y.?TC/_ &:J1M_0+X7T/SEOJLC2NL7X$XA\U7ZW&Z)VOO\ @5*:^_X%
M2W$=T*94[@ &7)S&^P)_A6Y,N%IOV<J!Z8+-"<$\CS/O8$_PK<F7"TW[.5 ]
M,%FA.">16[K@^$L/Y'C^NSK0=2OP7G_+LGU&G7  BA,
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M.:HG2#H[JN&9YT^JQS6><TR1SQY:;[=O';EO'IB8BU9Y6K6>2X%+RI[;PP
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M1'N>'>.7F1,S?;OR6M&\Q6LJHEQ4 T1(8
M          %MV%VXN*7F)$=4N5>\QQM';X:S+$TW\$7X?'@F):Y+^>?M$2(J
M:EXHO/J8HJ7*B\;[EU:>>XR-32G;MNNUW\.\I%Q3LO3CI[KK[^XR2BO3!=UW
MAHW\3!%U+W\/EK)2Z-RHO>G.._ CN;?ALPQUI=Z^H$!Z:=_G]F-VPA/3O3E4
M3BF*;#91&X(J]O==V\J0HK$1=NOX*O;Z :N,FO9=KT:EX+<0(S,5PW\=N'-R
MFUB)SX+X>.! >U>Y5].VY+N*W@:J(FS=\[MMVC<:^.V]>R]-^I?EO-K$;V78
M=^K?>08D/3NONQU?8O9<@&CC-\,%7=J7LVZS7Q6X*JZM/.K;P4V\5NE/^KW:
M/3Q($1-._3QU]EW.(&D>S5X[+]&[3@<2_MH.BL[*ED*M+"D95)FT5C+K:V>1
MC5='B1:/!B+5Z?!S6N>YU2HKYMD."VY(\[+R*/5&0[TY;H[;E\%]?+'4:^/#
M:Y%:]K8C7-5KV/2]D1CD5KX;TULB-56/;?\ 68YR7XG>X9K[Z748=1CY7PY*
M9*^OLSSK/JM&]9]4S#H<5X=CU>FSZ7+'N>?%?%;TQVXF(M'XU)VM6?"T1[7D
MUM>BHBHJ7*B*BZE1<45-RI<J;C(??/M/^BF_([EHM;96! ?"H,Y-?NDLH]43
M,B6=KD2+-2D%CD1&K]S9GZ72HK6IFPHDDL+0R]?@5"YV@UM-3AQ9\<[X\V.F
M2D_BWK%HW]$QOM,>$\E&N(:')IL^;3Y8VR8,M\5X_&I::S,>J=MZSW3$Q,<I
M5 !W'3"Q_/.GN+P!VOO=O^F&W-M%D2K,TJ.59BUUBDC1%NNNAP[34: CEP5$
M^C5F7@M7&ZH.APU5T>(G;+8[1MV;M:<-:'EFY",M-:R<VTLS;FST3JZQ9BKR
ME5E$55S)A(#E;,R,9$5,^6J$F^8D)F'>B1($S$8JHBK=Z;.0O+)1\H%D;-VV
ML]&2-1K44B3K$BJN1SX+)J'?&DXZI=_QF0F6QI*916M_?I=[D:C7,OK;UJ]'
MOL;65UF./<M7[_;NKJ*1':_25VO'IM&2?!:'J@Z2?9.AG0Y+;YM%M%-^^^FO
M,]CV^2MOCGPK3R4=\OV:$[5JU<IOQ\";+ONPV8*FU-J>&DU4-VA-F*<ZT3;Z
M$YCM"\]J>&_"\BE+[=0W*FS'1\?EW&QA/\;^U%7%=UW.HTT%W>G/?M^6.P@N
MT=Z<]MUW:!NX;]&O5JYQTIP4FPGZ-"XX+M37W:C4P8FA=R:=G.K9B3H;L+MB
MWIY=U_AB!N83O#%,=*:OGM)D)V'#OP\]G U,)^K<MWQ3@3V.T+J6Y5O[O+U
MVK'+RNK6G9J4F,=W*OV]Z=QK(;KKTT\X7]UUY,AKH3NYW78=P&RAJF*+V)NY
M4D,<NCNYW*06+WIAW_!?,DM=>B;KN53G:!*ONQ[TYU[#.BWIAIN2_>1FNO[%
M\^<%,D-;ENU:M6GGL S?XR)I\%1<>>PDHY%T$9=>M%P5/CSYAKLU=J+KW>FX
M,I.*:-!G147GTW\XF%%O0([-YV\XF)CT=["0A4M1<"J*(EA4 &60
M                                          "BJ AB9V8D7 CN6]5V
M>95SL[#5Z:N>!30@B/2R*J(15Q5=B+IU<ZO(N<Y56Z[MW+RA8B8;DW8KQU8?
M:9%U^WL3G7SM([EO5=B>.*\H5>^_#@O/QUF-RW(NQ-'KQV 6N=CO\DT>'BNX
MCO5+L-/CL7N+W.NQ7CMN3#!.<2,];K]^%WPY] +'[-R7]_Q^!!>_?V;-_H9H
MBZ4OTZ="7:/L\2$]4YU</._1?@!B>[7HNP7Y\$\2&]UW'PN]43$R/6_L1%[M
M"=NL@18F_P"Q-*]N/PPO PQ':;L=5_9BJ=A!B.U[+KKDUZ-/'OQ,SWZ[M*>&
M[PXD"*_1N^U>Y-'J!&CNTHO.&*\$V:4U&OB.O\.[7W_-3/%???O1-.S;Q\S7
MQ'W8[<$3P^:_("+&?X:-ZKI5-?*$&(Z[#Q\^W5AY&9[\>&"X78[>SYD&([G=
MBGEWW@87NUZM"<-NZ_#P. _V_O2__<'DH982E3:0K1Y3XD>F16L=^_REDI%8
M42O32(F+$J$5TI1H;OXS)B9:B*Q7JWG>JE4@2<O'FIJ/#E924@1IF:F8[T9
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MYUG:8[IA!&OX=GTN2<6IPY,&2O?3)6:3MZ8W[XGPM&\3'.)9@6M=>7'==,
M              !8Y]WV7EKHJ)?>J(B:UP\=7.S'&[&Z_.3:6N<ERXI=M5<,
M5N1.U;D1-:JB)>JH<D_0J]DMEMRZQI:8LI9:-2[,1G,6);:U#(]&LTR ]S46
M-(QHD%TY7+D=G(RBRLZQUSF]<U4<B=T+V?7L ,DF1I9&T%I&-RF6]E\V,RLU
MZ3A,H-&FM.=9^S3G3$M#BPEPAU*JQ*C4%<BQ9=TBU_T:'I72+IYH>'Q:MLD9
ML\<HT^&8M;?_ &EO>XH],6GM[3O6ENYO/1GJ^XCQ.:VIBG!II[]3GB:TF/\
M9U]_E\=IK'8WC:UZO@7W9/HW9<;&R]J;06CI;[/Y)[82$K.4RF5[Z1*5NI6@
ME5A0Y.T%&I+H:192EQZ8^+*3L[/I+)4V0J<^1A1X4LL<[<IA8VY?FJKXXKQ[
M-1F*S=(.-6XAJ\NJOCQXK9-O,QQ.T16(K7>9YVMM$=JT[=J8WVB.46KZ-\"I
MPW1XM'3+DRUQ;^?DF-YFTS:W9B.5*=J9FM(W[._?,[S( 'C/=
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M\7MA/S-LO^HY A+KG^Y</^7J/ZN%/'4;]UXC\WIOZV9^S@ @18@
M                            #JO^]9?BER<_I&?^S52.U =5_P!ZR_%+
MDY_2,_\ 9JI&W] OA?0_.6^JR-*ZQ?@3B'S5?K<;HG:^_P"!4IK[_@5+<1W0
MIE3N  9<G,;[ G^%;DRX6F_9RH'I@LT)P3R/,^]@3_"MR9<+3?LY4#TP6:$X
M)Y%;NN#X2P_D>/Z[.M!U*_!>?\NR?4:=< "*$P
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MTBN^O%CL60JC_K(VIPU>]731T8ZUYKV<7$JS:(Y1JL=8[7H]UQQW^N^.-_\
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M_P!C,BZBXM1;TT]Q5!$L*@ RR
M          !10H0Q,BW>MQB<Z];DT8?9Z^!1SL[#5CQ^14Q$>D4T&"(_&Y-=
MR:./.[6(C\+DU^'/.PMNNP33K7CL^9R%$V)VKPYY4QQ'W)<G-R\[UU%SWW)A
M<8%UKKT_&[C< 76F_'9HT)PU[=)A5;UOU:O7G45<M^&I%YT:OF1XC]*:M=W.
MG[ */>BJBWX7:_/G:0WNU\\[=VPR/=?P3AI]$[B&]VG:E]Z<><-=P&-[]-_'
MG=C<0XC\.>;MNI>!D>['G0FGT3?B0XBX7Z]"<Z=Z^@&*(_2E_'BNKM7T($2)
MI[^[5O[,-!DBOV;[EWZ/#3?J4@O?X7W[L?G?N7 #&]^"[5X7)]GF:Z*_?A\-
M7?NTF>-$T^6W8GJ:R*_1Q[_LT[@,41WX6S7Z>NQ-YKXT39C?^#SYF>+$U;<5
MX)S=PQUFM>[7=HO]._&Y-P&*(NKO7M^.G@1'O\L.=N.*%\1VK#'3Y7?/7<?P
M.4C*'1[*4&LVGM!.,I]#L_3)RKU6=B+]67D9&$L:,]&WHKXCLU(4"$WZ\>8B
M0H$-'1(C$7E2DVF*UB9M:8B(B-YF9G:(B/&9GE$1SF>3C>\5B;6F*UK$VM:9
MB(BL1O,S,\HB([Y\(Y]S@M]O]TV_W"9.8.32AS?56IRDPXT&H.@O1(U-L5+O
M1E3B.5%SX3Z[,YM)EW78RK:HY,Q_4/7H^HW1Y=W*)H1.X^H>F9TIJOEFRDVD
MM_5T?!2KS:PJ13G/SV4>S\GG0*-2H>I%EI.Y\RYB-;&G8TU'S6]8C&_,1;CH
M5T>CANAQX;1'E[^ZZBT<]\MHC>N_C&.-J1X3V9MMO:5,>G/2:>*\0RYZS/D,
M?N.FK.\;8JS/G3'A;):9R3OSB+17?:L  -N:>  "QSKCM#>[=]$9:C:"TF6:
MJRU\I9^'&LK9)T1N$2M5" U]>J,%5;<OW/I<2%36O:J*R)4IF&Y%1Z*WK06*
ML35+2UJDV>HDJ^>K%=J,E2:7*0\7S,_4)ADM+0M"YK5B1&K$B*F;"A-B17W,
M8Y4]-KH?]&^FY),F]D<GU+ZM[+/4J#+STY#8C/NC68__ !FM5-Z)>JNGJG%F
M(K,Y7N9 2! SG0X+"+>M3C_V-HOL6D[9=9,TF(GG&"NTY9_G[UQ^N)OMW)9Z
MHNCLZKB$ZO)7?#H8BU=XY6U%^6*/YD1;+O&_9M7'O[Y],0DPOX?9\#90&:,-
MZ\-7/?<0X;47AIX:DO\ CL-G"AK==HOT\/L\<2M*TZ1#;]JZ+D6^_P">M39P
MH>.]<?3G7I(D)/%?!//XZ3:0&Z+^/GY:NT"1#30FS'GY8DZ$FWCWZ.[NQ(\)
MJ+=WKIP3G0NPV,%EZ^*WIKNY4"5#3\%--VGGCY$QC='9IPO^U<4OV$:$W9KN
M]+KTV:5[R<Q-&G1ANOP3M32O@!(AIQV<]O>F&@FL35JTJFV[2G:NC:88::$V
M>MV'."$V&E]Z[_+YXH!E:F*)L3'9Q,VK<JIJU?/5XF)B<;U7Y8=EYG:EZZKF
MX)=Y\?#4!GU(FB_#@+L438B8;-W;YE;[NS#O31Q\"Z$S7?CRO/H&4B\R0M%^
MV]3"[9S=K)#='>8GU,'V=YU<?>JW_P#,U8/])$']05,[1R'R7TNN@]DVRZ4.
MG6=RET29KM)I542LR4O+UNM4-T*H-EHLHD99BAS\A,16I C1&]3%BO@WNS\S
M/:U4][HSQ/'H]?IM5EB\X\.3M6C'$3>8[-H\V+6K$SO,=]H:[TIX5DUW#M5I
M,4TKDSX^Q2<DS%(GM5GSIK6TQRCPK//\[R8[UV>(O79XGI+?>[/1,_)W5/\
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M+T?S<,X?CTF>V.V2N3):9Q6M:FU[;QM-J4G?T^;  #5&X
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M&0X3&0X<-B,APX;&L9#8U$1K(;&(C6,1J(B-8B(ER7)<2VI<7 TUO
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M8G'.29[7;Q8]HGM1MMOX]S?@ C)*P
M      '5>]ZS7_FER<_I&?\ LS4SM0GR+TON@SDUR[4>F4'*90YFNTNCU-:Q
M(2\M6ZW0W0:@LI%DEC.CT.?D(\9OT>-$8D*+$?"179Z,ST1R>[T9XGCT6OTV
MJRQ><>&\VM&.(F\Q-+5\V+6K$\YCOM')KO2SA.37<.U6DPS2N3/2*TMDF8I$
MQ>MO.FM;3MM6>ZL\WDR-?>NA?#B7WKL\3TE4]W8Z)B?_ (.ZK_K"R@_^92OW
MNST3/R=U3_6#E!_\RDZ?;?X;^!UOZ+#_ *A7[[2G%?Y1H?TF?_3/-IO79XB]
M=GB>DM][L]$S\G=4_P!8.4'_ ,RC[W9Z)GY.ZI_K!R@_^91]M_AOX'6?HL/^
MH/M*<6_E&A_29_\ 3.GM[ E5_P#E6Y,<-5IOV<J!Z8$)]Z)P3R.+3H[>Q?Z/
M&2JU]*MW8>QE0I-IJ+]*^YT_&MC;&J0X/TV5BR<QG2-4K<W(QD?+QHC$ZZ7?
MF*J/9FO:UR<IS6(A$G3SI)@XIJ\>HT]<M:4T]<4QEK6MNU7)DMO$4O>-MKQM
M.^_*>7C,S=7G1?4<)T633ZF^*][ZF^:)PVO:O9MCQ4B)[=,<]K>D[\MMMN?H
MN !I+?0                       "\_,LL;[[)VF3_ /=ZN?JF</TTT]<H
M<O49.:D9MBQ)6=EIB4F(:/=#5\":@O@1F)$AJV(Q70HCVH]CFO;?G-<CD13G
MBMM:LSW1:)_-+YY:S:MJQWS68Y^N)AXXMZXX:UU[U%Z[/$]);[W9Z)OY.ZI_
MK!R@_P#F0?>[/1,_)W5/]8.4'_S*6.^V_P -_ ZW]%A_U"L'VE.+?RC0?I,_
M^F>;3>NSQ%Z[/$]);[W9Z)GY.ZI_K!R@_P#F4?>[/1,_)W5/]8.4'_S*/MO\
M-_ ZS]%A_P!0?:4XM_*-#^DS_P"F>:]4%7Z/,X?_ $M,:_\ ]1$/7GZ+Z_\
M-O8#\R;)?L[33BVB>[K=$MS7,=DZJBM>US')_P (64+%KVJUR?WRZT54P.9Z
MR5EY*ATNG4:FPG0*?2I"2ILC!=%BQW0I.0E84G*PG1H[XD:*L.!!AL6)%>^)
M$5N?$>Y[G*L=]8'3/2\5IIJZ>F>LX;99MY:E*Q,7BD1V>QDR;SYL[[[>'>DW
MJXZ#ZOA%]5;4Y-/>,U<<4\C;);;L3;?M=O%CV]]&VV[^A !&25@
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M1O/C,RF3@O1W1</IY/2:>F&)V[5HC?)?;[_);>]O5$SM'A$*(5 /'>T
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MSP)"K<@%6)>M^JY43X\ZS-V["R$G/'%?ARIE.,3O/L  '(
M                  "BH5 %K6HA<  +5:FXN %$*@
M               45+RF:7 "S,3G[1F)N+P!2Y-A4 "W,38G*7%,SGE2\ 6Y
MB8C,3GE2X                                         6YJ;$*9B;N
M>TO %B,3=SVE4:FDN %JM12F8FQ.XO %N:F&X9I<
M
M
M
M                    M5MXS>>5+@!:C434A1&(7@ 45+RH LS$W<]HS$V)
MW%X MS4+@                               6JWGLN+@!;F)N&:FPN %
M%0(EQ4 45"F:A< *7)L*(TN
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M;+E7R3Q*IH3@7PD33OYY[3$SL,JE0!6.0  R
M
M
M
M
M
M
M
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M <@
M
M
M
M
M
M
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M#7Z+ZB6&9J8)PW%Q14O*F(  &0
M
M
M
M
M
M
M
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MB15[=6[>N\I$BJJX+NX;N<4TD1[_ )]WCY 7.=COUW]Z=VI.\AO=ANU\^:[
M]W'U^WOT7&GJ]6E9*6F)V=F($G)2<"--3<W-1H<O+2LK+PUB1YF9CQG-A0)>
M!":Z+%BQ'-APV-5[U1$$0Q,_05:K2TE+3,Y.3$"3DI2!&FIN;FXT.7E965EX
M;HTQ,S,Q%5D*!+P83'18T:(YL.$QJO<J(BG1Y]L/[7.-E;FX^3S)[-QY;)G3
M9I4J-3AK%EX]O)Z7>F9&BP_JOAV9E(K>LIDG%1'U**C:C/,1B2D"#*]L![7^
M9RK3,[DYR<SLQ)Y,Y2.L*JU6%UDO,V\FI>)>CWI]6+ LM BL1\C)/1D2JO1L
M_/L;"26E877_ $9?SSSAPL%U?]7_ -C]C7:VGN\QVL&"T?<(VY9,D3_'3OYM
M9^Y=\^Z;>3K;UD]9'V3Y3A_#\G[WB9IJ-12?N^W*V+%,?Q/A>\?=?>U]SWG)
MF;S>5*(EQ4F9"0   !:Y>>P"V)\^[TT[CMO>P/\ 9B.E(4CEVMY3D29CPUB9
M-:1.0OK2\O$16/MG,0HC;FQIEBQ(%GFN;G0X"Q:JF:Z-)N..#V-7LOX^6FTK
M;96ODHK,E]EYYB3+(C5AMM?6Y=61F6>EU6YSZ9+WPXMH)B&BM2$K*;#<D>9B
MK [Z$C(PH$*% @0H<&#!APX,&#!ALA0H4*$QL.%!A0F(C(4&%#8V'#A,1K(4
M-J,8B-1$2$^L[II%*VX;I;^Z6C;59*S[RDQ]PB8^/>)]U^]I/8[[6[,[=5'0
M7REJ<5U=/<ZSOH\=H]_>)_A$Q/Q*S]R^^O'E.45I-I4-J)CJ3QW^*XDZ%#YW
M)MW:^XLAL1<;L,._=N4V,-G>O#"Y+OGL(#6*7M8F*:D\UTIV\W$^$S1M^.I/
MEB8H3.Z[7JVKNOYN-C"AZ.;D\KUT< ,L)FE=BW\5\KMFTFPV>JZL/&[<8V-^
M2:+UTX>2;/.?#;H3TQ79V:P,D-GBG:EV/>NKN)S$UZ,,/7T,;&:4[_%,.W1>
M3(:</LV</%0+X;-J:5^?AIXDYFV[@G.W5PQ,3&;.U;NWO7636:;]2?9Z7:U
MO:F%VU?AW[K]NXEHW&Y.W<G.CF_$QNM=U^Q.!)8FG"]5P3X)W8KL N:MR7;/
M7#G3MN,T%-?.*\]^!C1MZW;+K]^CXWIP).G#M7GFX"E^O6N";DV]IE@MN3NY
MYVF-F*[K^W#5YX_&XD@%U)M,S$N0QPVXW\W:N>S0950Q_P"?_!*J*5 ,@
M
M
M
M
M
M
M
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M!$>FW5MVZK_AW&!7]G.S?O\ 0P.BIQ\N=:@9WQ%5-.&_9SX=Q'=$3;VKS\C
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MQR8  99    *7@5         +;P+@4O*@                 "BJ!4%$4J
M!15"*!4                   "W.YP N!;G<X#.YP N O**H%04O%X%0
M           HJ@5!2_G J                    %%47@5
M            **H%0412H                 %%47@5!;G<X%;P*@I>4S@+
M@6W\\^6G<510*@             **I4  450*@HBE0         !2\"H*(O.
M!4  6YR<W 7                              **MP10*@%%4"H%X
M        "BJ$4"H**MW*!% J           !2\"H   %%4"H*(I4
M       %+P*@MSN;T]2X "EXO J"W.YYYV%44"H
M
M
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M17JKGQ8K(36M<KHK42]>3;(WTN,EV4)B.L/E"L;:I^;GOEJ):.ES\[!1<?\
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M\2RQYL":5["<>K7HKH-=H<F75:>N7)759*1:;9(F*1BP6BNU;UCE-K3W;\T
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M%8M[8LO,07,C08C5Q;$A/8]JXHY#6.)=4.@R1,Z;+GT]O")F,V/_ (;=F_\
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M\5
M
M                                                     M52XHJ
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M/HUV1RL62J=B[:TQE2HU28BHJ*D.=IT[#1WT2K4F;S7/DJG)/=GRTS#P5%?
MF&1I:+&@O^D(L+"[N5-6SBG.D@/AXW*G=HN77ZH?7#FOCO7)CM:EZ6BU+UF8
MM6T3O%JS'=,3XOEGPTR4MCR5K?'>LUO2T1:MJVC::VB>4Q,<IB7FY>T3]G';
M#H^VH=)5&''J]C:I,1?W*6PA2ZLE:G!;>]*?4&LSH=/M!)PL)R0<[,CM3Z9(
M+%E'W0N.YCKT/4_RVY$;+90[-5.R%LZ-*UVS]6A)#FY";;>F>R]8$U*QFW1I
M.?DXG[])SLN]D>6B_68Y6*]C^A#[3;V55J<@%7?4Y)9JT636I375T:T_5(Z8
MID6(N="HUIV06]7)U!+U9)S]S)*L,9UD#J9I(LI#LCT%ZP::Z*Z7537'K(C:
MMN5::G;;G7NBN7[['W6]]CC;>E*N]8/5ODX=-M7HXMDT,SO>G.V32[^%N^;8
M=^5<D\Z\JY)WVO?BA!8Q>;KB\E)$P  !12H PK#U:L4QQP5+E1;\%1==^GP.
M97V=/MD[=9$72MG*[]*MMDW:Y&_<&:F?^5[/PU6]T6RU2CJ_J(3;U>ZB3:OI
MD5<999"*KWQ.' M5MYYO%.$Z?6X;8-3BKEQV\+=]9VVBU+1YU+1X6K,3]#TN
M$\8U.AS5U&DRVPY:^-9Y6CQK>L[UO2?&MHF/';>(EZ??1FZ6-@LKMG8=IK V
M@E:U(?O;)V61?H]5HTV]N<LC6J7%7Z33IIM^:B1&NEXZ71)28F(#V17?2+(F
MM,%YP4\M'(7E_MEDSM#*VIL+:&?LY6Y141)J1B?O4S 7%\G49.*CY2I2$71%
MDIV%%@N155J,?<Y.XG[/WV]UC,H'T&S.5-DC8&V$3JI:7K'6.AV,KLPJ(QB-
MFH[WQ+/3LP_1*5![Z<Z(Y&R\^QJ]3"KSTKZL]3HYMFTG:U6FCG-8C?/BC\:L
M1[I6(^/CC?OFU*Q$V65Z']:FEUW8P:SLZ35SM$3,[:?-/=YE[?<[3/\ %Y)V
MWVBN2\SV8[$;(F^[R7G02&O[/CW\IQ-/"F6O8Q['-?#>QKV/8YKV/8],YL1C
MVJK7PWHJ.9$8KF.:K7-56JBK,8]>/*<H1>EELV153PO7G0G'23&1MNJ[%.=1
MIV1/LU[T^TRM>NK#G7\ -XV)@ERWIX\^A(9%].44T3(EV[R[B8V.BICWIH]4
MYU ;IL7?W?%"2R-OQO[.5[<+C2M?RER+CSN,[(O:M^O!>>5 W;8J*OQW^?>9
MD?P7S-,V+CZZO7=VF9L7;SVIS<!N6Q=]W''GXH9&Q/M31QNU8?8:ML;E?5#*
MD5.&].><+P-LV+LN\OD96QM_?Z\Z#5MB<%YW%Z1.*>*<^@&U2)RF/Q2[M\S)
MUB?RN>XU;8G#LP\N<3(D7:J]N* ;1(B\>>XJD3UU?#$UB1>"\,/0RI%7?WI=
M\P-CUB;>>"Z-Y5'Z<<>'P0UZ1[MG;I\-/$OZWAW_ #Y\@V+8F_;AB52(NSGM
M0UV?N7O0KG\?%?)0-BL7??NO09R[/%I ZW>[N*]=Q\01/JC]:=G+L\6A(G9V
MM(/7<?$IUN]W<&=_5'ZT[/75YX>"%'15T7W<\]Q!ZSCW*6Y^[Q0,)BQ,+K^>
MWG04ZQ-OC=Y$3K>'/:6K'TZ.?,"6L7FZ[SO+5B+NY\.XA=:NJ_R^WT,2QN':
MM_.OAN G=9_C?#3V&-8B<>*IS=]A"6+L6_AA=SK,:Q=MW'3SW 3EC;^Y#"Z+
MP3BM]W80UB7[>S#E>=18Y_!.SUV@2715T)COT)REQA=%W]B$98B;?.XQ+&V>
M'KH[O@!)6)V<[>;C"Z(B?.].>PBNC=_>OI?]JD5T7G2O/V@3'QM.SC\->XCO
MB\KH[$\R*Z+=N\5,#G]@$A\3Y+K[$X]B$=T15UW<><,.[M(SH^S'?N^/9CMQ
M(<2->MVG"_=N^W2!+?&1-'?J^?/$B/BJN_R39]FG$P/?MQW;^&OR,+XF_NTK
MSNU8 9'/[_+?L\U,+GX[=VI-G/>F@QO?ALY^.LCYZK@B7WZD3%<-6M;TV)>!
MD>_;YZ]WKVGY=E>RR67L)0)^U%L:[3K.T"G0U?-5*IQT@P6NS55D""Q$='FY
MR,J9DO)2<*/-S$16L@P7N<C3BPZ?OMI\F^1I)R@T-\"WV4"!G0EH-,G$^Y%%
MF+EN_=+6X"18<!\-417TNGK,5)]^9$^A7OC0NEOTK^FGE%RU5W[N6]KT6H)!
M>_[E4:63Z'0*'!>JW0*32H;E@P5S51D6<C+'J$S<KIF:B*KKY%Z*]76JU\UR
MYM]+I9VGMVCW7+'^RI/=$QW9+Q%>>]8R=R,NE_6?H^&]K#@[.KUD;QY.EO<L
M5O\ ;9(GOB>_%29OO'9M./>)<NWM'/;O6ER@MGK'Y)5J-CK%QDBRT_:!Z_1;
M6VD@.1T**R&Z"]RV<I,=JJGT>6BK59F$Y&S4W AN?+OZ\3FJN*JJJJJJJJWJ
MJJJN<JJJXJYRJKE6]555555552YK$0N+%\&X#I=!AC#IL5<=>^T]]\EOOLE^
M^]O7/*.ZL1&T*R\<X_J^(YISZO+.2_=6O=CQU^\Q4[J5[M]N=I\ZTVM,S-K6
MW%P![#Q@   "BK<!1RX'T-T7.BO;3+':V2L;8BENGZC,71YR:B7PZ91*:V(V
M''J]9F[E9*2$OG(BZ8\U&5DK)PHTQ$:P_ONA1T'+<Y=[50[-V0DTA2DNZ%%M
M!:2=9$2BV;D(CT19F>C,3]]FHK4?]SZ7 59VH1&JD)K838L:'Z!70HZ#]B,A
M5DX-E[(2:OCQDA1J_:*;APTK5I:BQ%3Z;4HT-+F08>>YE/IL%WT2G0%6'!1\
M1T:/&CWIMTZQ<,I.+%V<NMO7S<??7%$QRR9MN[TUQ[Q:_?RK/:2/T#ZOLW%<
MD9LT6PZ"EO/R;;6SS$\\>'>/HODV[-.<1O>.S'\AT!/9]6*R!65;1;/0$GJ_
M484N^U-K9F$C:G:"=@HKD1$57?0*1+1'.2G4F Y(,)J-C3*QYQ7QS[Z9#NT]
MB?!+O%>PK#9HUJNC?\B=!@W:<5PX)]OCH*Q:S69=1EOFS7MDRY+3:][3O,S^
MR(B-HK6-JUB(K6(B(A:_0Z'#IL5,&#'7%BQU[-*4C:L1_;,SO-K3O-K3-K3,
MS,D*#K_C>2+L)S&88:.</7P#&=WGMNYX;29#A[MV&KYG6=I6%#Q3#NU;NW63
MH<+1QQ79ZK\!"AXIJT]RW8KO7P)K&8;D7MP\OCP N8Q+]'!-OR)<.'\?L3?\
MBK&8^NK#E-G>3(;,+^Y-^WCJ7<!<R'=J[-B87^"=JDID/5IV\[5U)VE&,QQU
M]R_9M["8QMUW?]N]4T)H N;#X\.S!/#@2F-[U\+]&_#0F\HS;=BO-W.!+:S1
MM77\O("K&:D[>==^O["2B7W(FS'<A1$S=]YF1EUWBO/<FP"K4NX)XX:-Z;S+
M#;K7E-7.PM:V_<GC>FU=1G73=LUX<H PQ74G.'#?QU&2&V_%4W=VCO0QM3.7
M8B7=O/.%Y*0 7PVZUOQN^SX[M18U+UW<Z]W.!(4XSZ/SBE_-VPN*(A4Y0Q
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M&+_L*>M7T%/Q*Y(_T:6'_9NGD+]<OW#1?.Y?ZD)TZC_X1K_F</\ 7L^K0 0
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MS]'F*E!DYF-"2/"EYB) :J0HL2"J16,=^%#5')@I^R_V-/I"_D6RE?T5GO\
MNG1R<3TU+36^HPTM'?6V7'6T>/.)M$QRY\X=[%PS4Y*Q>FFSWI;WMJX<EJSS
MVY3%9B>Y\2@^VO[&GTA?R+92OZ*SW_=']C3Z0OY%LI7]%9[_ +IP_=C2?RK3
M_I\7^9]/W&UG\DU/Z#+_ )'Q*#[:_L:?2%_(ME*_HK/?]T?V-/I"_D6RE?T5
MGO\ NC]V-)_*M/\ I\7^8_<;6?R34_H,O^1S&>ZO_CVMO^BV<_::A'?J.DY[
MMWT1LJ-@,LUKZM;?)]:ZR=,FLG$W(2T_7Z+,TZ4CSKK04:.V4A1HR(Q\=T&%
M%BI#:JN5D-[M"'=?8^_GG1\4*U=9V>F3BN2V.]<E?(X8[5+1:N\5YQO69CDM
M+U48+XN#XZ9*7QVC/GF:WK-+;3?>.5HB>;( "/4D@    #^)RD_WO5S_ #/5
M/U?,GCMR']SRW^32_P#N89[$F4G^]ZN?YGJGZOF3QVY#^YY;_)I?_<PR=^I?
MWO$/;IOV9U?>O+OX;[-5^W E  G% (#]%R49&[6V[JCJ'8NS=9M36&RD:>=3
M*%(1:A.MDY=\*''FEEX/UNHA/C061(BX-=%8G\8^E$]FITA/R+92OZ*S_P#W
M3IYN(8,=NSDS8L=N4]F^2E)VGNG:UHG;T3ML[F#A^HRU[6+!FR5WV[5,5[UW
MCOC>M9C>/&'Q,#[:_L:?2%_(ME*_HK/?]T?V-/I"_D6RE?T5GO\ NGR_=C2?
MRK3_ *?%_F?;]QM9_)-3^@R_Y'Q*#[:_L:?2%_(ME*_HK/?]T?V-/I"_D6RE
M?T5GO^Z/W8TG\JT_Z?%_F/W&UG\DU/Z#+_D?$H/MK^QI](7\BV4K^BL]_P!T
M?V-/I"_D6RE?T5GO^Z/W8TG\JT_Z?%_F/W&UG\DU/Z#+_D?$IR\>P;_A8Y)?
M\JM-^R%=/F'^QI](7\BV4K^BL]_W3E$]B[T&LLMDNDSDQM#:C)?;B@4*G3-H
M%GZO5K/S<G3Y-L>RU9EH*S$S$;U<)(LQ&A069R_6BQ&-3%3Q>DG%=+;AVOK7
M4X+6MH]3%:QFQS,S.&\1$1%MYF9Y1$=[W.C/"=57B7#[6TNHK6NNTEK3.')$
M1$9\<S,S-=HB(YS,\HAZ&*:$*F.$MZ<[$,A4)=(        +7+<7'\%E/RET
M.QUGZQ:BTM3E:-0*#3YFJ5:ISL1(<M)R4I#6+&C/72Y;D1D*$Q'18\9\.!!8
M^+%8U>5*3:8K6)FUIB(B(WF9F=HB(CG,S/*(<;WBL3:TQ6M8F;6F8B(B(WF9
MF>41$<YF>40T&6[+E97)S9FJVPMI6Y*S]G*++NF9^I3T5(<-C=$*!!8E\6:G
M)J)= DY*79%FIN8>R!+PGQ'7'GZ^U4]NM;?+E,U&R-B8M0L3DIZQT!9"%&67
MM%:Z Q?JS-IIN6??*R$94ZR#9R2B]0QN:M3CST9$9 ^>/:P^U.M'TD;8OZF)
M.TG)K0)N,VQUEXC\S/N1T%UHZY"AKF1ZY4(:JYD-ZQ(='E(BR$J[/=-QYCB9
MZM"QO0?J[QZ2M-5K*UR:N=K4QVVM33>,<N<6S1XWYQ2>5.<=N:O]/^LO+K;9
M-'H;SCT43-+Y:S-<FIVY6YQSK@GNBG?DCG?E/8K8UF"78(F"(B(B(B:$1$3!
M-B)@AF*(A4EB(1" &"(_-TJB)M6Y$\</'X&1G!^IY/,@MN[7(Q;*V+M9:5KU
M^K%H-FZU5I=<;KUFI&2C2S6WX9SX[&HN&=?@?6U&]DOTF:@QL25R'Y0G,B,6
M(U\:D2\FBMSLW_Z>GI6Y;]#%NB*B*J-S4O//S\5TV*=LN?#CGT7RXZ3^:UHE
MW]-PK59HWQ:;/DCTTQ7M'YZQ,?K<>P/OZT'LI>DI2X;XL[D1RAPX</-SWP:(
MV>1,]+VW+3IJ;S[[EOS,Y6W7/S7'R%;[(];"R:YMJ;*6FLTY'(W_ .<%GZO1
M6JY5N1&Q*E)2L.(JK@SJWO1ZX-5QRP<3T^7EBSX<D^C'EQWG_EM+&IX9J<//
M+IL^*(\;XKTCOV[[1$/SX&&&^_%%14VI==WII[#,=V)=%:[0ISJ^[U=$:T&4
M;+Q2[424Y5*/9O)DV%:&T-5IDW-4^+.1IA8T"C67^E2D6#%=#K<PR8C5"55_
M4QJ53YYD5+XD-D3@QIU/F9R8EY.4@1)J;FX\&5E)6 QSX\S,S$1L&7EX,-J*
MY\:/&>R%#:U%57/:B(M]QZA_LE>@G+Y ,CM!LI,0H/[JZK=:.W,Y#1CG3%I*
MC A=;))%:KNLE:'*PY>CRF:]T-R2D2.S&8>YT>]8_2*-%H+8ZS'E]7%L...7
M*DQ[KDV_%K/9CT7O6><1*1^K#HU/$.(TRVB?L?137/EF.7:O$[X<43^->O:M
MZ:4M'*9B7)LR%==RFG4FK<FI.XS%$*E6EN0       '59]Z[_%/DQ_23&_92
MM'143U\SO5^]=_BGR8_I)C?LI6CHJ)Z^9:/JM^",/SF?ZVRI76W\-Y_FM/\
M555+':4+RQVE"1)[I1G/^'[7I'^[I_P3K ?YYRA?M]:$YQ#@[]W3_@G6 _SS
ME"_;ZT)SB%-NE/PGQ#\MU7UUUX.B7P7P[\BTOU-  '@MA      XDO;K?P4,
MLG^8J9^T='.6TXDO;K?P4,LG^8J9^T='/8Z/?"&A_+--]=1XG27X-XA^1:OZ
MC(\QQ=+OYR^8"Z7?SE\P7/CNA1I1?3S.Z?[I=_Z!RW_G!87]36A.E@OIYG=/
M]TN_] Y;_P X+"_J:T)H'6=\#:GY6#_J,21.JKX<T?R=3_TN9W @ 576\
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M"?#B2\S*2Z)!D'PWL<^HS,G!O1L1[F_&2O7===CL1+L;UU;U7!$0] 7W<'H
M?\'.3&)E2M%))"M?E0@2\U3V1X>;,TFPT!RQ:-+W.1%A1:[&5U=F67WK*OI4
M*(C8L&,PU'IMTBKP[0Y,L3'EK^Y8*SM.^2\3':F/&N.N]YWC:=HK/OHWW'H)
MT;MQ3B&+#,3Y#%[MJ+1RVQTGWL3'=;);:E9CG&\V^++L<T.DLDI.4E&19F,R
M4EH$JR-.3$6;FXK)>$R"V+-34=7QYF9B-8CX\Q%>Z+&BJ^+$<Y[U4W!1"I4:
M97.B-N4  #(
M
M
M *7 J6JO<8F-V)1\W-PU:O3T*JB+J0S.;>84V;.>PQ6?SLHF;FZ="Z]?/K>5
M78O9L5+^?L,\1MY'3^2NG5NX<-7Q.3+ YEU]^A?#>6.9I39]OCK^PE77Z>'/
M.PCZ+D5=%]R^'-^@,(RMOPYQUI\/2\C/;?JQT_#[=Y/<W&_0J8<\_&[ YMZ7
M[^[;\P-=$AWKHQ1-"\]RD5[4TIBN&'9YFS5M]ZZTU</7RN(CV87\$5.=GCW
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MZ?[I=_Z!RW_G!87]36A- ZSO@;4_*P?]1B2)U5?#FC^3J?\ I<SN!  JNMX
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M)_'5'MMA:.5CHZJ0;U1SK,T5%@S=:15:^&V?<^4I+8C7(DY'>QT!>X%T4/8
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MV'+CI><V3-EF]\TUBMK4KRQ4VB9Y4KO,\^=[6GNVB+@ :DW0
M
M
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M=.OQ?Y7_ ,^*#^S, [9I4CI_\,:[Y>/ZG&N3U<? G#_F[_790 &G-W
M       '\3E)_O>KG^9ZI^KYD\=N0_N>6_R:7_W,,]B3*3_>]7/\SU3]7S)X
M[<A_<\M_DTO_ +F&3OU+^]XA[=-^S.K[UY=_#?9JOVX$H $XH!=B3W8;^$I.
M_HRM3^M;-GH6'GG^[#Q$3I*3JJJ)_P V5J=.ZJ6;X<]QZ%38[53\)O>A6+K7
M^%I_)L/[<BU74Y\#_P#^7G_9C9@8^N9_*;_VD'7,_E-_[2$:)69 8^N9_*;_
M -I!US/Y3?\ M(!D!CZYG\IO_:0=<S^4W_M(!D!8D1JX(YJKL14+P
M !:[0O;Y%Q8], .AC[T-THWVARI68R6R4RKJ;8"BI6*K"8]%AOM+:AK7L9%1
MBXQ)"ARTHC6Q$582S[W,5O7/OZP!]1=.++A$RD98\I=N'QNOA6BMI79N0?J^
MY$O.OI]$AIN@4:2D(5Z7(JL541+SY=+D]%^&1H^'Z73Q&TTQ5F_SMX[>6?\
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M?TWM9=CHAT=Q\+T&'35B/*=GMY[1WWSWB)O,SXQ'*E?Q*U\=YFH -=;.
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MU-:Y]1;;SNU>-Z8Y]6*DQ7;N[?;M'OAJ%0#2V^        *7%0
M
M
M                                                  %%0J *&!S;
ME5;L-?:NGNT]AGN*8'';F,)%=#5,4)3D1JX:+NPHJ7G(W1476G:FOLYQ+'P]
M?.GG'5J,CTN6_5KOU[AVWIY+?V?(,RBII]=-QB5+L=6"?.[S)CV7XIX$?=KU
M\[4\0PC/9?>J?;<15;K1.*<[.=JSW-V:.;[O3N,+V[--WCJOYV :Y[-*]Z<\
M]I%>S6B<W:M^[7I-FYGV:OEB17LOU;E31SN71W@:Q\+#1HN\//>17,O5-J>7
MH;-[.=&.Q=_F1GLQT=NC'X+IW :B)#P7F[?SH(L2'COU+MY^PW#V8?'G7QXD
M1\+<G.B[8OQ T[X=^C3AX<Z?B0HD*Y5TZ.>*&Y<S[=?RTD5[/M30!HWPN?3T
M(KF8+?BFWU-W$A;EPYN39LW$-\+3@O.U%Y[@--%@]F_ROYXD)\-="IV_'G2I
MNG0]W.E%0C1(6"^6OLV8:.T#11I='(K7(CF.:K7(J(Y%:Y%:]KFK>CFN:JM<
MU45%:MRHJ'7?]H;[!"R64%9^U62EU/L+;*+ULS,T-T)8-C;03"_67]Y@-5;-
M3T9VF:D846FQ'8S%/A7K'A]C!\)4T=W.A/,C.AIJV\I=\3U>$<;U6@RQFTN6
MV.W=:.^EZ_>Y*3YMZ^V-X[ZS%MICQ^-<!TG$<,X-7AKEIWUF>5\=OOL=XVM2
MWLG:8Y6B:[Q/EA9<L@%M,FE?F++VYL]4+.5J657?19^%FPYJ BHB3E.FV*^4
MJ4C$16NASDC&CP7-<V]S5<B+^1H>HGTC.BW83*Q08EFK?6<D:_37(]TLL=JP
MY^F3#D5$G*/4H.;.4R;8KE>D25BM;$7"/"C0U?#=T]^GC[ 6WE@5G+09+(D[
ME#LG#ZR/$I#83$MK2("*KE8LC :D&T<O";_],TMD.>5J7OIBN6Y+!]%^L[2Z
MSLXM5V=+J9VC>T[8,D_B7M]SF?O,DQX16]Y5NZ6=5.LT/:S:/M:S2QO.T1OJ
M,4=_GXXCW2L1WWQQORF;8ZQ#KZ@1X$6#%B08T.)"C08CH4:#&8Z'%A16.5KX
M<6$]&OA1&.16NAQ&M>U47.1%P%Y)\3NB@ !D     %%0LZM.>SGX&0 ?JN2#
M+U;;)[/I4[#VKKUE9[.:Y\6B5*8DF1\V[-2;E6N62G6-5&JD.=EIB'@BYE[4
MNYQ.CU[QUE5L\DO)V_L_0<H4E#1C'S\&^S%HW,8B9SGS4E!F*3-1WXNB19FE
M7N7!K6)>=>56WE,Q-AX?%>C>AUO\)TN++.VT7FO9R1ZHR4[.2(]46_L>[PCI
M/Q#03^]-7EPUWW\G$]K%,^F<5XMCF?7-)=^'(#[>SH_VS2!+U>LU+)[4XJ-1
M\O;"16'34B*J(YL.OTUT[3.I1RIF1)Q9"+$:JN679FN1O+M83*/0;42;*C9N
MMTBT,@]C8K9NB5&4JD#JW?@N>Z2BQNI1=21DA.VM1+CRJ6M1-&' _K;%90*]
M9B;94+-UNKV?GH;T>R;HE1FZ7':_4_/DHL'.=H^L]'+@FQ"-^)]3NFOO;2:G
M+@GPIEK&:GLBT32\1Z[3DE*/">NS54VKK-+BSQW3?#:<%_;-9C)2T^JL8X]C
MU7FQ47%%WWW^AD1_;SM3FX\^G(S[=3I'602#!F+72=LY*$C4^C6UI,O5H[D3
M!V?5Y5U.K<6(Y/\ UDQ4)BYUS\Q;W-=ROY'_ 'FRGOZJ#;[)=-RSD1&Q:C8^
MN0IJ'G87QGTZM0)>*UN+OWB!-Q7)]56Q%2\C_B'5?Q7#O-,>+4U].'+$3MZZ
M9?)6W]5>UX]Z1>&=;?!]1M&3)ETMO1J,4[;^.U\4Y:;>NTU\.4.UTCMV[27I
M%WW<<>=QP^Y*?;E]&ZU'5LB6XF++33\VZ5MA1*E255ZZ6-FY6'4Z?]72L2--
MR\-6XM6_ZIR-Y.LO]AK7PTBV5MG92TC%8V(JT.T5)J;FL=H5\.4FXL2&NI61
M&LB-?>Q[6O1433=9P?5Z;[OIL^'UY,5Z1]%IK%9^B9;SH>-Z/5?P?5:?/ZL6
M;'>T>VL6WB?5,1+]J;$X+PP\-'S+D?NTKSP(2HY&Y[FN1JZ'*U<U;MC]"]^"
M\"C8J87.3L7[3S7J)^>FQ>R_X%V>FIWB0T?HQ\AUB[O("<CMCKTWEV>NWN2\
MU^?N:5ZS=W+SS>!L$B<XCK%Y3Y&OZS<O?\\2O6)O[E]0-@D1>44HL1>;R!GI
MO[E]1UFY5[;O"\";GKM[T]2BN7^4GP(2Q-W>J%.LW- F+$3^5X_(MSTYONYN
M(O6+M3N'6;T E*_=Y=VOT+%B<$QYTZ_+@0EBIK=AO7["K+WHJL:YZ(F*M:KD
M1$TJJI>B(FM5V:@)*Q4VW\,$[?(L5^Q.?,_-;<Y6[+67@?2K2VGL[9V6O5/I
M%=KE+I,%+L518D_-2[$N3%454NTJ<=^5;VTW1OLFD6'&RCRM?FH2+G25D*=4
M+0QW77W=7,08,O28EZI<F94UU*MS513OZ/A6JU'W#39\WA[EBO>(]LUK,1],
MO.UO&-)IOX1J=/@^=S8\<S[(M:)GV1&[E75Z[>?/MXF%T1-O/;]IU=LK_O,U
MEI9(L*PF3.MUB,BN2'/6KJTK19)R+@UZ2-,A5&H(K?PEAQ(C4>MS,]N+DXI,
MM7M]^D-:I(L"DU>AV$DHF<U(5E:-!6>ZIVAKZO6G5.;9%;I2/(-IT3!+D1+T
M7<>']6/%L^W:PTTU9^-GR5B?^#'&6\3ZK5AH_$NM?@VGWBN?)JK1R[.FQ3;G
M\O+Y+',>RT^J)=\>TEJJ=1I1U0J\_(4F0AM<Y\]59R6ITDUK$5SO^-3L6! 5
M6M2_-:]SUT-:JW(<4N7[VX'1ZL(DQ A6MBVVJD!'I]S;#R;JPU8K%S5@Q*O&
M?)4. ]'IFN1\_GM1%<UK[KEZ&>4C+):ZVDU$GK86HM!:F<B*CGS%H*O/55[E
M1;T7-G(T6$BM6ZZZ&BHJ)==<A^<JU%NW:-UVQ-">1O\ PSJ<P5VMJ]5DR]TS
M3#6,5?9-K=NUH]=8QS[$=\6Z[=1?>NBT>/#$[Q&3/:<MH]<4IY.L3ZIMDCVN
MRCTA_>3[=U;KY3)K8VBV0E79S(=6M#$6TU<S5;F]9#E&LDJ-*N7\-B.@3D2"
M_-_?XJ-O=P5Y=NE=E)RH3BSEOK:V@M.[K.MARU1GXGW,EWXHCI2D2_44J55K
M5S$? DV1',N:^(^Z\_ <Q-A5&HF@DCA/1;0:':=-I<6.T?QFW;R_I<G:R?1V
MMD7<8Z6<1U^\:K5Y<E)_BHF,>']%CBN/Z9K,^M9U::$P1,$1,$1-B)JYXES6
MW%P-@V:Z  R      "EYCB/NUW(FE56Y$3:JZM5W=K RFZLM96J5VI2='HE.
MG:M5:C';+2%-ILK%G)^=F'+]6#+2L!CXL5^-[LUMS&WO>K&HKCE+Z"/L<\JF
M6MTI6(TJ^P]A(KF/?:NORL5D6H2]Z(_]S=&<L*;J\14_M<W$^B4J]<[Z9%1K
MV-[G_0L]G-DPR%4Y(-CJ/U]=CP4A52U]82%.6EJ6"9[/I:0V,ITBYU[FTVF,
MEY9B+=%69B*^/$CSI1UBZ/A_:QXY^R=3&\>2QVCL4MW>[9(WBNT]]*]J_A:M
M8F+)(Z)]6>NXEV,N6)TFDG:?*Y*SY3)7_8XIVF=_"]NS3;G6;]S@2]GS[O+$
M?]#M5EZ<L-N="F)3)Q39NZ(J)<]&VLJ\J_\ >T5?JQ:-28O6(B*R<J#'K$EH
M7:ZLA8^ET*FR-&HE.D:12:;+LE:=3*;*P9*0D9>&GU($K*P&PX4)C4Q5&I>Y
MU[WJYZN<[^D9#1$T7(FA-"7<ZM1)9"ONU)SW*NPKQQ[I)J^(Y/*:K),Q$SV,
M5=ZXL<>BE-^_;E-K3:\_&M.T++]'>BVBX7B\GI,45F8CRF:VULV68\<F3:-_
M3%:Q6E9W[-8W8F,35BOPUX_#7M)L* N%^*^'AL,L*"B?#:J=N@EL9HP^"G@M
MA8V,NV+O7AHYU;R5#A\?+[$^!D9"\^Q/F360L4X8;>W<!CAPO"_APWW^!-9"
MNTIZW_'R0O9#T:UPX<\W(26,\-W#[.Z\"UC-'<B;,?CH4ELA_#MX<W8;2Z'#
MW;>*X\^),8RY-'HGHG* 48RZ[LN3LYQU$ID._'G?CMVJ&0]^"X:K^S=J)36>
M2:>['?N[5 HR'HU^5WIYZR4UF&[S7GOUX%6,T7Z//GG DM9ACHV>N_R[@*M9
MK5-'//:2&,OQV<Z_+5Q#&[>Q-'?S@9D;W:[]8%6MOX)Z_ RZDV:M^S1JV#1N
M35SL3["^&R^Y5YV7IVZ-7:!=#9BJKSN[-O89+T[$QV:-0\BJ-5UV&'P#,*-:
MKEOU)HY\R4A1$1"NE435K] 3(B7Z-%_*<\"1=J+6HB;"ZXX]_L841-9< <@
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MG_EHXN@=?_TYP_\ D.D_HV'_ ".U_P"I^)?R_5_TC+_F<HO]FJZ5/Y;;6?\
MV'93_P M#^S5=*G\MMK/_L.RG_EHXN@/_3G#_P"0Z3^C8?\ (?\ J?B7\OU?
M](R_YG*+_9JNE3^6VUG_ -AV4_\ +0_LU72I_+;:S_[#LI_Y:.+H#_TYP_\
MD.D_HV'_ "'_ *GXE_+]7_2,O^9VQ?88^TKR[Y3.D)1K)V\RFU^T]G9BREL9
MZ/2:A+T"'+1)NGR<G$DH[G2%%DIE'R[XKW,1LPC%5?KM>F!WBSSD/=O/X4M
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M[:>A6GKEXOPZEHWK]E8K3'I\G/E.?JWKSCQ[GH",3 O*-2[G<5*>+L
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M_P"M.+__ '+6?TC)_F<YGWQGTK?\,K-_T%H7H/OC/I6_X96;_H+0O0X,P/\
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MUH2/^L[X&U/RL'_48DB=57PYH_DZG_I<SN!  JNMX
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MW<B$XQ0?P4X)Y&4I/NOA
M
M
M                                   !;=K+@"5BHCC"N&GG5XXW$C>6
MJB*G/*'#N]GH8AB(BM5JWIHU^.OR4E7*FG9SSK**EYSB649%UZKNY4U?+46/
M9KYNY[C(YN:N"8<_#N[BB+VIXWZ\/+L C-35KNNN77=\<<3&K=:=O'UU=E^P
MDN8BXIX<\^6+'7IU[_AP BN9?>J<X\WD=S;^-WV;,-_;H)SF[.[GP,3FHNCP
MY\-8&M>SOV=NO<MVG8F!%<WG3V*F_5X&T<S=<NKGA\B.]F.Q=5W/@H&I<S2B
MZ\-GVZ.PP/9VIPU=G/B;)T/GS[=J=Q@<W=VHNO=LO U$2%AX7Z\<<=VU>TB/
MAZ>_PU8:=VHVZP\-NU/3TUZL2/$AHM]R=GH!IG,P3"_BFC[$TWXD9\+G7\]B
MFV<S[>W7OUW:^PC/;IV^"]O;Q TSX.[TQV;.&HAOAZ5V=Z=FOYF]?#3@NN^_
M1HX$.)"TX<[MOF!IGLV]_/V=Y"BP.R[7=S\T-W$A?;=AP5"*^%=S@O#G'2!I
M'P]J7\_+41W,PO3'9V[/ANVF[="39V*0GP;M"?9LV7>/@!Q==-SV3N2;+@R8
MJ%9I7[GK8OAW0;:6=AP)2K/B-OZM*Q+YJ25?@HOX?W0A_3,S^U3K%;#S.GCT
MV/8[Y7LC"SE4BTS]V=BY=7/;:ZS$O,3$*4@9RYKJ]2+HE1HL1&HCHL1S9JG-
M6]8=1BL:KT]$M\/;L^?**1HD"^]%1%1R*UR*B*BM<ESFN145'-<ER.:Z]KD^
MJY')@;MT<Z>Z[A_9I%_LC3QR\AFF9BL?[*_.V/EW1YV.._R<RT'I1U<\.XGV
MLEJ?8^IG_P"HP1$3:?\ :X^5,O/OF>SDG;:,D/)FAO1$2Y45%T*BHJ*FU%3!
M472BI@NTR9Z'H!=-7V(F2#*S]*J]*DDR=VQCJ^,ZNV8E(+*=4)AV*NKEG;X5
M/FU>^]T2<D4D*@KGOBQ8LVY(;&]3SID>R#RS9&W3$_/T);663@N<K;6V1A3%
M1D84%%56OJU.1CJI1'9MV>LW ?)-<Y&,GXD3ZB3ST>ZP.'Z_LTC)]CYYY>0S
MS%9F?1CO[S)S[HB8O,<YI57GI)U<<2X;VKSB^R=-7GY?3[VB*^G)CV[>+;XT
MS$XXGNR2XPD4J86Q4NPQTIVII3BFMNE%P6XR(Z\WB):'NN !D
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M_P#5AI_VVN%^C5?H:_\ >;I]IOC'IT?Z>_\ V7G@YW-Z>HSD/0^^]E>C)_\
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MRC'@S7F?DXK3_8['!]/.76:3%$;SDU.#''\_+6O]KU(V_%?-2XM;H+BE*]X
M            XD?;L?P3LLG^9:)^UM /,=V\5\STXO;L?P3LLG^9:)^UM /,
M=V\5\RQG4]\'ZC\MM]1A5BZ[/A/3?D-/^HU(47T\RI1?3S)<0X[PGNG7XO\
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M3M6-5BBT\MHB]NQ,SOW1':WWY/3U9H[O)"XM9HWZ%+BG2[8
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M_P X+"_J:T)H'6=\#:GY6#_J,21.JKX<T?R=3_TN9W @ 576\
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MB8YQ/.)CQ@ !AD
M
M
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MN7ZDY0RHR['7RGEAN*M:B<WJ5\$.,QOZO[7&5$QV%X!R9@
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M]%J\Y3)Z3J=/COEI^G3<K4)&8AKF1)>=DH\.:E8S'IBUT*/"AO1R8HK45,2
M44V*T1,;3&\>AKD3MM,<ICG$QWQ,>AZS'08Z4M-RRY*;%Y1*:^&JV@HTM$J<
MNQ6I] KTJWZ)7:<YC7.ZMTG5(,S#8QUSNH6"]S6Y^:GUPAT /=V?::RN2^V$
MQDFMK4FRMA[?5"#&H50FXW5R=G+:149*PDC1'KF2U,M+#2!)3,5RI!EZI+R$
M=ZPV34Y%._PQ]^C1PQX8Z]J%0NF/1Z_#==EP]F?(WF<FGMX6Q6GE7?[['/F6
MCOWB)VVM&]T.A'2:G%-!BS=J/+TB,6IIXURUC:;;?>Y(\^L]VTS7WU;1$@ &
MJMO       7@ 4O*@          !U6?>N_Q3Y,?TDQOV4K1T5$]?,[U?O7?X
MI\F/Z28W[*5HZ*B>OF6CZK?@C#\YG^MLJ5UM_#>?YK3_ %552QVE"\L=I0D2
M>Z49S_A^UZ1_NZ?\$ZP'^><H7[?6A.<0X._=T_X)U@/\\Y0OV^M"<XA3;I3\
M)\0_+=5]==>#HE\%\._(M+]30 !X+80     .)+VZW\%#+)_F*F?M'1SEM.)
M+VZW\%#+)_F*F?M'1SV.CWPAH?RS3?74>)TE^#>(?D6K^HR/,<72[^<OF NE
MW\Y?,%SX[H4:47T\SNG^Z7?^@<M_YP6%_4UH3I8+Z>9W3_=+O_0.6_\ ."PO
MZFM":!UG? VI^5@_ZC$D3JJ^'-'\G4_]+F=P( %5UO
M         <47MQ?X*.6K\V);]>4H\PY_X3OYRGIX^W%_@HY:OS8EOUY2CS#G
M_A._G*6+ZG?X!J?RNWU.!6;KM^$-)^1Q]?F6EC^>]"\L?SWH2Y/=*%Y[I=V[
MW33^\[+'^=5EOU+4CMRG4:]TT_O.RQ_G59;]2U([<I4OK"^&-;\K%]1B7%ZL
M?@+A_P C-_U.8 !IC?        '"9[P__!*RE?Y?D_\ _>)98\V!-*]AZ3_O
M#_\ !*RE?Y?D_P#_ 'B66/-@32O861ZG_@W-^69?J=.JWUU_"V#\@Q?7ZE<
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M2>O$.'8\=K1.ITE:X<U9GSK5K&V++Z9B](B+3^$K?U;_ -&"B*5-"2*
M  O  I>5
M
M
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M\^:8]3AOZ/?L+>C[8-8$S-V<F[>56"K7I4+<3GW2EVQ$Q1T*B2<.0HL/-?\
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MW)JU_ SHER<H$1$U=R%;D4X=_L_P%-/ N .;&P  R
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M]OK*0).CY)<NU5;*_1(4"F62RD5"*]T&+!9="DZ-;.9BN<L"+"9U<M(6B?=
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MRG%]']D16,>6E[8\V&)F?)VWWI,3,1,UO28F+3$1VHM$>]ED !JK<
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M        <)GO#_\ !*RE?Y?D_P#_ 'B66/-@32O8>D_[P_\ P2LI7^7Y/_\
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MCOB>4[3"H /@[
M
M
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M%V=RZ^'B=S2\0U&#GASYL/S62^/^I,.EJ^':?41,9\&'-$\MLN*F2-O9>LN
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MY7_SXH/[,P#MFE2.G_PQKOEX_J<:Y/5Q\"</^;O]=E  :<W<
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M?9$1^QROEO;WUK6^5:9_;+"B+?CCVW\W_,S 'TB'S1U1>=7QY[N]%[LOT_\
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M[SX4B/!9GJ4U>2^@U.*TS./#J?<M^Z/*4BUZQX;1:.UM'C>9GOWFX $1IG
M
M
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M8NCO0CAW#/.T^")S;;3J,LQDS3$]^UIB(QQ/C&.M(GQW6(Q$+P#5VV@
M             XD?;L?P3LLG^9:)^UM /,>N7'!=*^9Z]V7K(99C*59*LV(M
ME34J]F;008$O5::LQ,2J34*6FY>>@L6/*Q(,Q#S)J5@1;X<1JKF(U;VJJ+QA
M-]W_ .BDO_X,8?\ 2*T?]9DK] NG6DX7I<N#48]1>U]1.6)Q5QVKV9Q8Z;3V
MLE)WWI/AMMMS0[UB=7VLXMK,.HT^33TICTU<,QFMDK;M1ERWWCL8KQV=KQWS
M$[Q/)YIUR["BHNQ=7F>EI][_ '13_)C#_I%:3^LRB^[_ '12N7_FQA_TBM)_
M69O7VX.&_@=9^CP_]]H/VE>*?A]#^DS_ .G<9_NG2?\ -_E>_/B@_LS .V:?
M(71)Z#V3+(?(5BEY,[.ML[(UZ>@5*J06U"H3_P!)G)65;)P8N?/S$P^'F2[$
M9F0U:QUV<Y,[$^O2#>E'%,>MU^IU6*+UQYK5FL7B(O&V.E9WBLVCOK/=,\D_
M=$N$9-!P[2Z3--+9,-+5M..9FDS.2]_-FU:S,;6COK', !X#8@
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M+EV'I9_>_P!T4_R8P_Z16D_K,?>_W13_ "8P_P"D5I/ZS'VX.&_@=9^CP_\
M?/M*\4_#Z'])G_T[S3+EV"Y=AZ6?WO\ =%/\F,/^D5I/ZS'WO]T4_P F,/\
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MQ+!K,^72VQXHS1:N*^6;SY3#DQQM%L-(Y3:)GSHY>E]E@ A9.H
M                .*+VXO\ !1RU?FQ+?KRE'F'O1<YV"_A*>O?EVR)6:RCV
M4K=B+84Y*M9JT,HV3JU.68CRJ34NR/"F6L^D2L2%,0KHT"$_.AQ&JN;=?<JH
M<8">[_\ 127'_@QAXX_WPVC_ *S)7Z!=.=)PO39<.HQY[VR9YRUG%7':.S./
M'3:9ODI.^])\-MO%#_6)T UG%]5@SZ;)IZ4QZ>,5HS7R5M-O*9+[Q%,5XVVM
M'?,3OOR>:;<NPL<U=B]V]#TMOO?[HI_DQA_TBM)_698_W?\ Z*2)^+&'_2*T
MG]9&\SUP<-_ ZW]'A_[Z/_M*<4_#Z'])G_T[BZ]TU3_YG98_SJLM^I:D=N0^
M/>B1T%LF&0^3K-/R9V;2SDK7YN4GJK";/U"?^DS,E!BR\M$SJA,3#H?5PHT1
MN;"5K79V<Y%<B'V$0?TIXKCUVOU&JQ1>N/+:DUB\1%X[.*E)WBLVCOK/=,\M
MD]]#^#9>'\-TNCS6I;)@KDBUL<S-)[67)DCLS:M9[K1$[UCGN  U]LH
M  #A,]X?_@E92O\ +\G_ /[Q++GFPHBWK@NH]=_I&]':R.56R-2L-;JE)6K,
M5>)3XE0IJS,S*)'?2ZC*U:27Z1)Q8,PSJ9Z2EH]S(C4?U>8^]BN:O&BWW?\
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M@ \%L0
M
M
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MQ4         "EQ4 4N0J                  *7%0    I<5
M         "EQ4 4N%Q4 "EQ4 4N07%0                         *7%0
M   %$0J                                    %+BH
M     I<FPJ *7(5  I<+BH I<5               *7(5  %+BH HA4
M       *7%0 !2Y-A4                              %%0J    %+BH
M            447%0   %+BH            "EQ4 "EQ4
M  "ER%0!2X(A4 4N%Q4 4NW%0         !2Y"H IFIS<+D*@
M
M
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M#&[6]7P[E'5\.Y39=2N_LO\ B.I7_&Y[0;M9U7#N4N2#Q[D^//;>;'JN/?\
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M7:RH!D
M
M
M
M
M
M
M
M
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MD*(J\Z2X=GTL;K4\"X Y&P  R
M
M
M
M
M
M
M
M
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M[E,3.PQHM^C$NS%7=Y^AE1$*F)]7_P "QK+OLYYW%]X*F=O2PH"H,L@
M
M
M
M
M
M
M
M
M
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M$S7(45=G@.?_ )_Y!NLZK:O9J]>!>C;BH&W_ .A4I<5 B!1$*@&2(
M
M
M
M
M
M
M
M
M
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M(
M
M
M
M
M
M
M
M
M
M   *7<WJ+N;U*@,;1Z  !D             4NYO%W-ZE0&-O4  ,@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
#/__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
